A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)
Phase: PHASE3
Conditions: COPD
Sponsor: Pearl Therapeutics, Inc.

 
 
Revised Clinical Study Protocol 
Study Code 
PT010005 
NCT #  
NCT02465567 
Date: 
   
  21 JUNE 2019 
 
 
 
 
 
 
 
 
 
 
 
A Randomized, Double-Blind, Multi-Center, Parallel Group Study to Assess 
the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD 
Exacerbations over a 52-Week Treatment Period in Subjects With 
Moderate to Very Severe COPD 
 
 
This submission /document contains trade secrets and confidential commercial information, disclosure of which 
is prohibited without providing advance notice to AstraZeneca and opportunity to object. 
The following Amendment(s) are included in this revised protocol: 
  
Amendment No.        
Date of Amendment           
Version 1 
18 MAY 2015 
Version 2, Amendment 1 
04 JULY 2015 
Version 1.1 
17 AUGUST 2015 
Version 3, Amendment 4 
08 JANUARY 2016 
Version 4, Amendment 3  
25 AUGUST 2016 
Version 4.1 
19 SEPTEMBER 2016 
Version 5, Amendment 4 
03 NOVEMBER 2017 
Version 6, Amendment 5 
27 MARCH 2018 
Version 6.1 
21 JUNE 2019 
 
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 1 of 194
CLINICAL STUDY PROTOCOL:  PT010005-05
Study Title:
A Randomized, Double-Blind, Multi-Center, Parallel Group Study to Assess 
the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD 
Exacerbations over a 52-Week Treatment Period in Subjects With Moderate 
to Very Severe COPD
Study Number:
PT010005-05
Study Phase:
Phase III
Product Name:
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
(PT010, BGF metered dose inhaler [MDI]) 
Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF 
MDI) 
Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
IND Number:
118313
EudraCT Number:
2014-005671-92
Indication:
COPD
Investigators:
Multicenter
Sponsor:
Pearl Therapeutics, Inc. 
Sponsor Contact:
Version Number
Date
Original Protocol
Version 1.0
18 May 2015
Amended Protocol
Version 2.0
04 July 2015
Amended Protocol 
Version 1.1 
17 August 2015
Amended Protocol
Version 3.0
08 January 2016
Amended Protocol
Version 4.0
25 August 2016
Amended Protocol
Version 4.1
19 September 2016
Amended Protocol
Version 5.0
03 November 2017
Amended Protocol
Version 6.0
27 March 2018
Amended Protocol
Version 6.1
21 June 2019
Confidentiality Statement
Property of Pearl Therapeutics, Inc. This document is confidential and may not be used, divulged, published, or otherwise disclosed 
without consent of Pearl Therapeutics, Inc.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 2 of 194
SUMMARY OF CHANGES FROM VERSION 6.0 INCLUDED IN THIS PROTOCOL 
AMENDMENT VERSION 6.1
Sections(s)/Description of Change
Rationale
Synopsis, Section 2.2
Added secondary objective: to assess the 
effect of BGF MDI relative to GFF MDI and 
BFF MDI on COPD exacerbations.
This is to cover additional COPD-
exacerbation-related endpoints not 
covered by the primary objective.
Synopsis, Sections 3.1.2, 3.1.3, and 9.4.3.7
Rate of severe COPD exacerbations is now a 
secondary efficacy endpoint instead of an 
“other” efficacy endpoint. 
Severe exacerbations are highly 
clinically relevant and are a predictor 
of mortality
Synopsis, Sections 3.1.3, 3.3.1, 9.4.3.3,
9.4.3.5, 9.4.3.6, 9.4.4.1, 9.4.4.2, and 9.4.4.5
Removed analysis of the following other 
endpoints out of Protocol:
x
Compliance for EQ 5D
x
Change from baseline in morning pre
dose trough, AUC0 4, and peak change 
from baseline in forced vital capacity 
(FVC), peak expiratory flow rate 
(PEFR), and forced expiratory flow 
between 25% and 75% of FVC 
(FEF25 75).
x
Individual components of the TDI: 
functional impairment, magnitude of 
task, and magnitude of effort over 24 
weeks, over 52 weeks, and at each
post randomization visit
x
Individual domains of the SGRQ: 
Symptoms, Activity, and Impacts over 
24 weeks, over 52 weeks, and at each 
post randomization visit
x
EXACT symptom domain scores for 
breathlessness, cough and sputum, and 
chest symptoms over 24 weeks, over 
52 weeks and over each 4-week 
In our previous studies, these
endpoints did not provide further 
insights into the primary and 
secondary endpoints and were 
consequently not discussed in the 
CSR. Furthermore, removal of these 
endpoints will reduce the volume of 
output for the CSR and facilitate 
focused review.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 3 of 194
Sections(s)/Description of Change
Rationale
interval of the 52 week treatment 
period
x
Rate and time to first COPD 
exacerbation treated with systemic 
steroids
x
Rate and time to first COPD 
exacerbation treated with antibiotics
Synopsis, Section 3.3.2.2
For 24-hour Holter monitoring sub-study 
endpoints, added the following endpoints:
x
Change from baseline in the 
frequency of supraventricular ectopic 
beats 
x
Incidence of withdrawal criteria being 
met during 24-hour Holter monitoring
Added the “isolated” for the following 
endpoints:
x
Change from baseline in the 
frequency of isolated ventricular 
ectopic events (including a single 
premature ventricular contraction 
[PVC])
x
Change from baseline in the 
frequency of isolated supraventricular 
ectopic events
Removed the following endpoint: 
x
Incidence of sustained ventricular 
tachycardia (SVT) [defined as PVCs 
lasting>30 seconds]
This is to reflect previous Holter study 
endpoints from similar studies.
Section 3.4
The addition of “due to COPD” is for 
clarification purpose. The reason for 
addition of “Calls to any health-care 
provider” is to cover all types of visits 
for the analysis.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 4 of 194
Sections(s)/Description of Change
Rationale
For health care resource utilization endpoints,
added “due to COPD” for the endpoint “The 
number of days missed work”. 
Added “Calls to any health-care provider” for 
the following endpoints:
x
The percentage of subjects with 
telephone calls to health care 
providers
x
The mean number of telephone calls 
to health care providers
x
The percentage of subjects with visits 
to health care providers
x
The mean number of visits to health 
care providers
Section 9.4.2.1
Updated the definition for the duration of 
moderate or severe COPD exacerbations. A 
CRF-recorded COPD exacerbation resulting 
in a hospitalization or death will be 
considered as a countable moderate to severe 
(and also severe) COPD exacerbation 
regardless of whether systemic corticosteroids 
or systemic antibiotics were used to treat the 
exacerbation.
Avoid the exclusion of meaningful
COPD exacerbation records from the 
analysis
Section 9.4.2.1
Clarified that the start day of a COPD 
exacerbation will not be excluded from the 
time-at-risk of a COPD exacerbation.
Provide a clarification for the
calculation
Synopsis, Sections 9.4.2.1, 9.4.3.1, 9.4.3.3, 
9.4.3.4, 9.4.3.5, 9.4.4.4, 9.4.5.1, and 9.4.5.2
Updated analyses to include the log baseline 
blood eosinophil count as a covariate instead 
of baseline blood eosinophil count.
Eosinophil counts are skewed to the 
right and transformation reduces the 
influence of a few outlying high
values. 
Sections 9.4.5.2, and 9.4.5.3
For FEV1 AUC 0-4, it is clarified that this is 
a linear mixed repeated measures (RM)
ANCOVA analysis (which is the analysis 
type also being used for pre-dose trough 
FEV1) instead of ANCOVA. 
This analysis model was incompletely 
stated before as an ANCOVA without 
reference to RM.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 5 of 194
Sections(s)/Description of Change
Rationale
Section 9.4.5.4
For rate of decline in pre-dose FEV1 and 
FEV1 AUC0-4, added treatment and smoking 
status at screening as categorical covariates, 
and added the interaction between screening 
smoking status and time and the interaction 
between baseline FEV1 and time in the 
model.
These terms were inadvertently 
omitted in the previous version of 
protocol.
Section 9.4.6
The non-inferiority (NI) margin was updated 
from 0.1 to 1.1 for the comparisons of BGF 
MDI 160/14.4/9.6 g to BFF MDI 320/9.6 g 
on COPD exacerbations.
This NI margin was incorrect in the 
prior version of the protocol
Section 9.4.8
Criteria for upper limit for Glucose were 
changed for potentially clinically significant 
laboratory values.
This was done to align with revised 
safety thresholds based on medical 
history.
Other administrative changes to correct and/or clarify protocol language were also 
addressed. These changes included edits for consistency, grammar, and typographical 
errors, which are not summarized in this table. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 6 of 194
SYNOPSIS
Sponsor:
Pearl Therapeutics, Inc. (“Pearl”)
Name of Finished Product:
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, 
BGF metered dose inhaler [MDI])
Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI) 
Budesonide and Formoterol fumarate Inhalation Aerosol (PT009, BFF MDI) 
Name of Active Ingredients:
Budesonide, Glycopyrronium, and Formoterol Fumarate
Glycopyrronium and Formoterol Fumarate
Budesonide and Formoterol Fumarate
Study Title:
A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the 
Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations 
over a 52-Week Treatment Period in Subjects with Moderate to Very Severe COPD 
Study Number:  PT010005-05
Study Phase: Phase III
Primary Objective: 
•
To assess the effect of BGF MDI relative to GFF MDI and BFF MDI on the rate 
of moderate or severe chronic obstructive pulmonary disease (COPD) 
exacerbations
Secondary Objectives:
•
To assess the effect of BGF MDI relative to GFF MDI and BFF MDI on 
symptoms of COPD
•
To assess the effect of BGF MDI relative to GFF MDI and BFF MDI on quality 
of life
•
To assess the effect of BGF MDI relative to GFF MDI and BFF MDI on all-
cause mortality
•
To assess the effect of BGF MDI relative to GFF MDI and BFF MDI on COPD 
exacerbations
Safety Objective:
x
To assess the safety of BGF MDI relative to GFF MDI and BFF MDI
4-Hour Pulmonary Function Test (PFT) Sub-study Objective:
•
To assess the effects of BGF MDI relative to GFF MDI and BFF MDI on lung 
function

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 7 of 194
24-Hour Holter Monitoring Sub-study Objective:
•
To evaluate the cardiovascular safety of BGF MDI relative to GFF MDI and BFF 
MDI as evaluated by 24-hour Holter monitoring
Health Care Resource Utilization (HCRU) Objective:
•
To assess overall and COPD-specific Healthcare Resource Utilization of BGF 
MDI GFF MDI, and BFF MDI
Study Design:
This is a randomized, double-blind, multi-center, parallel group study to assess the 
efficacy and safety of BGF MDI 320/14.4/9.6 g and BGF MDI 160/14.4/9.6 g 
relative to GFF MDI 14.4/9.6 g and BFF MDI 320/9.6 g over a 52-week treatment 
period in approximately 8,400 subjects with moderate to very severe COPD with an 
increased risk of experiencing a COPD exacerbation and that remain symptomatic on 
the COPD Assessment Test (CAT  10) on two or more inhaled maintenance 
treatments. 
To be considered eligible for the study, subjects must have documented history of
COPD exacerbations. Subjects with a post-bronchodilator FEV1 < 50% of predicted 
normal must have  1 moderate or severe COPD exacerbation in the previous 12 
months. Subjects with a post-bronchodilator FEV1  50% of predicted normal must 
have  2 moderate exacerbations or  1 severe COPD exacerbation in the previous 
12 months. In addition, post-bronchodilator FEV1 for these subjects during screening 
should be  25% and < 65% of the predicted normal value calculated using 
appropriate reference equations.  
Subjects will undergo a Screening Period of 1 to 4 weeks in duration. During the 
screening period subjects that are receiving an ICS/LABA will discontinue the 
ICS/LABA, but will continue the ICS component for the remainder of the screening 
period. Similarly, subjects treated with an ICS as part of their inhaled maintenance 
therapy will also be permitted to continue their ICS for the remainder of the 
screening period. All subjects will receive open-label Atrovent® hydrofluoroalkane 
(HFA; ipratropium bromide inhalation aerosol) administered QID for maintenance 
during Screening.  Ventolin® HFA (albuterol sulfate inhalation aerosol) will be 
provided for rescue use throughout the study.
In order to allow for adequate washout of previous maintenance medications, 
subjects will undergo a Washout Period of at least 1 week (at least 2 weeks if taking
Spiriva), but not greater than 26 days in duration prior to returning to the clinic for
Visit 2. In instances where an exacerbation has occurred during the Screening 
Period, the Screening Period may be extended to a maximum of 10 weeks (to 
account for a course of oral corticosteroids of up to 2 weeks in duration and a 4-week 
period after treatment of the exacerbation). 
Subjects who successfully complete the Screening Period will then be randomized in 
a 1:1:1:1 scheme to BGF MDI 320/14.4/9.6 g BID, BGF MDI 160/14.4/9.6 g 
BID, BFF MDI 320/9.6 g BID, or GFF MDI 14.4/9.6 g BID, respectively. 
Approximately 2,100 subjects will be randomized to each treatment arm. 
Randomization will be stratified by exacerbation history (1 or 2 moderate or severe 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 8 of 194
exacerbations), post-bronchodilator FEV1 (25% to <50% predicted or 50% to 65% 
predicted), blood eosinophil count <150 cells per mm3 or 150 cells per mm3), and 
country. Up to a 1:2 ratio for the blood eosinophil strata was targeted with twice as 
many randomized subjects in the  150 cells per mm3 category. Following 
randomization, subjects will enter the Treatment Period and undergo 10 additional 
treatment visits over 52 weeks. 
Subjects who discontinue study treatment prior to Week 52 (Visit 14) will be 
encouraged to remain in the study to complete all remaining study visits during the 
52-week treatment period. Subjects who agree to continue to be followed post 
treatment discontinuation will sign an ICF addendum. All subjects who agree to 
continue study participation beyond treatment discontinuation will complete a 
Treatment Discontinuation/Withdrawal Visit (refer to Table 8, and Sections 8.9 and 
8.10) prior to transitioning back to regularly scheduled study visits. Subjects 
participating in the Holter Monitoring sub-study who discontinue from treatment will 
only complete regularly scheduled visits and not complete any remaining Holter sub-
study assessments, however subjects participating in the PFT sub-study will continue 
with serial PFTs only. Treatment discontinuation subjects will return to appropriate 
maintenance COPD medications, per the investigator’s discretion. For subjects 
recorded as Treatment Discontinuations that do not complete at least one post-
treatment data collection, a telephone follow-up call is required at least 14 days after 
last study drug dose. These subjects will be followed for vital status at 52 weeks post 
randomization in accordance with the informed consent.
If a subject chooses not to continue with study assessments, at a minimum the 
subject will complete the Treatment Discontinuation/Withdrawal Visit (refer to
Sections 8.9 and 8.10). These subjects will return to appropriate maintenance COPD 
medications, per the investigator’s discretion. A follow-up telephone call will be 
performed at least 14 days after the last study drug dose. In the event the Treatment 
Discontinuation/Withdrawal Visit is performed >14 days post last study drug dosing, 
a follow-up TC will not be required. These subjects will be followed for vital status 
at 52 weeks post randomization in accordance with the informed consent.
4-Hour Pulmonary Function Test Sub-study: Serial PFTs will be conducted over 
4 hours in a subset of approximately 3,060 subjects (765 subjects per treatment 
group) at selected visits throughout the 52-week Treatment Period. Those subjects 
who do not meet FEV1 Baseline Stability criteria will not be permitted to participate 
in the PFT Sub-study, but will be permitted to participate in the main study providing 
they satisfy all other eligibility criteria. Sub-study was previously open to all 
eosinophil levels, now only subjects who have a blood eosinophil level of  150 cells 
per mm3 at Visit 1 will be permitted to participate in the PFT Sub-study.
24-Hour Holter Monitoring Sub-study: Holter Monitoring will be conducted over 
24 hours in a subset of approximately 800 randomized (200 subjects from each 
treatment group) at Visit 3 (Holter Monitoring Baseline) and Visit 8 (Week 16).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 10 of 194
Duration of Study: The entire study period is scheduled to take approximately 
60 weeks (expected range between 56 to 64 weeks) for each individual subject.  The 
study is anticipated to run for approximately 30 months and is not expected to 
exceed 50 months.
Efficacy Assessments:
Primary Efficacy Endpoint:
•
Rate of moderate or severe COPD exacerbations
Secondary Efficacy Endpoints: Secondary endpoints that differ between 
approaches (US vs. ex-US) are indicated in parentheses. Endpoints which are not 
considered secondary for either regulatory approach have been included under other 
efficacy endpoints.
•
Time to first moderate or severe COPD exacerbation
•
Change from baseline in average daily rescue Ventolin HFA use over 24 weeks
•
Transition Dyspnea Index (TDI) focal score over 24 weeks (ex-United States 
[US] [ex-US])
•
Change from baseline in the Exacerbations of Chronic Pulmonary Disease Tool
(EXACT) total score over 52 weeks (ex-US)
•
Change from baseline in St. George’s Respiratory Questionnaire (SGRQ) total 
score over 24 weeks (ex-US)
•
Percentage of subjects achieving a minimal clinically important difference 
(MCID) of 4 units or more in SGRQ total score at Week 24 (US)
•
Time to death (all cause)
•
Rate of severe COPD exacerbations
Safety Endpoints:
•
Adverse events (AEs)
•
12-lead electrocardiograms (ECGs)
•
Clinical laboratory testing
•
Vital sign measurements
PFT Sub-study Endpoints:
The primary PFT endpoints are:
•
Change from baseline in morning pre-dose trough FEV1 at Week 24 (US) and 
over 24 weeks (ex-US) for the comparison of BGF MDI to GFF MDI
•
FEV1 area under the curve from 0 to 4 hours (AUC0-4) at Week 24 (US) and over 
24 weeks (ex-US) for the comparison of BGF MDI to BFF MDI
Other PFT endpoints include:

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 11 of 194
•
Change from baseline in morning pre-dose trough FEV1 over 24 weeks, over 
Weeks 12 to 24, over 52 weeks and at each post-randomization visit 
•
FEV1 AUC0-4 over 24 weeks, over Weeks 12 to 24, over 52 weeks and at each 
post-randomization visit where measured
•
Peak change from baseline in FEV1 over 24 weeks, over Weeks 12 to 24, over 52 
weeks and at each post-randomization visit where measured
•
Rate of decline in pre-dose FEV1 over 52 weeks
•
Rate of decline in FEV1 AUC0-4 over 52 weeks
•
Time to onset of action on Day 1
24-Hour Holter Monitoring Sub-study Endpoints (Assessed at Week 16)
Primary Endpoint:
•
Change from baseline in mean heart rate averaged over 24 hours
Secondary Endpoints:
•
Change from baseline in mean night-time (22:00 to 06:00) and day-time (06:00 
to 22:00) heart rate
•
Change from baseline in the maximum 24-hour heart rate
•
Change from baseline in the minimum 24-hour heart rate
•
Change from baseline in the frequency of isolated ventricular ectopic events 
(including a single premature ventricular contraction [PVC])
•
Change from baseline in the frequency of ventricular couplets (defined as two 
PVCs preceded or followed by regular beats)
•
Change from baseline in the frequency of ventricular runs (defined as three or 
more PVCs preceded or followed by regular beats)
•
Change from baseline in the frequency of supraventricular ectopic beats
•
Change from baseline in the frequency of isolated supraventricular ectopic events
•
Change from baseline in the frequency of supraventricular couplets
•
Change from baseline in the frequency of supraventricular runs
•
Incidence of withdrawal criteria being met during 24-hour Holter monitoring
•
Incidence of atrial fibrillation with rapid ventricular response (>100 beats per 
minute [bpm])
Statistical Methods:
Primary Efficacy Analysis: The rate of moderate or severe COPD exacerbations 
will be analyzed using negative binomial regression.  COPD exacerbations will be 
considered separate events provided that more than 7 days are between the recorded 
stop date of the earlier event and start date of the later event. Time at risk of 
experiencing an exacerbation will be used as an offset variable in the model. Time 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 13 of 194
Further details will be provided in the Statistical Analysis Plan (SAP).
Data Monitoring Committee: An independent, external DMC will be set up to
review all serious adverse events (including deaths and all hospitalizations) and pre-
defined cardiovascular events.  Members of the DMC will review these data 
generated externally and independently of Pearl at predetermined intervals.  If 
significant safety issues arise in between scheduled meetings, ad-hoc meetings will 
be scheduled to review the data. Based on the safety implications of the data, the 
DMC may recommend modification or termination of the study. An interim efficacy 
analysis will be performed at which an independent Data Monitoring Committee will 
review unblinded efficacy data and determine if the study can be stopped early for 
unequivocal efficacy.
Clinical Endpoint Committee: An external clinical endpoint committee will be 
established for this study. The committee will provide systematic and unbiased 
assessment of pre-defined, Investigator reported adverse events. The committee will 
consist of experts who will provide a centralized review functioning independently 
of Pearl. Three Clinical Endpoint Adjudication Charters will outline the clinical 
endpoints for adjudication.
•
Cardiovascular and Cerebrovascular Clinical Endpoint Adjudication Charter
•
Cause-Specific Mortality Clinical Endpoint Adjudication 
•
Pneumonia Clinical Endpoint Adjudication Charter

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 14 of 194
TABLE OF CONTENTS
SUMMARY OF CHANGES FROM VERSION 6.0 INCLUDED IN THIS PROTOCOL
AMENDMENT VERSION 6.1 .........................................................................................2 
SYNOPSIS.................................................................................................................................6 
TABLE OF CONTENTS.........................................................................................................14 
LIST OF IN-TEXT TABLES ..................................................................................................20 
LIST OF IN-TEXT FIGURES.................................................................................................21 
LIST OF APPENDICES..........................................................................................................21 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS..........................................22 
TRADEMARK INFORMATION ...........................................................................................26 
1 
INTRODUCTION ...........................................................................................................27 
1.1 
Study Rationale......................................................................................................29 
2 
STUDY OBJECTIVES....................................................................................................30 
2.1 
Primary Objective ..................................................................................................30 
2.2 
Secondary Objectives.............................................................................................30 
2.3 
Safety Objective.....................................................................................................30 
2.4 
4-Hour Pulmonary Function Test Sub-study Objective.........................................30 
2.5 
24-Hour Holter Monitoring Sub-study Objective..................................................30 
2.6 
Health Care Resource Utilization Objective..........................................................30 
3 
STUDY ENDPOINTS.....................................................................................................31 
3.1 
Efficacy Endpoints.................................................................................................31 
3.1.1 
Primary Endpoint.........................................................................................31 
3.1.2 
Secondary Endpoints ...................................................................................31 
3.1.3 
Other Efficacy Endpoints.............................................................................31 
3.2 
Safety Endpoints....................................................................................................32 
3.3 
Sub-Study Endpoints .............................................................................................32 
3.3.1 
4-Hour Pulmonary Function Test Sub-study Endpoints..............................32 
3.3.2 
24-Hour Holter Monitoring Sub-Study Endpoints Assessed at Visit 8 
(Week 16).....................................................................................................33 
3.3.2.1 
Primary 24-Hour Holter Monitoring Sub-Study Endpoints 
Endpoint.............................................................................................33 
3.3.2.2 
Secondary 24-Hour Holter Monitoring Sub-Study Endpoints ..........33 
3.3.3 
Other Endpoints:..........................................................................................34 
3.4 
Health Care Resource Utilization Endpoints .........................................................34 
4 
INVESTIGATIONAL PLAN..........................................................................................35 
4.1 
Overall Study Design and Plan..............................................................................35 
4.2 
Rationale of Study Design .....................................................................................41 
4.3 
Rationale of Dose/Regimen and Duration of Treatment .......................................42 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 15 of 194
5 
STUDY POPULATION SELECTION AND WITHDRAWAL CRITERIA .................43 
5.1 
Inclusion Criteria ...................................................................................................43 
5.2 
Exclusion Criteria ..................................................................................................45 
5.2.1 
24-Hour Holter Monitoring Sub-study Exclusion Criteria..........................50 
5.3 
Subject Identification.............................................................................................50 
5.4 
Prior, Concomitant, and Prohibited Medications...................................................51 
5.4.1 
Allowed Medications to Treat a COPD Exacerbation.................................51 
5.4.2 
Pneumococcal and Annual Influenza Vaccination ......................................51 
5.4.3 
Prohibited COPD Medications and Required Washout Prior to Visit 2......52 
5.4.4 
Other Prohibited Medications......................................................................54 
5.5 
Other Restrictions, Illicit Drugs, or Drugs of Abuse .............................................56 
5.5.1 
Illicit Drugs ..................................................................................................56 
5.5.2 
Dietary Restrictions .....................................................................................56 
5.6 
Smoking Status ......................................................................................................56 
5.7 
Reasons for Treatment Discontinuation or Study Withdrawal..............................56 
6 
LABELING, PACKAGING, STORAGE, DISPENSING, AND RETURN OF 
CLINICAL SUPPLIES....................................................................................................59 
6.1 
Subject Information ...............................................................................................59 
6.2 
Product Descriptions..............................................................................................59 
6.3 
Primary Packaging and Labeling Information.......................................................60 
6.4 
Secondary Packaging and Labeling Information (Box).........................................61 
6.5 
Emergency Unblinding of Treatment Assignment ................................................62 
6.6 
Storage Requirements ............................................................................................62 
6.7 
Instructions for Preparation of Treatments for Administration and Dispensing....62 
6.7.1 
BGF MDI, GFF MDI, and BFF MDI ..........................................................62 
6.7.2 
Atrovent® HFA (Ipratropium Bromide) ......................................................63 
6.7.3 
Ventolin HFA® (Albuterol Sulfate) .............................................................63 
6.8 
Drug Accountability/Return of Clinical Supplies..................................................63 
7 
STUDY PROCEDURES .................................................................................................65 
7.1 
Efficacy Assessments.............................................................................................65 
7.1.1 
Pulmonary Function Tests ...........................................................................65 
7.1.1.1 
Characterization of Reversibility.......................................................66 
7.1.1.2 
FEV1 Baseline Stability Criteria........................................................67 
7.1.2 
Subject Electronic Diary Data Collection....................................................67 
7.1.2.1 
Rescue Medication Use......................................................................68 
7.1.2.2 
Medication Compliance.....................................................................68 
7.1.2.3 
Major/minor Symptom Worsening Assessment and Alert System ...68 
7.1.3 
COPD Exacerbation.....................................................................................69 
7.1.3.1 
Severity of COPD Exacerbation........................................................69 
7.1.3.2 
Duration of COPD Exacerbation .......................................................70 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 16 of 194
7.1.3.3 
Approach for Capturing COPD Exacerbations..................................70 
7.1.3.4 
Other Information ..............................................................................70 
7.1.3.5 
Investigator-Judged COPD Exacerbations ........................................71 
7.1.4 
Subject Questionnaires.................................................................................71 
7.1.4.1 
Chronic Obstructive Pulmonary Disease Assessment Test (CAT)....71 
7.1.4.2 
Baseline and Transition Dyspnea Indices..........................................72 
7.1.4.3 
St. George’s Respiratory Questionnaire ............................................72 
7.1.4.4 
European Quality-of-Life-5 Dimensions Questionnaire....................73 
7.1.4.5 
Exacerbations of Chronic Pulmonary Disease Tool (EXACT) .........73 
7.2 
Safety Assessments................................................................................................74 
7.2.1 
Medical/Surgical History and Physical Examination ..................................74 
7.2.2 
Vital Sign Measurements.............................................................................74 
7.2.3 
12-Lead Electrocardiogram .........................................................................75 
7.2.4 
Clinical Laboratory Tests.............................................................................76 
7.2.4.1 
Hematology........................................................................................76 
7.2.4.2 
Clinical Chemistry .............................................................................77 
7.2.4.3 
Urinalysis ...........................................................................................79 
7.2.4.4 
Pregnancy Test...................................................................................79 
7.2.5 
Holter Monitoring 24-Hour Continuous Electrocardiography ....................79 
7.3 
Adverse Events ......................................................................................................80 
7.3.1 
Performing Adverse Event Assessments .....................................................80 
7.3.2 
Adverse Event Definitions...........................................................................81 
7.3.3 
Pre-Randomization Adverse Events ............................................................81 
7.3.4 
Severity ........................................................................................................82 
7.3.5 
Relationship .................................................................................................82 
7.3.6 
Chronic Obstructive Pulmonary Disease Exacerbations .............................82 
7.3.7 
Adverse Events of Special Interest ..............................................................83 
7.3.7.1 
LABA and LAMA Effects.................................................................83 
7.3.7.2 
Local Steroid Effects..........................................................................83 
7.3.7.3 
Pneumonia..........................................................................................83 
7.3.7.4 
Paradoxical Bronchospasm................................................................84 
7.3.8 
Major Adverse Cardiovascular Events ........................................................84 
7.3.9 
Clinical Laboratory Adverse Events............................................................84 
7.3.10 
Serious Adverse Events ...............................................................................85 
7.3.10.1 
Reporting of Serious Adverse Events................................................86 
7.3.10.2 
Supplemental Investigations of SAEs................................................86 
7.3.10.3 
Post-Study Follow Up of Adverse Events .........................................86 
7.3.10.4 
Notification of Post-Study Serious Adverse Events..........................86 
7.3.10.5 
Investigational Research Board/Independent Ethics Committee 
Notification of Serious Adverse Events.............................................87 
7.3.10.6 
Health Authority Safety Reports........................................................87 
7.3.11 
Overdose ......................................................................................................87 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 17 of 194
7.3.12 
Pregnancy.....................................................................................................87 
7.3.13 
Paternal Exposure ........................................................................................88 
7.3.14 
Hy’s Law......................................................................................................88 
7.3.15 
Use of Steroids during the Study .................................................................88 
7.3.16 
Clinical Endpoint Committee ......................................................................88 
7.3.16.1 
Cardiovascular and Cerebrovascular Clinical Endpoint 
Adjudication Charter..........................................................................89 
7.3.16.2 
Cause-Specific Mortality Clinical Endpoint Adjudication Charter...89 
7.3.16.3 
Pneumonia Clinical Endpoint Adjudication Charter .........................89 
7.3.17 
Data Monitoring Committee........................................................................89 
7.4 
Health Care Resource Utilization ..........................................................................89 
7.5 
Termination of the Study .......................................................................................89 
8 
STUDY ACTIVITIES .....................................................................................................90 
8.1 
Visit 1 (Screening) .................................................................................................99 
8.2 
Visit 2...................................................................................................................100 
8.3 
Visit 3...................................................................................................................101 
8.4 
Visit 4 (Randomization, Day 1)...........................................................................102 
8.5 
In-Clinic Visits 5, 7, 10, and 12 (Weeks 4, 12, 24, 36) .......................................104 
8.6 
In-Clinic Visit 8 (Weeks 16) For 24 –Hour Holter Monitoring Sub-Study 
Subjects Only.......................................................................................................105 
8.7 
Telephone Visits 6, 8, 9, 11, and 13 (Weeks 8, 16, 20, 28, and 44) ....................106 
8.8 
Final Visit (Visit 14; Week 52)............................................................................106 
8.9 
Procedures for Treatment Discontinuation and Study Withdrawal Subjects.......108 
8.10 
Unscheduled Visit and Treatment Discontinuation/Withdrawal Visit ................108 
8.11 
Follow-up Telephone Call ...................................................................................109 
8.12 
52-Week Post-Randomization Vital Status Confirmation...................................109 
8.13 
Completion of the Study......................................................................................110 
9 
PLANNED STATISTICAL METHODS ......................................................................111 
9.1 
Introduction..........................................................................................................111 
9.2 
Protocol Variables................................................................................................111 
9.2.1 
Efficacy Endpoints.....................................................................................111 
9.2.2 
Safety Endpoints........................................................................................111 
9.3 
Study Populations ................................................................................................111 
9.4 
Efficacy Analysis.................................................................................................112 
9.4.1 
Estimands...................................................................................................112 
9.4.2 
Primary Efficacy Analysis.........................................................................114 
9.4.2.1 
Rate of Moderate or Severe COPD Exacerbations..........................114 
9.4.3 
Analysis of Secondary Endpoints..............................................................115 
9.4.3.1 
Time to First COPD Exacerbation: Moderate or Severe .................115 
9.4.3.2 
Time to Death: All Cause, Respiratory............................................115 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 18 of 194
9.4.3.3 
Transition Dyspnea Index................................................................115 
9.4.3.4 
Rescue Ventolin HFA Use...............................................................116 
9.4.3.5 
St. George’s Respiratory Questionnaire ..........................................117 
9.4.3.6 
Exacerbations of Chronic Pulmonary Disease Tool (EXACT).......117 
9.4.3.7 
Rate of Severe COPD Exacerbations...............................................118 
9.4.4 
Analysis of Other Endpoints......................................................................118 
9.4.4.1 
Time to First COPD Exacerbation: of Any Severity .......................118 
9.4.4.2 
Rate of COPD Exacerbations: of Any Severity...............................118 
9.4.4.3 
Time to Treatment Failure ...............................................................118 
9.4.4.4 
Percentage of Days with “No Rescue Ventolin HFA Use” Over 
the Treatment Period........................................................................118 
9.4.4.5 
European Quality-of-Life-5 Dimension-5 Level Questionnaire......119 
9.4.5 
Analysis of PFT Sub Study........................................................................119 
9.4.5.1 
Change from Baseline in Morning Pre-dose Trough FEV1 at 
Week 24 (US) and Over 24 Weeks (ex US) for the comparison of 
BGF MDI to GFF MDI....................................................................119 
9.4.5.2 
FEV1 AUC0-4 at Week 24 (US) and Over 24 Weeks (ex-US).........119 
9.4.5.3 
Other PFT Sub-study Analyses........................................................120 
9.4.5.4 
Rate of decline in pre-dose FEV1 and FEV1 AUC0-4 over 52 
weeks................................................................................................120 
9.4.5.5 
Time to Onset on Day 1...................................................................120 
9.4.6 
Control of Type I Error..............................................................................120 
9.4.7 
Safety Analysis ..........................................................................................121 
9.4.7.1 
Adverse Events ................................................................................121 
9.4.7.2 
MACE Events Determined by Clinical Endpoint Committee.........122 
9.4.7.3 
Pneumonia Events Determined by CEC..........................................122 
9.4.8 
Clinical Laboratory Measurements............................................................122 
9.4.9 
Vital Signs..................................................................................................122 
9.4.10 
ECGs..........................................................................................................123 
9.4.11 
Health Care Resource Utilization ..............................................................123 
9.4.12 
24-Hour Holter Monitoring........................................................................123 
9.5 
Randomization.....................................................................................................124 
9.6 
Experimental Design............................................................................................124 
9.7 
Sample Size..........................................................................................................125 
9.8 
Data Validation and Transformation ...................................................................125 
9.9 
Interim Analysis...................................................................................................125 
9.10 
Analysis Plan .......................................................................................................126 
9.11 
Handling of Missing Data....................................................................................126 
9.12 
Statistical Software ..............................................................................................127 
10 ADMINISTRATIVE CONSIDERATIONS..................................................................128 
10.1 
Regulatory Authority Approval ...........................................................................128 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 19 of 194
10.2 
Ethical Conduct of the Study and Institutional Review Board or Independent 
Ethics Committee Approval.................................................................................128 
10.3 
Subject Information and Consent.........................................................................128 
10.4 
Laboratory Accreditation.....................................................................................129 
10.5 
Confidentiality .....................................................................................................129 
10.5.1 
Confidentiality of Data ..............................................................................129 
10.5.2 
Confidentiality of Subject/Patient Records................................................129 
10.6 
Quality Control and Assurance............................................................................129 
10.7 
Data Management ................................................................................................129 
10.8 
Study Monitoring.................................................................................................130 
10.9 
Retention of Data .................................................................................................131 
10.10 Financial Disclosure.............................................................................................131 
10.11 Investigator’s Final Report ..................................................................................131 
10.12 Publication Policy................................................................................................131 
11 REFERENCE LIST .......................................................................................................133 
12 APPENDICES ...............................................................................................................135 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 20 of 194
LIST OF IN-TEXT TABLES
Table 1. 
Prohibited COPD Medications and Required Washout Periods Prior to 
Visit 2
....................................................................................................................52 
Table 2. 
Other Prohibited Respiratory/Nasal Medications and Required 
Washout Periods Prior to Visit 2 .................................................................................54 
Table 3. 
Non-COPD Medications Allowed Under Certain Conditions...................54 
Table 4. 
Prohibited Medications..............................................................................55 
Table 5. 
Product Descriptions..................................................................................60 
Table 6. 
Description of Boxes..................................................................................61 
Table 7. 
Clinical Laboratory Tests...........................................................................78 
Table 8. 
Schedule of Events.....................................................................................91 
Table 8-1. 
Timed Assessments for all Post-randomization In-clinic Visits for 
Subjects Participating in the PFT Sub-study (Visits 4, 5, 7, 10, 12, and 14; Day 1, 
Weeks 4, 12, 24, 36, and 52)........................................................................................94 
Table 8-2. 
Timed Assessments for all Post-randomization In-clinic Visits for 
Subjects not Participating in the PFT Sub-study (Visits 4, 5, 7, 10, 12, and 14; 
Day 1, Weeks 4, 12, 24, 36, and 52)............................................................................96 
Table 8-3. 
Assessments to be collected at Post-randomization Telephone Visits 
(Visits 6, 8, 9, 11, and 13; Weeks 8, 16, 20, 28, and 44).............................................97 
Table 8-4. 
Schedule of Events at Visit 3 (Screening Period) and Visit 8 (Week 
16) for 24-Hour Holter Monitoring Sub-study ............................................................98 
Table A1-1. 
Recommended Minimal Scale Factors for Time, Volume, and Flow on 
Graphical Output........................................................................................................137 
Table A1-2. 
Summary of Equipment Quality Control.................................................138 
Table A1-3. Range and Accuracy Recommendations Specified for Forced Expiratory 
Maneuvers..................................................................................................................141 
Table A3-1. 
Classification of Severity of Airflow Limitation in COPD 
(Based on Post-bronchodilator FEV1) .......................................................................144 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 21 of 194
LIST OF IN-TEXT FIGURES
Figure 1. 
Study Design..............................................................................................41 
Figure 2. 
Example of a Usable Spirogram ..............................................................142 
LIST OF APPENDICES
Appendix 1 
Spirometry Performance Recommendations ...........................................136 
Appendix 2 
Spirometry Assessment Criteria ..............................................................142 
Appendix 3 
Classification of COPD Severity - GOLD Guidelines (2014).................144 
Appendix 4 
Subject Instructions for Use of BGF MDI, GFF MDI, and BFF MDI....145 
Appendix 5 
Instructions for Use of Atrovent® HFA Inhalation Aerosol Device........154 
Appendix 6 
Instructions for Use of Ventolin HFA Inhaler .........................................160 
Appendix 7 
COPD Assessment Test...........................................................................168 
Appendix 8 
St. George’s Respiratory Questionnaire ..................................................169 
Appendix 9 
BDI/TDI Questionnaire ...........................................................................175 
Appendix 10 EuroQol 5 Dimensions Questionnaire .....................................................181 
Appendix 11 Exacerbations of Chronic Obstructive Pulmonary Disease (EXACT)....184 
Appendix 12 Dose Indicator Display Reading Instructions ..........................................189 
Appendix 13 Rules for Evaluation of Abnormal Liver Laboratory Values ..................190 
Appendix 14 Sponsor Signatory....................................................................................193 
Appendix 15 Investigator’s Agreement and Signature Page.........................................194 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 22 of 194
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
AE
adverse event
ALT
alanine aminotransferase
AESI
adverse event of special interest
ANCOVA
analysis of covariance
AR(1)
autoregressive order 1
AST
aspartate aminotransferase
ATS
American Thoracic Society
AUC0-4
area under the curve from 0 to 4 hours
BD MDI
Budesonide Metered Dose Inhaler
BDI
Baseline Dyspnea Index
BFF MDI
Budesonide and Formoterol Fumarate Metered Dose Inhaler
BGF MDI
Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose 
Inhaler
BID
bis in die, twice daily
bpm
beats per minute
BMP
Basic Metabolic Panel
BTPS
body temperature and pressure saturated
CAT
Chronic Obstructive Pulmonary Disease Assessment Test
CCU
Coronary Care Unit
CCV
cardio- and cerebrovascular
CFR
Code of Federal Regulations
CI
confidence interval
CKD-EPI
Chronic Kidney Disease Epidemiology Collaboration
cm
centimeter
CONSORT
Consolidated Standards of Reporting Trials
COPD
chronic obstructive pulmonary disease
CT
computed tomography
CTCAE
Common Terminology Criteria for Adverse Events
DBP
diastolic blood pressure

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 23 of 194
DMC
Data Monitoring Committee
DPI
dry powder inhaler
ECG
electrocardiogram
eCRF
electronic Case Report Form
eDiary
electronic Diary
eg
exempli gratia; for example,
EQ-5D-5L
EuroQol 5 Dimensions Questionnaire 5-level 
ER
Emergency Room
ERS
European Respiratory Society
EU
European Union
ex-actuator
dose delivered from the actuator (i.e., mouthpiece) of the MDI 
ex-US
outside the United States
EXACT
Exacerbations of Chronic Pulmonary Disease Tool – Patient Reported 
Outcomes
FDA
Food and Drug Administration
FEV1
forced expiratory volume in 1 second
FEF25-75
forced expiratory flow between 25% and 75% of FVC
FF MDI
Formoterol Fumarate Metered Dose Inhaler
FVC
forced vital capacity
GCP
Good Clinical Practice
GFF MDI
Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler
GOLD
Global Initiative for Chronic Obstructive Lung Disease
GP MDI
Glycopyrronium Metered Dose Inhaler
hCG
human chorionic gonadotropin
HCRU
Health Care Resource Utilization
HFA
hydrofluoroalkane
HR
heart rate
IB
Investigator’s Brochure
ICF
Informed Consent Form
ICH
International Conference on Harmonisation 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 24 of 194
ICMJE
International Committee of Medical Journal Editors
ICS
inhaled corticosteroid
ICU
Intensive Care Unit
ie
id est; that is
IEC
Independent Ethics Committee
IM
intramuscular
IRB
Institutional Review Board
ITT
Intent-to-Treat
IV
intravenous
IWRS
Interactive Web Response System
JRS
Japanese Respiratory Society
L
liter
LABA
long-acting ȕ2 agonist
LAMA
long-acting muscarinic antagonist
LPLV
last patient last visit 
MACE
major adverse cardiovascular event
MCID
minimal clinically important difference
MDI
metered dose inhaler
MedDRA
Medical Dictionary for Regulatory Activities
g
microgram
mITT
Modified Intent-to-Treat 
mL
milliliter
mm
millimeter
mmHg
millimeter of mercury
msec (ms)
millisecond
NSVT
Non-sustained ventricular tachycardia
NYHA
New Your Heart Association
OCS
oral corticosteroid
OTC
over-the-counter

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 25 of 194
PCS
potentially clinically significant
PEFR
peak expiratory flow rate
PFT
pulmonary function test
PIN
personal identification number
PP
Per-Protocol
PT003
Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
PT009
Budesonide and Formoterol Fumarate Inhalation Aerosol
PT010
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation 
Aerosol
PVC
Premature ventricular contraction
QID
quater in die; four times daily
QoL
Quality of Life
QTcF
QT corrected using Fridericia’s formula
RM
repeated measures
SABA
short-acting ȕ2-agonist
SAE
serious adverse event
SAMA
short-acting muscarinic antagonist
SAP
Statistical Analysis Plan
SBP
systolic blood pressure
SD
standard deviation
SGRQ
St. George’s Respiratory Questionnaire
SNRI
selective norepinephrine reuptake inhibitor
SSRI
selective serotonin reuptake inhibitor
SUSAR
Suspected Unexpected Serious Adverse Reaction
SVT
Sustained ventricular tachycardia
TC
telephone call
TDI
Transition Dyspnea Index
TEAE
treatment-emergent adverse event
US
United States
VAS
visual analog scale

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 26 of 194
VC
vital capacity
VPB
Ventricular premature beats
TRADEMARK INFORMATION
Trademarks Not Owned By Pearl Therapeutics, Inc.
Atrovent
Oxis
SAS
Spiriva
Symbicort
Turbuhaler
Ventolin

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 27 of 194
1
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable
disease characterized by persistent airflow limitation that is usually progressive and
associated with an enhanced chronic inflammatory response in the airways and the lung to
noxious particles or gases.  Exacerbations and co-morbidities contribute to the overall
severity in individual patients. Chronic obstructive pulmonary disease is a leading cause of
morbidity and mortality worldwide and results in significant economic and social burden that
is both substantial and increasing. Pharmacologic therapy in COPD is used to reduce
symptoms, reduce the frequency and severity of exacerbations, and improve health status and
exercise tolerance [Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2014);
Japanese Respiratory Society (JRS, 2013).
Bronchodilator medications are central to the symptomatic management of COPD.  The 
principal bronchodilator treatments are ȕ2-agonists, anticholinergics, and methylxanthines 
used as monotherapy or in combination.  Treatment with long-acting bronchodilators is more 
convenient and more effective at producing maintained symptom relief than treatment with 
short-acting bronchodilators.
Regular treatment with inhaled corticosteroids (ICS) improves symptoms, lung function, and 
quality of life and reduces the frequency of exacerbations in subjects with COPD with a 
forced expiratory volume in 1 second (FEV1) value of <60% of predicted.  Withdrawal from 
treatment of ICS may lead to exacerbations in some patients.  When combined with a 
long-acting ȕ2-agonist (LABA), an ICS is more effective than the individual components in 
improving lung function, quality of life, and reducing exacerbations in subjects with 
moderate to very severe COPD [GOLD, 2014].  
Pearl Therapeutics, Inc. (hereinafter referred to as Pearl) is developing the fixed-dose ICS/ 
long-acting anti-muscarinic agent (LAMA)/LABA triple combination product, Budesonide, 
Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010), hereafter referred to 
as budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler (BGF MDI), 
for the treatment of patients with COPD.  Budesonide and Formoterol Fumarate Inhalation 
Aerosol (PT009, hereinafter referred to as budesonide and formoterol fumarate (BFF) MDI  
Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003)
hereinafter referred to as glycopyrronium and formoterol fumarate (GFF) MDI is being 
developed as a BID maintenance bronchodilator treatment in patients with COPD.  
Budesonide is a well-established corticosteroid approved worldwide in mono- and 
combination therapies for treatment of asthma and allergic rhinitis.  It is available in both 
intranasal and orally inhaled formulations.  Inhaled budesonide in combination with 
formoterol fumarate dehydrate, i.e., Symbicort is approved for use in patients with COPD. 
Glycopyrronium is a LAMA which exerts its bronchodilatory effect via muscarinic receptors 
located on smooth muscle cells within the trachea and bronchi. Glycopyrronium is approved 
in many countries in multiple formulations for different indications, including for the 
treatment of COPD.  In addition, tiotropium bromide (Spiriva®) is approved worldwide as a 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 28 of 194
powder for inhalation.  It has been shown to reduce the rate of COPD exacerbations and to 
improve the effectiveness of pulmonary rehabilitation (Niewoehner, 2005; Casaburi, 2005).
Formoterol fumarate is a selective LABA approved worldwide for use in asthma and COPD.  
Formoterol fumarate is also approved worldwide in combination with budesonide (e.g., 
Symbicort® MDI, Symbicort® Turbuhaler® (TBH [AstraZeneca, LP]) for use in patients with 
asthma and COPD.  When inhaled, formoterol fumarate acts locally in the lung as a 
bronchodilator. Formoterol fumarate stimulates ȕ2-adrenoreceptors in the airways, inducing 
airway smooth muscle relaxation and reducing or preventing bronchoconstriction.
In clinical studies, Symbicort MDI 320/9 g administered BID demonstrated significant 
improvements in lung function compared with Budesonide MDI 320 g BID, formoterol 
fumarate (Oxis® Turbuhaler) 9 g BID, or placebo, in patients with COPD.  In the clinical 
studies, improvements in secondary endpoints of morning and evening peak expiratory flow 
and reduction in rescue medication use were supportive of the efficacy of Symbicort MDI 
320/9 g (Rennard, 2009; Tashkin, 2008).
The GOLD guidelines suggest a stepwise approach to the management of COPD.  For 
patients, with few symptoms and a low risk of exacerbations (Group A), a short-acting 
bronchodilator is recommended.  Long-acting bronchodilators, such as long acting ȕ2
agonists (LABAs) and long acting muscarinic antagonists (LAMAs) are recommended for 
patients with more significant symptoms, but a low risk of exacerbation (Group B).  For 
patients with severe breathlessness, the alternative choice is a combination of long-acting 
bronchodilators.  In patients that have few symptoms, but a high risk of exacerbations 
(Group C), the first choice of therapy is a fixed combination of an inhaled corticosteroid 
(ICS)/LABA or a LAMA.  In patients with many symptoms, and a high risk of exacerbations 
(Group D), the first choice is an ICS/LABA or LAMA; with some evidence for a further 
reduction in exacerbations with triple therapy (i.e., ICS/LABA/LAMA); however, further 
studies of triple therapy are needed [GOLD, 2014].  Note that administration of triple therapy 
requires the use of at least two separate inhalers, and that all three products are not available 
in a single metered dose inhaler (MDI) or dry powder inhaler (DPI).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 29 of 194
1.1
Study Rationale
BGF MDI is a novel, fixed-dose, triple combination MDI product formulated with 
budesonide, glycopyrronium, and formoterol fumarate for use in subjects with COPD.  As 
described in the GOLD COPD guidelines, in some patients, the addition of a LABA/ICS to a 
LAMA improves lung function, quality of life, and may further reduce exacerbations.  For 
patients categorized in Group D (those with severe or very severe disease, many symptoms, 
and high risk of exacerbations), the first choice of treatment is an ICS/LABA or LAMA, with
some evidence for a further reduction in exacerbations with triple therapy; however, further 
studies of triple therapy are needed [GOLD, 2014].  Pearl is conducting this study to evaluate 
the treatment effect of BGF MDI (LABA/ICS/LAMA therapy) relative to GFF MDI 
(LAMA/LABA therapy) and BFF MDI (ICS/LABA therapy) on the rate of moderate or 
severe COPD exacerbations over a 52-week treatment period in subjects with moderate to 
very severe COPD who have a history of COPD exacerbations.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 30 of 194
2
STUDY OBJECTIVES
2.1
Primary Objective
•
To assess the effect of BGF MDI relative to GFF MDI and BFF MDI on the rate of 
moderate or severe COPD exacerbations
2.2
Secondary Objectives
•
To assess the effect of BGF MDI relative to GFF MDI and BFF MDI on symptoms of 
COPD
•
To assess the effect of BGF MDI relative to GFF MDI and BFF MDI on quality of life
•
To assess the effect of BGF MDI relative to GFF MDI and BFF MDI on all-cause mortality
•
To assess the effect of BGF MDI relative to GFF MDI and BFF MDI on COPD 
exacerbations
2.3
Safety Objective
•
To assess the safety of BGF MDI relative to GFF MDI and BFF MDI
2.4
4-Hour Pulmonary Function Test Sub-Study Objective
•
To assess the effect of BGF MDI relative to GFF MDI and BFF MDI on lung function
2.5
24-Hour Holter Monitoring Sub-study Objective
•
To evaluate the cardiovascular safety of BGF MDI, GFF MDI, and BFF MDI as evaluated 
by 24-hour Holter monitoring
2.6
Health Care Resource Utilization Objective
•
To assess overall and COPD-specific Healthcare Resource Utilization of BGF MDI, GFF 
MDI, and BFF MDI

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 31 of 194
3
STUDY ENDPOINTS
3.1
Efficacy Endpoints
3.1.1
Primary Endpoint
•
Rate of moderate or severe COPD exacerbations
3.1.2
Secondary Endpoints
Secondary endpoints that differ between approaches (US vs. ex-US) are indicated in 
parentheses. Endpoints which are not considered secondary for either regulatory approach 
have been included under other efficacy endpoint.
•
Time to first moderate or severe COPD exacerbation
•
Change from baseline in average daily rescue Ventolin HFA use over 24weeks
•
Transition Dyspnea Index (TDI) focal score over 24 weeks (ex-United States [US] 
[ex-US])
•
Change from baseline in the Exacerbations of Chronic Pulmonary Disease Tool –
(EXACT) total score over 52 weeks (ex-US)
•
Change from baseline in St. George’s Respiratory Questionnaire (SGRQ) total score over 
24 weeks (ex-US)
•
Percentage of subjects achieving an MCID of 4 units or more in SGRQ total score at Week 
24 (US)
•
Time to death (all cause)
•
Rate of severe COPD exacerbations
3.1.3
Other Efficacy Endpoints
Wherever stated, analyses of an endpoint at each post-randomization visit will only be 
performed at time points where the endpoint will be assessed per the schedule of 
assessments.
•
Rate of COPD exacerbations of any severity
•
Time to first COPD exacerbation of any severity
•
Time to first severe COPD exacerbation
•
Change from baseline in average daily rescue Ventolin HFA use over 52 weeks
•
Time to death (respiratory)
•
Time to treatment failure (treatment discontinuation for any cause, moderate or severe 
exacerbation, or death)

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 32 of 194
•
Change from baseline in: the EXACT total score, the EXACT Respiratory Symptoms 
(E-RS) total score over 24 weeks, over 52 weeks, and over each 4-week interval of the 
52-week treatment period
•
Percentage of days with “no rescue Ventolin HFA use”
•
TDI focal score over 24 weeks (US), over 52 weeks, and at each post-randomization visit
•
Percentage of subjects achieving an MCID threshold of 1 unit or more on average over 24 
weeks in TDI focal score
•
Percentage of subjects achieving an MCID threshold of 1 unit or more on average over 52 
weeks in TDI focal score
•
Change from baseline in SGRQ total score over 52 weeks, and at each post-randomization 
visit
•
Percentage of subjects achieving an MCID of 4 units or more in SGRQ total score over 52 
weeks, at Week 52, and over 24 weeks
•
EuroQol 5 Dimensions Questionnaire (EQ-5D-5L) variables including the EQ-5D index 
score, the EQ-5D Visual Analog Score (VAS), and each of the five-dimension single item 
5-level responses at each post-randomization visit. 
3.2
Safety Endpoints
•
Adverse events (AEs)
•
12-lead electrocardiograms (ECGs)
•
Clinical laboratory testing
•
Vital sign measurements
3.3
Sub-Study Endpoints
3.3.1 4-Hour Pulmonary Function Test Sub-Study Endpoints 
The primary PFT endpoints are:
•
Change from baseline in morning pre-dose trough FEV1 at Week 24 (US) and over 
24 weeks (ex-US) for the comparison of BGF MDI to GFF MDI
•
FEV1 area under the curve from 0 to 4 hours (AUC0-4) at Week 24 (US) and over 24 weeks 
(ex-US) for the comparison of BGF MDI to BFF MDI
Other PFT Sub-Study Endpoints:
•
Change from baseline in morning pre-dose trough FEV1 over 24 weeks, over Weeks 12 to 
24, over 52 weeks and at each post-randomization visit

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 33 of 194
•
FEV1 AUC0-4 over 24 weeks, over Weeks 12 to 24, over 52 weeks and at each 
post-randomization visit where measured
•
Peak change from baseline in FEV1 over 24 weeks, over Weeks 12 to 24, over 52 weeks 
and at each post-randomization visit where measured
•
Rate of decline in pre-dose FEV1 over 52 weeks
•
Rate of decline in FEV1 AUC0-4 over 52 weeks
•
Time to onset of action on Day 1
3.3.2
24-Hour Holter Monitoring Sub-Study Endpoints Assessed at Visit 8 
(Week 16) 
3.3.2.1
Primary 24-Hour Holter Monitoring Sub-Study Endpoints Endpoint
•
Change from baseline in mean heart rate averaged over 24 hours
3.3.2.2
Secondary 24-Hour Holter Monitoring Sub-Study Endpoints 
• Change from baseline in mean nighttime (22:00 to 06:00) and daytime (06:00 to 22:00) 
heart rate
• Change from baseline in the maximum 24-hour heart rate
•
Change from baseline in the minimum 24-hour heart rate
•
Change from baseline in the frequency of isolated ventricular ectopic events (including a 
single premature ventricular contraction [PVC])
•
Change from baseline in the frequency of ventricular couplets (defined as two PVCs 
preceded or followed by regular beats)
•
Change from baseline in the frequency of ventricular runs (defined as three or more PVCs 
preceded or followed by regular beats)
•
Change from baseline in the frequency of supraventricular ectopic beats
•
Change from baseline in the frequency of isolated supraventricular ectopic events
•
Change from baseline in the frequency of supraventricular couplets
•
Change from baseline in the frequency of supraventricular runs
•
Incidence of withdrawal criteria being met during 24-hour Holter monitoring
•
Incidence of atrial fibrillation with rapid ventricular response (>100 beats per minute 
[bpm])

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 34 of 194
3.3.3
Other Endpoints:
•
Proportion of subjects with maximum heart rate >180, >160-180, >140-160, >120-140,
>100-120, and 100 bpm or less
•
Proportion of subjects with minimum heart rate >60, >50-60, >40-50, and 40 bpm
•
Proportion of subjects in each category of change from baseline in the number of PVCs 
per hour (no change, increase of >0-<60, 60-<120, and 120, and decrease of >0-<60, 60-
<120, and 120)
3.4
Health Care Resource Utilization Endpoints
•
The number of days missed work due to COPD
•
The number of days that primary caregivers of subjects missed from work as a result of the 
subject’s COPD 
•
The percentage of subjects with telephone calls to health care providers
o
Calls to any health-care provider (physician or other)
o
Calls to physician
o
Calls to other healthcare provider
•
The mean number of telephone calls to health care providers
o
Calls to any health-care provider (physician or other)
o
Calls to physician
o
Calls to other healthcare provider
•
The percentage of subjects with visits to health care providers
o
Visits to any health-care provider (general practitioner [GP], specialist, or other)
o
Visits to GP
o
Visits to specialist
o
Visits to other healthcare provider
•
The mean number of visits to health care providers
o
Visits to any health-care provider (GP, specialist, or other)
o
Visits to GP
o
Visits to specialist
o
Visits to other healthcare provider
•
The percentage of subjects with Emergency Room (ER) visits
•
The mean number of visits to ERs
•
The percentage of subjects hospitalized
•
The mean number of subject hospitalizations 
•
The mean number of days in the hospital

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 35 of 194
•
The mean number of hospitalizations in which subject spent some time in the Intensive 
Care Unit (ICU) or the Coronary Care Unit (CCU)
•
The percentage of subjects hospitalized with some time spent in the ICU or CCU
•
The mean number of days in the hospital with some time spent in the ICU or CCU
•
The mean number of hospitalizations in which subject spent no time in the ICU or the CCU
•
The percentage of subjects hospitalized with no time in the ICU or CCU
•
The mean number of days in the hospital with no time spent in the ICU or CCU
•
The mean number of days in Intensive Care Units (ICU)
•
The percentage of subjects in the Intensive Care Unit (ICU)
•
The mean number of days in Coronary Care Units (CCU)
•
The percentage of subjects in the Coronary Care Units (CCU)
x
The percentage of subjects who required ambulance transport
x
The mean number of times ambulance transport was required
4
INVESTIGATIONAL PLAN
4.1
Overall Study Design and Plan
This is a randomized, double-blind, multi-center, parallel group study to assess the efficacy 
and safety of BGF MDI 320/14.4/9.6 g and BGF MDI 160/14.4/9.6 g relative to 
GFF MDI 14.4/9.6 g and BFF MDI 320/9.6 g over a 52-week treatment period in 8,400
subjects with moderate to very severe COPD with an increased risk of experiencing a COPD 
exacerbation and that remain symptomatic (CAT  10) on two or more inhaled maintenance 
treatments. 
To be considered eligible for the study, subjects must have documented history of COPD 
exacerbation(s). Subjects with a post-bronchodilator FEV1 < 50% of predicted normal are 
required to have  1 moderate or severe COPD exacerbation in the 12 months prior to 
Screening (Visit 1). Subjects with a post-bronchodilator FEV1  50% of predicted normal are 
required to have  2 moderate exacerbations or  1 severe COPD exacerbation (hospitalized) 
in the 12 months prior to Screening (Visit 1). In addition, post-bronchodilator FEV1 obtained 
at Visit 2 must be  25% and < 65% of the predicted normal value calculated using 
appropriate reference equations.  

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 36 of 194
At Visit 1 (Screening), all subjects are to sign an Informed Consent Form (ICF) prior to the
conduct of any screening assessments. The Investigator will evaluate subjects to determine
eligibility for participation (i.e., inclusion/exclusion criteria). Subjects who screen fail due to 
spirometry criteria will not be allowed to re-screen. Providing the subject meets the eligibility 
criteria, the Investigator or designee will review current COPD medications and, if necessary, 
will make arrangements to adjust the prohibited COPD therapy to protocol-allowable COPD 
therapy as described in Section 5.4.
All subjects will undergo a Screening Period of 1 to 4 weeks in duration and will receive 
sponsor-provided open-label Atrovent® hydrofluoroalkane (HFA; ipratropium bromide 
inhalation aerosol) administered QID for maintenance during Screening.  All subjects will 
receive sponsor-provided Ventolin® HFA (albuterol sulfate inhalation aerosol) for rescue use 
throughout the study.
During the screening period subjects that are receiving an ICS/LABA will discontinue the 
ICS/LABA but will continue the ICS component for the remainder of the screening period.   
All subjects will receive sponsor-provided open-label Atrovent® hydrofluoroalkane (HFA; 
ipratropium bromide inhalation aerosol) administered QID for COPD maintenance. All 
subjects will receive sponsor-provided Ventolin® HFA (albuterol sulfate inhalation aerosol) 
for rescue use throughout the study. NOTE: ICS and Atrovent HFA administered during 
screening will be discontinued at Visit 4 prior to randomization.
In instances where a moderate or severe exacerbation has occurred during the Screening 
Period, the Screening Period may be extended to a maximum of 10 weeks (to account for a 
course of oral corticosteroids [OCS] of up to 2 weeks in duration and a 4-week period after 
treatment for exacerbation) without the need to repeat completed visits.
In order to allow for an adequate washout of previous maintenance medications, subjects will 
undergo a Washout Period of at least 1 week (at least 2 weeks if taking Spiriva), but not 
greater than 26 days in duration prior to returning to the clinic for Visit 2.
Subjects will be issued and trained on an electronic diary (eDiary) use at Screening (Visit 1)
and will be instructed to collect practice data during the Screening Period (between Visit 1 
and Visit 4). Subject eDiary compliance will be reviewed at Visits 2 and 3, and the subject 
will be retrained if necessary.
Reversibility to a SABA and to a SAMA will be tested on two separate test days.  At Visit 2,
reversibility to Ventolin HFA (SABA) will be evaluated (see Section 7.1.1.1).  The 
spirometry data obtained at Visit 2 will be used as an inclusion criterion (Section 5.1).  In 
addition, at Visits 1and 4, the burden of disease will be assessed through the COPD 
Assessment Test (CAT).  Subjects will complete the CAT at Screening (Visit 1) and this 
assessment will be used as an entry criterion. Subjects will also complete the CAT at 
Randomization (Visit 4) to characterize the population on maximal therapy.  Subject eDiary 
compliance will be reviewed, and the subject will be retrained, if appropriate (See Section 
7.1.2).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 37 of 194
At Visit 3, reversibility to Atrovent HFA (short-acting muscarinic antagonist) will be 
evaluated (see Section 7.1.1.1).  The spirometry data obtained at this visit will not be used as 
an entry criterion but will be used to characterize the population.  Subject eDiary compliance 
will be reviewed, and the subject will be retrained, if appropriate. 
This study includes 2 sub-studies, a PFT sub-study, and a 24-hour Holter Monitoring sub-
study.  A subset of sites will be identified and designated for participation in the PFT and 24-
Hour Holter monitoring sub-studies. Individual subjects will be allowed to participate in both 
sub-studies. 
A subset of approximately 3,060 subjects (765 subjects per treatment arm) at designated 
study sites will be invited to participate in the PFT sub-study. In these subjects, serial PFTs 
will be conducted over 4 hours at selected visits throughout the 52-week Treatment Period
(see Section 7.1.1 and Table 8-1 for selected visits and collection times). PFT sub-study 
subjects will be required to meet FEV1 baseline stability criteria (the baseline FEV1 at Visit 4 
must be within ±20% or 200 mL of mean of the pre-dose FEV1 values obtained at the two 
preceding visits; see Section 7.1.2.2) to be eligible for PFT sub-study participation. Those 
subjects who do not meet FEV1 Baseline Stability criteria will not be permitted to participate 
in the PFT sub-study but will be permitted to participate in the main study providing they 
satisfy all other eligibility criteria. While the PFT sub-study was previously open to all 
eosinophil levels, now only subjects who have a blood eosinophil level of 
 150 cells per mm3 at Visit 1 will be permitted to participate in the PFT sub-study.
Subjects who successfully complete the Screening Period will then be randomized in a 
1:1:1:1 scheme to BGF MDI 320/14.4/9.6 g BID, BGF MDI 160/14.4/9.6 g BID, 
BFF MDI 320/9.6 g BID, or GFF MDI 14.4/9.6 g BID, respectively.  
Approximately 2,100 subjects will be randomized to each treatment arm. Randomization will 
be stratified by exacerbation history (1 or  2 moderate or severe exacerbations), 
post-bronchodilator FEV1 (25% to <50% or 50% to 65% predicted), blood eosinophil count 
(<150 cells per mm3 or 150 cells per mm3), and country. Up to a 1:2 ratio for the blood 
eosinophil strata was targeted with twice as many randomized subjects in the 
 150 cells per mm3 category. 
Following randomization, subjects will enter the Treatment Period and undergo 5 additional 
in-clinic treatment visits and 6 telephone call visits over 52 weeks. 
At Visit 4 (Randomization Visit; Treatment Day 1), subjects eDiary compliance will be 
reviewed. Subjects who are unable to meet the compliance requirement (>70% subject 
completion of eDiary assessments) in the last 7 days preceding the Randomization Visit will 
be screen failed (refer to Section 7.1.2). All Sponsor-provided medications provided during 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 38 of 194
the Screening Period will be discontinued and collected by site personnel for accountability.  
See Section 8 for details of the assessments to be performed at each of these visits. 
A subset of approximately 800 subjects (200 subjects from each treatment group) at 
designated study sites will be invited to participate in the 24-Hour Holter Monitor sub-study.  
In these subjects, a 24-hour Holter monitor will be collected between Visit 3 and Visit 4 
(Holter Monitor Baseline) and Visit 8 (Week 16). Those subjects who do not satisfy the 
baseline 24-hour Holter Monitor Sub-study eligibility criteria will be screen failed and will 
not be eligible to re-screen (See Section 7.2.5).
Throughout the course of the study the subjects will be required to complete the following 
questionnaires; Baseline Dyspnea Index/Transition Dyspnea Index (BDI/TDI) , St. George’s
Respiratory Questionnaire (SGRQ), EuroQol 5 Dimensions Questionnaire (EQ-5D-5L), 
Chronic Obstructive Pulmonary Disease Assessment Test  (CAT) and Exacerbations of 
Chronic Pulmonary Disease Tool – Patient Reported Outcomes (EXACT) (see Section 8 for 
details and timing of the assessments).  Site will be requested to complete HCRU 
questionnaire throughout the study (see Section 8 for details and timing of the assessments). 
Subjects who discontinue study treatment prior to Week 52 (Visit 14) will be encouraged to 
remain in the study to complete all remaining study visits during the 52-week treatment 
period. Subjects who agree to continue to be followed post treatment discontinuation will
sign an ICF addendum. All subjects who agree to continue study participation beyond 
treatment discontinuation will complete a Treatment Discontinuation Visit (refer to Sections
8.9 and 8.10) prior to transitioning back to regularly scheduled study visits. Subjects 
participating in the Holter Monitoring sub-study who discontinue from treatment will only 
complete regularly scheduled visits and not complete any remaining Holter sub-study 
assessments, however subjects participating in the PFT sub-study will continue with serial 
PFTs. Treatment discontinuation subjects will return to appropriate maintenance COPD 
medications, per the investigator’s discretion. For subjects recorded as Treatment 
Discontinuations that do not complete at least one post-treatment data collection a telephone 
follow-up call is required at least 14 days after last study drug dose and vital status must be 
captured at 52 weeks post randomization.
If a subject chooses not to continue with study assessments, at a minimum the subject will 
complete the Treatment Discontinuation/Withdrawal Visit (refer to Table 8). These subjects 
will return to appropriate maintenance COPD medications, per the investigator’s discretion.
A follow-up telephone call will be performed at least 14 days after the last study drug dose. 
In the event the Treatment Discontinuation/Withdrawal Visit is performed >14 days post last 
study drug dosing; a follow-up phone call will not be required. These subjects will be 
followed for vital status at 52 weeks post randomization in accordance with the informed 
consent.
Further details will be provided in the Statistical Analysis Plan (SAP).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 39 of 194
General Considerations for Treatment Visits 4 through 14 
•
Subjects that are randomized will be instructed to discontinue Atrovent HFA and ICS used 
during the screening period, and only use sponsor-provided inhaled study medications for 
the remainder of the study.
•
At the start of each study visit, prior to any study procedures being performed, site 
personnel must confirm the subject withheld all COPD medications, including study 
medication, rescue Ventolin HFA or locally available product (where necessary), for at
least 6 hours, by confirming the last time of dosing for all COPD medication(s).  
•
Note: Subjects who inadvertently took COPD medication(s) within 6 hours of the start of 
study procedures must be rescheduled as soon as is practical but within the specified visit 
window.  In addition, before the in-clinic dose is administered, the site must confirm the 
subject met all other protocol specified requirements (e.g., FEV1 baseline stability and 
eDiary compliance).
•
Subjects not participating in the PFT sub-study will be required to return to the clinic 
approximately the same time as Visit 4 for all treatment visits (± 2 hours) but not to exceed 
12:00 PM and will be required to remain at the clinic until completion of all 
protocol-defined assessments.
•
The in-clinic dosing time for study drug (BGF MDI, GFF MDI, and BFF MDI) will be 
recorded as the time of administration of the second puff.
•
All post-randomization visits will be scheduled relative to Visit 4 (Day 1).  Thus Visit 5,
will be scheduled 4 weeks ±2 days of Visit 4, and Visits 6, 7, 8, 9, 10, 11, 12, 13, and 14 
will be scheduled 8, 12, 16, 20, 24, 28, 36, 44 and 52 weeks ±5 days of Visit 4,
respectively.  Sites should make every effort to maintain subjects within the scheduled visit 
window.  If a visit falls outside the expected visit window the subsequent visit should still 
be scheduled as planned relative to Visit 4. 
4-Hour PFT Sub-study Subjects only
•
At the start of each study visit, prior to any study procedures being performed, site 
personnel must confirm the subject withheld all COPD medications, including study 
medication, rescue Ventolin HFA or locally available product (where necessary), for at
least 6 hours, by confirming the last time of dosing for all COPD medication(s).
Note: Subjects who inadvertently took COPD medication(s) within 6 hours of the start of 
study procedures must be delayed (but not to exceed dosing by 10am) or rescheduled within 
the specified visit window.  
•
Subjects enrolled in the PFT sub-study must not ingest xanthine and/or xanthine analogue 
(caffeine)-containing foods, beverages or caffeine containing medications for at least 
6 hours prior to each study visit and for the duration of each study visit.  Examples of such 
products include coffee, tea, chocolate, and cola.  Decaffeinated beverages are acceptable. 
Subjects will be required to refrain from smoking (nicotine gums or patches are allowed) 
for at least 4 hours prior to each study visit and throughout the duration of each study visit.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 40 of 194
•
In order to minimize diurnal variance, sites should make every effort to assess subjects at 
the same time throughout the study and to discuss the importance of dosing in a timely 
manner every 12 hours.
•
Subjects participating in the PFT sub-study will be required to return to the clinic at 
approximately the same time as Visit 4 for all treatment visits (± 2 hours), All in-clinic 
dosing must occur prior to 10 AM; timing of visits must be planned accordingly. The
subjects will be required to remain at the clinic until completion of all protocol-defined
assessments.
•
To ensure standardization of dosing times, it is recommended that sites encourage subjects 
to maintain a dosing schedule consistent with their in-clinic dosing time and that sites call 
the subject on the day before a scheduled visit to remind the subject of the following:
•
To take their last dose the evening before the scheduled visit;
•
To bring their study medications and eDiary with them to the clinic and to withhold all 
COPD medications (locally available products, if applicable) for at least 6 hours prior to
PFTs;
•
To refrain from ingesting xanthine (caffeine)-containing foods and beverages for at least 
6 hours prior to each study visit and for the duration of each study visit;
•
To refrain from smoking for at least 4 hours prior to the study visit and throughout
the duration of each study visit.
•
Site personnel will instruct subjects not to take any COPD medications, without site 
personnel permission, during a visit until all study procedures have been completed, and 
the subject is discharged.  Site personnel should take every precaution to prevent subject 
use of COPD medications during the test day.  Site personnel may request the subject to 
surrender all COPD medications prior to the start of the visit before performing any study 
procedures and return the COPD medications to the subject at the end of the visit when all 
study procedures are completed.  Subjects will be asked to abstain wherever possible from 
using rescue Ventolin HFA during study visits.  If a subject is experiencing severe 
symptoms and requires Ventolin® HFA for relief of COPD symptoms at any time during a 
test day, site personnel must note the time and justification of use in the subject’s chart and 
all subsequent spirometry assessments should be stopped.  However, safety assessments 
should be continued at the discretion of the Investigator.
The overall study design is summarized and illustrated in Figure 1.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 41 of 194
Figure 1. Study Design
Abbreviations:  BFF=Budesonide and Formoterol Fumarate; BGF=Budesonide, Glycopyrronium, and Formoterol Fumarate; 
GFF=Glycopyrronium and Formoterol Fumarate; BD=Bronchodilator, MDI=metered dose inhaler
4.2
Rationale of Study Design
BGF MDI is a novel, fixed-dose triple combination MDI product formulated with 
budesonide, glycopyrronium, and formoterol fumarate for treatment of subjects with COPD.  
As described in the GOLD COPD guidelines, in some patients, the addition of a LABA/ICS 
to a LAMA improves lung function, quality of life, and may further reduce exacerbations.  
For patients categorized in Group D (those with severe or very severe disease, many 
symptoms, and high risk of exacerbations), the first choice of treatment is an ICS/LABA or 
LAMA, with some evidence for a further reduction in exacerbations with triple therapy; 
however, further studies of triple therapy are needed [GOLD, 2014]. 
This study is designed to evaluate the treatment effect of BGF MDI (LABA/ICS/LAMA 
therapy) relative to GFF MDI (LAMA/LABA therapy) and BFF MDI (ICS/LABA therapy) 
on the rate of moderate or severe COPD exacerbations over a 1-year treatment period in 
subjects with moderate to very severe COPD, who have a history of COPD exacerbations.  
To that end, this study will assess the long-term (52 weeks) efficacy and safety of BGF MDI 
at doses of 320/14.4/9.6 g and 160/14.4/9.6 g relative to GFF MDI 14.4/9.6 g and 
BFF MDI 320/9.6 g, all administered BID, on the rate of moderate or severe COPD 
exacerbations in subjects with a history of previous COPD exacerbations.
Consistent with this objective, this study will evaluate a patient population that remains 
symptomatic despite treatment with 2 or more inhaled maintenance medications.  Subjects 
with a post-bronchodilator FEV1 <50% of predicted normal must have a documented history 
of   1 moderate or severe COPD exacerbation in the previous 12 months. Subjects with a 
post-bronchodilator FEV1  50% of predicted normal must have a documented history of  2 
moderate exacerbations or a documented history of 1 severe COPD exacerbation in the 12 
months prior to Screening (Visit 1).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 42 of 194
A randomized, double-blind, parallel group design was adopted in order to minimize bias in 
treatment allocation and to allow unbiased comparisons of treatment groups.
4.3 Rationale of Dose/Regimen and Duration of Treatment
The safety and efficacy of the individual components, budesonide, glycopyrronium, and 
formoterol fumarate are well characterized, and all 3 components are components (alone or 
in combination) of approved inhalation products for the treatment of patients with COPD.
The doses of the glycopyrronium and formoterol fumarate components of BGF MDI and 
BFF MDI match the doses utilized in the GFF MDI development program.  
 
 
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 43 of 194
Note: The End of Study is defined as the date on which data are collected for the last 
subject’s Follow-up Telephone Call.
5
STUDY POPULATION SELECTION AND WITHDRAWAL 
CRITERIA
5.1
Inclusion Criteria
Each subject must meet the following criteria to be enrolled in this study.
1. Give their signed written informed consent to participate.
2. Are at least 40 years of age and no older than 80 years at Visit 1.
3. A female is eligible to enter and participate in the study if she is of:
a.
Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, 
including any female who is 2 years post-menopausal)
b.
Childbearing potential has a negative serum pregnancy test at Visit 1, and agrees to 
one of the following acceptable contraceptive methods used consistently and correctly 
as outlined below (i.e., in accordance with the approved product label and the 
instructions of the physician for the duration of the study – from Visit 1 (Screening) 
until 14 days after the Final Visit):
-
Complete abstinence from intercourse (when it is preferred and usual lifestyle of the 
patient); or
-
Implants of levonorgestrel inserted for at least 1 month prior to the study drug
administration but not beyond the third successive year following insertion; or

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 44 of 194
-
Injectable progestogen administered for at least 1 month prior to study drug 
administration; or
-
Oral contraceptive (combined or progestogen only) administered for at least one 
monthly cycle prior to study drug administration; or
-
Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) 
plus spermicidal agent (foam/gel/film/cream/suppository); or
-
An intrauterine device, inserted by a qualified physician, with published data showing 
that the highest expected failure rate is less than 1% per year; or
-
Estrogenic vaginal ring; or
-
Percutaneous contraceptive patches.
-
Note: The acceptable contraceptive methods listed above are subject to locally 
approved contraceptive methods.
4. COPD Diagnosis: Subjects with an established clinical history of COPD as defined by the 
American Thoracic Society (ATS)/European Respiratory Society (ERS) [Celli, 2004] or by 
locally applicable guidelines, e.g., JRS Guidelines [JRS, 2013] characterized by:
-
Progressive airflow limitation associated with an abnormal inflammatory response of 
the lungs to noxious particles or gases, primarily caused by cigarette smoking. 
5. Tobacco Use: Current or former smokers with a history of at least 10 pack-years of 
cigarette smoking.  [Number of pack-years = (number of cigarettes per day / 20) x number 
of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 
20 years represent 10 pack-years)]. 
6. COPD Severity: Subjects with an established clinical history of COPD and severity defined
as:
-
At Visit 1, FEV1/FVC ratio must be <0.70 and FEV1 must be <65% predicted
normal value calculated using NHANES III reference equations (Or reference norms 
applicable to other regions, e.g., for Japan, use JRS reference equations; [JRS, 
2013]).
-
At Visit 2, post-bronchodilator FEV1/FVC ratio of <0.70 and post-bronchodilator 
FEV1 must be 25% to <65% predicted normal value, calculated using NHANES III
reference equations (Or reference norms applicable to other regions, e.g., for Japan, 
use JRS reference equations [JRS, 2013])
-
At Visit 4, the average of the -60 min and -30 min pre-dose FEV1 assessments must 
be <65% predicted normal value, calculated using NHANES III reference equations
(Or reference norms applicable to other regions, e.g., for Japan, use JRS reference 
equations [JRS, 2013]). Note: This criterion applies to subjects in the PFT sub-study 
only
Symptomatic (CAT 10) at Screening (Visit 1).
7. Required COPD Maintenance Therapy: 
-
All Subjects must have been on two or more inhaled maintenance therapies for the 
management of their COPD for at least 6 weeks prior to Screening.  Scheduled SABA 
and/or scheduled SAMA are considered inhaled maintenance therapies. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 45 of 194
8. History of Exacerbations: 

Subjects with a post-bronchodilator FEV1 <50% of predicted normal must have a 
documented history of  1 moderate or severe COPD exacerbation in the 12 months 
prior to Screening (Visit 1). 

Subjects with a post-bronchodilator FEV1  50% of predicted normal must have a 
documented history of  2 moderate exacerbations or a documented history of 1 
severe COPD exacerbation in the 12 months prior to Screening (Visit 1).
Note:  
Prior use of antibiotics and/or oral corticosteroids alone does not qualify as a COPD 
exacerbation history unless the use was associated with treatment of worsening 
symptoms of COPD (e.g. increased dyspnea, increased sputum volume, or a change 
in sputum purulence (color)).  Subject verbal reports are not acceptable. 
- Antibiotics or corticosteroids used for the treatment of URI with no lower 
respiratory symptoms do not qualify for the treatment of COPD exacerbation.
9. Subject is willing and, in the opinion of the investigator, able to adjust current COPD 
therapy, as required by the protocol.
10. Screening clinical laboratory tests must be acceptable to the Investigator.
11. Screening ECG must be acceptable to the Investigator.
12. Chest x-ray or computed tomography (CT) scan of the chest/lungs within 6 months prior to 
Visit 1 must be acceptable to the Investigator. Subjects who have a chest x-ray that reveals 
clinically significant abnormalities not believed to be due to the presence of COPD should 
not be included. A chest x-ray must be conducted if the most recent chest x-ray or CT scan 
are more than 6 months old at the time of Visit 1 except in countries with restrictive 
radiology assessment practice where only subjects who have had a chest x-ray or CT scan 
(thorax) performed outside of the study in the last 6 months are allowed to be enrolled. 
Alternatively, in these countries, an MRI may be used instead of a CT scan or chest x-ray 
as per local practice assessment.
13. Compliance: Subjects must be willing to remain at the study center as required per protocol 
to complete all visit assessments.
5.2
Exclusion Criteria
Subjects who meet any of the following criteria will be excluded from the study.
1. Significant diseases or conditions other than COPD, which, in the opinion of the 
Investigator, may put the subject at risk because of participation in the study or may 
influence either the results of the study or the subject’s ability to participate in the study.
2. Women who are pregnant or lactating or are planning to become pregnant during the 
course of the study, or women of childbearing potential who are not using an acceptable 
method of contraception.
3. Respiratory:
a.
Asthma: Subjects, who in the opinion of the Investigator, have a current diagnosis 
of asthma. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 46 of 194
b. Alpha-1 Antitrypsin Deficiency: Subjects who have alpha-1 antitrypsin deficiency 
as the cause of COPD.
c.
Other Respiratory Disorders: Subjects who have other active pulmonary disease 
such as active tuberculosis, lung cancer, significant bronchiectasis (high resolution 
CT evidence of bronchiectasis that causes repeated acute exacerbations), 
sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary 
hypertension, or uncontrolled sleep apnea (i.e., in the opinion of the Investigator 
severity of the disorder would impact the conduct of the study).  Note: Allergic 
rhinitis is not exclusionary.
d. Lung Volume Reduction: Subjects who have undergone lung volume reduction 
surgery, lobectomy or bronchoscopic lung volume reduction (endobronchial 
blockers, airway bypass, endobronchial valves, thermal vapor ablation, biological 
sealants, and airway implants) within 6 months of Visit 1.
e.
Hospitalization: Subjects who have been hospitalized due to poorly controlled
COPD within 6 weeks prior to Visit 1 (Screening) with less than a 4-week washout
of corticosteroids and/or antibiotics prior to Visit 1 (Screening).
f.
Poorly Controlled COPD: Subjects who have poorly controlled COPD, defined
as acute worsening of COPD that requires treatment with oral corticosteroids
or antibiotics within 6 weeks prior to Visit 1 (Screening) with less than a 4-week
washout of corticosteroids and/or antibiotics prior to Visit 1 (Screening). 
g.   Lower Respiratory Tract Infection: Subjects who had lower respiratory tract
infections that required antibiotics within 6 weeks prior to Visit 1 (Screening) with 
less than a 4-week washout of antibiotics prior to Visit 1 (Screening).
h. Other Respiratory tract infections (e.g., upper respiratory tract infection) that have 
not resolved at least 7 days prior to Screening.
i.
Chest x-ray (frontal and lateral) with suspicion of pneumonia or other 
condition/abnormality that will require additional investigation/treatment or put the 
subject at risk because of participation in the study.
j.
Risk factors for pneumonia: immune suppression (HIV) severe neurological 
disorders affecting control of the upper airway or other risk factors that in the 
opinion of the Investigator would put the subject at substantial risk of pneumonia.
k. Pneumonia not clinically resolved within 14 days of Visit 1.
l.
Spirometry Performance: 
•
Acceptability: Subjects who cannot perform acceptable spirometry (i.e., meet 
ATS/ERS acceptability criteria)
•
Repeatability:  Subjects who cannot perform technically acceptable spirometry 
with at least 3 acceptable flow-volume curves with 2 or more meeting ATS
repeatability criteria for FEV1 during at least 1 of the pre-bronchodilator
assessments at Visit 2 (-60 minute or -30 minute) and at the post-bronchodilator 
assessment at Visit 2.
NOTE: Subjects who have met all of the inclusion criteria but have failed 
to meet acceptability or repeatability criteria at Visit 1, may continue to 
Visit 2.  Provided these subjects meet all spirometry criteria at Visit 2,
including acceptability and repeatability, they are eligible for inclusion in 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 47 of 194
the main study, but they are excluded from participating in the PFT sub-
study.  Subjects who fail to meet acceptability and repeatability criteria at 
Visit 2 must be screen failed.
•
FEV1 Baseline Stability (for PFT sub-study only):  Subjects who cannot meet 
protocol-specified baseline stability criteria.  FEV1 baseline stability is defined 
as the average of the -60 minute and -30-minute pre-dose FEV1 assessments at 
Visit 4 being within ±20% or 200 mL of the mean of the pre-bronchodilator 
FEV1 assessments obtained at the 2 preceding visits (average of pre-dose FEV1
assessments obtained at Visit 2 and Visit 3).
m. Oxygen: Subjects receiving long-term-oxygen therapy (LTOT) or nocturnal oxygen
therapy required for greater than 15 hours a day.  Note:  As needed oxygen use is
not exclusionary.
n.   Subject use of any non-invasive positive pressure ventilation device. Note: Subjects 
using continuous positive airway pressure or bi-level positive airway pressure for 
Sleep Apnea Syndrome are allowed in the study if not used for ventilatory support.
o.   Change in smoking status (i.e., start or stop smoking) or initiation of a smoking 
cessation program within 6 weeks of Visit 1 and throughout the Screening Period 
(Visit 1 to Visit 4).
p.   Pulmonary Rehabilitation: Subjects who have participated in the acute phase of a 
pulmonary rehabilitation program within 4 weeks prior to Visit 1 (Screening) or 
who are scheduled to enter the acute phase of a pulmonary rehabilitation program
during the study. These subjects will be allowed to rescreen after completion of the 
acute phase of pulmonary rehabilitation. Subjects who are in the maintenance phase 
of a pulmonary rehabilitation program are not to be excluded.
q.   Subjects who have initiated or altered the dose regimen of intranasal 
corticosteroids, intranasal antihistamines, or a combination thereof within 7 days 
prior to Visit 1 or during the Screening Period (Visit 1 to Visit 4).
4. Cardiac disease:
a.
Subjects who have unstable ischemic heart disease, left ventricular failure, or 
documented myocardial infarction within 6 months of enrollment.  Subjects with a 
recent history of acute coronary syndrome, or who have undergone percutaneous 
coronary intervention or coronary artery bypass graft within the past 3 months are 
to be excluded.
b. Subjects with congestive heart failure (CHF NYHA Class III/IV).
c.
Clinically significant abnormal ECG: A clinically significant abnormal ECG is 
defined as (but not limited to) any of the following:
•
Clinically significant conduction abnormalities [e.g., left bundle branch block, 
Wolff-Parkinson-White syndrome or evidence of second degree 
(Mobitz Type II) or third-degree atrioventricular block (unless pacemaker or 
defibrillator has been inserted)].
•
Clinically significant arrhythmias (e.g., atrial fibrillation with irregular 
ventricular response, atrial flutter, ventricular tachycardia). Note: atrial 
fibrillation that has been clinically stable for at least 6 months and that has been 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 48 of 194
appropriately treated with anticoagulation and controlled with a rate control 
strategy (i.e., selective beta blocker, calcium channel blocker, digoxin or 
ablation therapy) for at least 6 months is allowed for inclusion. In such subjects, 
if atrial fibrillation is present at Visit 1, resting ventricular rate must be <100 
beats per minute (bpm). 
•
QT interval corrected for heart rate (using Fridericia’s formula; QTcF) 
500 milliseconds (msec) in subjects with QRS <120 msec and QTcF 530 
msec in subjects with QRS 120 msec  
•
Ventricular rate <45 bpm.
•
ST-T wave abnormalities deemed to be clinically significant by the Investigator.  
Note: Subjects with non-specific ST-T wave abnormalities that are not deemed 
clinically significant (per Investigator) are allowed.
•
Any other ECG abnormalities not listed above that in the opinion of the 
Investigator are clinically significant.
d. Clinically Uncontrolled Hypertension: Subjects who have clinically significant 
uncontrolled hypertension.
5. Neurological:
a.
Subjects with seizures requiring anticonvulsants within 12 months prior to Visit 1
(Screening). Note: Subjects treated with anticonvulsant medication for 12 months or 
more with no seizure events are eligible.
b. Subjects taking selective serotonin reuptake inhibitors (SSRIs) or 
serotonin-norepinephrine reuptake inhibitors (SNRIs) whose dose has not been stable 
for at least four weeks prior to Visit 1 or is altered at any point during the Screening 
Period (Visit 1 to Visit 4) or exceeds the maximum recommended dose.
c.
Subjects who have experienced a cerebrovascular accident within 6 months prior to 
Visit 1.
6. Renal:
a.
Subjects with symptomatic prostatic hypertrophy that is clinically significant and not 
adequately controlled with appropriate therapy in the opinion of the Investigator.  
Subjects with a trans-urethral resection of prostate or full resection of the prostate
within 6 months prior to Visit 1 are excluded from the study. 
b. Subjects with bladder neck obstruction or urinary retention that is clinically significant 
in the opinion of the Investigator. 
c.
Subjects with a calculated creatinine clearance 30 mL/minute using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [Levey, 2009] at 
Visit 1 and on repeat testing prior to Visit 2.
Note: Subjects with overactive bladder syndrome treated with oral anticholinergics who 
have been on treatment for at least 1 month are allowed in the study.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 49 of 194
7. Endocrine:
a.
Subjects, who in the opinion of the Investigator, have uncontrolled hypo- or 
hyperthyroidism, hypokalemia, or hyperadrenergic state.
b. Subjects, who in the opinion of the Investigator, have uncontrolled Type I or II 
diabetes.
8. Liver: Subjects with abnormal liver function tests defined as AST, ALT, or total 
bilirubin 1.5 times upper limit of normal at Visit 1 and on repeat testing prior to Visit 2.
Note: Chronic stable hepatitis B and C is acceptable if the subject otherwise meets study 
entry criteria.
9. Cancer: Subjects who have cancer that has not been in complete remission for at least five 
years.  Note: Subjects with squamous cell carcinoma of the skin, basal cell carcinoma of 
the skin, or localized prostate cancer are eligible, if in the opinion of the Investigator, the 
condition has been adequately worked up, is clinically controlled and the subject’s 
participation in the study would not represent a safety concern.
10. Glaucoma: Subjects with a diagnosis of narrow angle glaucoma, which, in the opinion of 
the Investigator, have not been adequately treated.  All medications approved for control of 
intraocular pressures are allowed including topical ophthalmic non-selective beta-blockers 
(such as betaxolol, carteolol, levobunolol, metipranolol, and timolol), and prostaglandin 
analogues.
11. Drug Allergy: Subjects who have a history of hypersensitivity to ȕ2-agonists, budesonide or 
any other corticosteroid components, glycopyrronium or other muscarinic anticholinergics, 
or any component of the MDI or dry powder inhaler (DPI).
12. Substance Abuse: Subjects, who in the opinion of the Investigator, significantly abuse 
alcohol or drugs.
13. Medication prior to spirometry: Subjects who are medically unable to withhold their short-
acting bronchodilators for the 6-hour period required prior to spirometry testing at each 
study visit will be ineligible to participate in the PFT sub-study.
14. Prohibited Medications: Subjects who, in the opinion of the Investigator, would be unable 
to abstain from protocol-defined prohibited medications during the screening period and 
treatment phases of this study (refer to Section 5.4).
15. Subjects using any herbal inhalation and nebulizer products within 2 weeks prior to Visit 1 
(Screening) and do not agree to stop using them during the study drug treatment.
Note: Nebulized products (e.g. albuterol/salbutamol, ipratropium) are acceptable, but 
requires a minimum of a 6-hour washout prior to Visit 1 and must be discontinued at Visit 
1 and throughout the study.
16. Vaccinations Subjects who received a live attenuated vaccination within 7 days prior to 
Visit 1 (Screening).
17. Non-compliance: Subjects unable to comply with study procedures including 
non-compliance with diary completion (i.e., <70% subject completion of diary assessments 
in the last 7 days preceding Visit 4).
18. Affiliations with Investigator site: Study Investigators, sub-Investigators, study 
coordinators, employees of a participating Investigator or immediate family members 
of the aforementioned are excluded from participation in this study. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 50 of 194
19. Questionable Validity of Consent: Subjects with a history of psychiatric disease, 
intellectual deficiency, poor motivation, substance abuse (including drug and alcohol), 
or other conditions that will limit the validity of informed consent to participate in the 
study. 
20. Subjects using prohibited medications (refer to Table 5-1)
21. Investigational Drugs or Devices: Treatment with investigational study drug or device in 
another clinical study within the last 30 days or five half-lives prior to Visit 1 (Screening), 
whichever is longer.  
Note: Subject participation in observational studies (i.e., studies that do not require change 
to medication or an additional intervention) is not exclusionary.
22. Hand-to-Breath Coordination: Subjects who require the use of a spacer device to 
compensate for poor hand-to-breath coordination with a MDI.  Note: Use of a nebulizer to 
deliver maintenance COPD medications is prohibited throughout the study.
23. Previous Participation: Subjects who were previously enrolled in any PT009 or PT010 
study conducted or sponsored by Pearl Therapeutics, Inc.
5.2.1
24-Hour Holter Monitoring Sub-study Exclusion Criteria
Subjects with a pacemaker or implantable cardioverter-defibrillator (ICD)/cardiac
resynchronization therapy (CRT)/cardiac resynchronization therapy-defibrillator (CRT_D) 
devices will not be allowed into the Holter monitor sub-study.
Clinically significant abnormal findings during the baseline Holter monitor recording defined
as (but not limited to) any of the following:
1. Average HR 40 bpm for any 1 hour.
2.
Second-degree AV block (Type 2) or third-degree AV block.
3. Sinus pause of:
•
2.5 seconds duration during daytime
•
3.0 seconds duration during nighttime
4. Any episode of ventricular flutter and/or ventricular fibrillation.
5. Any episode of non-sustained ventricular tachycardia (NSVT) with symptoms of 
hypotension or syncope or asymptomatic non-sustained VT >15 ventricular premature 
beats (VPB’s) in a row.
6. Sustained ventricular tachycardia (SVT) (>30 seconds in duration)
7. Five or more episodes of NSVT/ 24 hours
8. Greater than 500 VPB/hr
5.3
Subject Identification
All subjects who undergo screening procedures will be assigned a unique screening 
identification number at Screening (Visit 1).  Only subjects continuing to meet entry 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 51 of 194
inclusion/exclusion criteria at Visit 4 will be assigned a unique subject randomization 
number. Randomization will be centralized through the use of an IWRS.
5.4
Prior, Concomitant, and Prohibited Medications
All prescription and over-the-counter (OTC) medications taken by the subject during 30 days 
before Visit 1 (Screening) will be recorded on the prior/concomitant medications electronic 
Case Report Form (eCRF).  Any additions, deletions, or changes in the dose of these 
medications while in the study should be entered on the eCRF.  Any current ongoing 
medications, including OTC drugs and herbal supplements, will be allowed provided they are 
not prohibited by the protocol (see Section 5.4.3) and are approved by the Investigator.  
Subjects should also be instructed to contact the Investigator if they develop any illnesses.
All concomitant medications taken during the study will be recorded on the Concomitant 
Medications eCRF page with indication, total daily dose, and dates of drug administration.
5.4.1
Allowed Medications to Treat a COPD Exacerbation
Medications to treat an exacerbation should not be used for more than 14 days. Recent data 
have suggested that treatment with systemic steroids for shorter periods of time results in 
similar outcomes with less systemic steroid exposure. Therefore, it is recommended that 
subjects are treated with a 5 day course of steroids (Leuppi, 2013) and no longer than 14 
days. During a COPD exacerbation, it is important for subjects to be treated as deemed 
appropriate by the treating health care provider. However, all supplemental medication used 
to treat the COPD exacerbation should be discontinued as soon as is practical. 
In the instance a subject is hospitalized for a severe COPD exacerbation and study drug is 
interrupted to allow COPD medications to be prescribed, the subject may be able to restart 
study drug upon stopping the COPD medications. If a subject is not able to discontinue 
prescribed COPD medications during the exacerbation treatment (Table 1) within 14 days, 
then the subject must be permanently discontinued from the study drug and encouraged to 
complete the remaining study visits.
5.4.2
Pneumococcal and Annual Influenza Vaccination
All subjects should be vaccinated with pneumococcal vaccine per local guidelines policies, 
availability, and affordability as described in current global recommendations (GOLD, 
2016).  For subjects that have been previously vaccinated with pneumococcal vaccine, the 
investigator should assess whether a booster vaccination is required.  Annual influenza 
vaccine should also be administered per local guidelines.  Pneumococcal and/or annual 
influenza vaccine can be given at Visit 1 or at any other visit throughout the study at the 
discretion of the investigator; however, administration should occur after obtaining all 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 52 of 194
requisite PFT assessments for that specific test day.  There should be at least 7 days between 
vaccination and subsequent PFT assessments.
5.4.3
Prohibited COPD Medications and Required Washout Prior to Visit 2
Subjects that meet the screening criteria at Visit 1 that are being treated with any of the 
medications listed in Table 1 need to discontinue these medications and observe the 
minimum washout requirement before returning for Visit 2. These medications are prohibited 
throughout the course of the study, and should a subject require use of any of the listed 
medications, they should be discontinued.
Table 1.
Prohibited COPD Medications and Required Washout Periods 
Prior to Visit 2
Class of Medication
Minimum Washout Period Prior to Visit 2
LAMAs
Tiotropium: 14 days
Aclidinium: 7 days
Glycopyrronium: 7 days
Umeclidinium: 7 days 
Short-acting muscarinic antagonists (SAMA)a
6 hours
LABAs (inhaled)
7 days (14 days for indacaterol and olodaterol)
Fixed-combinations of LABA/LAMA
7 days (14 days for indacaterol/glycopyrronium        
and olodaterol/tiotropium)
Fixed-combinations of LABA/ICS
7 days 
Fixed-combinations of SABAs and SAMAs 
6 hours
SABAsb
6 hours
Oral ȕ-agonists
2 days 
Theophylline (total daily dose >400 mg/day)c
7 days
Abbreviations:  COPD=chronic obstructive pulmonary disease; HFA=hydrofluoroalkane; ICS=inhaled 
corticosteroid; LABA=long-acting ȕ2-agonist; LAMA=long-acting muscarinic antagonist; SABA=short-
acting ȕ2-agonist
a
Discontinue and use only sponsor-provided  Atrovent HFA during screening 
b
Discontinue and use only sponsor-provided  rescue Ventolin HFA throughout the study
c
Theophylline (<400 mg/day) is permitted provided the subject has been on a stable dose of therapy for at 
least 4 weeks prior to Randomization. 
Note: Roflumilast (or any PDE4 inhibitor) is allowed provided the subject has been on a stable dose of 
therapy for at least 2 months prior to Randomization.
Subjects who have received depot corticosteroids including intra-articular or intraocular 
corticosteroids require a 6 weeks washout prior to Screening (Visit 1).  Subjects that have 
received oral, intravenous or intramuscular corticosteroids for any reason require a minimum 
of a 4-week washout prior to Screening (Visit 1).
Note:

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 53 of 194
•
Subjects who are steroid dependent and maintained on an equivalent of up to 5 mg 
prednisone per day or up to 10 mg every other day for at least 3 months prior to Visit 1 
are eligible for enrollment, provided the dose of oral steroids remains consistent and does 
not exceed this threshold for the last two weeks prior to randomization (Visit 4).
•
During the Treatment Period (Visit 4 to Visit 14), subjects may be treated with systemic 
corticosteroids if required.
Subjects who meet all entry criteria but are using 1 or more of the prohibited COPD 
medications (previously listed) will have their maintenance therapy for COPD adjusted as 
follows:
•
Subjects taking COPD medications (listed previously) at Visit 1 (Screening) will 
discontinue these medications for the duration of the Study and be switched to 
Sponsor-provided Atrovent HFA administered 4 times daily (QID) and Sponsor-provided 
Ventolin HFA to be administered up to 4 times per day, as needed, for control of 
symptoms during the Screening Period.
•
Subjects receiving a maintenance dose of an ICS as part of a fixed-dose combination 
therapy containing fluticasone and salmeterol, mometasone and formoterol, budesonide
and formoterol or fluticasone and formoterol or other approved fixed dose ICS/LABA 
combinations must have been on the ICS component for at least 4 weeks prior to Visit 1 
(Screening) and maintained on a stable dose for at least 4 weeks prior to Visit 1 
(Screening).  These subjects will be switched to the corresponding dose of fluticasone,
mometasone, or budesonide administered as a single agent BID, with Sponsor-provided 
Atrovent HFA administered QID, and Sponsor-provided Ventolin HFA to be 
administered up to QID, as needed, to control symptoms during the Screening Period.
•
Subjects receiving a maintenance dose of an ICS that is not administered as a fixed-dose 
combination together with a LABA will continue the ICS provided they have been
maintained on a stable dose for at least 4 weeks prior to Visit 1 (Screening).
•
All subjects treated with either a LABA (salmeterol, formoterol, indacaterol, vilanterol, 
olodaterol), or currently-marketed LAMA (tiotropium, aclidinium, glycopyrronium, 
umeclidinium) administered alone, as a loose combination, or as a fixed combination 
(e.g., umeclidinium/vilanterol, glycopyrronium/indacaterol, aclidinium
bromide/formoterol fumarate ) will have these medications discontinued and replaced
with Sponsor-provided Atrovent  HFA administered QID, and Sponsor-provided 
Ventolin HFA to be administered up to QID, as needed for control of symptoms during 
the Screening Period.
Note: All adjusted maintenance therapy for COPD, including ICS will be stopped at 
randomization.
It is preferred that Atrovent and Ventolin be US-sourced products.  In cases where it is not 
possible for the US-sourced product to be used, a locally available product will be provided 
by the Sponsor. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 54 of 194
Subjects receiving the following respiratory medications must discontinue these medications
at the initial Screening Visit (Visit 1).  The minimum cessation period must be met prior to 
returning for Visit 2.  These medications are not permitted during the study (Table 2).
Table 2.
Other Prohibited Respiratory/Nasal Medications and Required 
Washout Periods Prior to Visit 2
Class of Medication
Minimum Washout Period Prior to Visit 2
Leukotriene antagonists (eg, zafirlukast, 
montelukast, and zilueton) 
7 days
Cromoglycate
7 days
Nedocromil
7 days
Ketotifen a
7 days
a
Ketotifen eye drops and inhalation solution (where available) are allowed.
5.4.4
Other Prohibited Medications
Table 3 lists certain non-COPD medications that can be used under the stated conditions 
during this study.  Each concomitant drug must be individually assessed against all exclusion 
criteria.
Table 3.
Non-COPD Medications Allowed Under Certain Conditions
Medications Allowed Under Certain 
Conditions
Condition
SSRIs or SNRIs
Treatment regimen has been stable for at 
least 4 weeks prior to Visit 1 and not altered 
during the Screening Period, and does not 
exceed the maximum recommended dose
Intranasal corticosteroids, intranasal 
antihistamines, or combination thereof
Administered at constant dose and dosing 
regimen for at least 7 days prior to Screening 
(Visit 1) and during the Screening Period
Abbreviations:  COPD=chronic obstructive pulmonary disease; SNRI=serotonin–norepinephrine reuptake 
inhibitors; SSRI=selective serotonin reuptake inhibitors
Note: Use of cutaneous topical medications, including cutaneous topical corticosteroids, are permitted 
provided they are not applied to more than 20% of  the subject’s body surface area 
Subjects requiring medications presented in Table 4 are prohibited from participating in this 
study.  Subjects who recently discontinued use of these medications may be considered for 
study enrollment provided they have met the minimum Washout Period prior to Visit 1
(Screening).  These medications are prohibited throughout the course of the study, and, 
should a subject require use of any of the listed medications, the subject should be 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 55 of 194
discontinued from randomized treatment but encouraged to continue in  the study and 
complete all remaining study visits. 
Table 4.
Prohibited Medications
Prohibited Medications
Minimum Cessation Period Prior to 
Screening (Visit 1)
Any drug with potential to significantly prolong the 
QT intervala
14 days or 5 half-lives, whichever is longer
Other investigational drugs
30 days or 5 half-lives, whichever is longer 
Non-selective ȕ-blocking agents (Except 
Carvedilol)
7 days
Cardiac antiarrhythmics Class Ia, III
7 days (amiodarone 3 months)
Anticonvulsants for seizure disorder
Allowed if stable dose for 12 months and free of 
seizures for 1 year 
Anticonvulsants for other indications
Allowed if stable dose for at least 3 months and free of 
seizures for 1 year
Tricyclic antidepressantsb
14 days
Monoamine oxidase inhibitors
14 days 
Anti-tumor necrosis factor Į antibodies 
(eg, infliximab and any other members of this class 
of drugs)
30 days or 5 half-lives, whichever is longer
Monoclonal antibodies
30 days or 5 half-lives, whichever is longer
Antipsychotic drugs b
30 days
Systemic calcineurin inhibitors, protease inhibitors 
30 days
Systemic anticholinergics c
7 days
Chinese complementary and alternative 
bronchodilatory medicines (CAM), ie, herbal 
therapies (eg, Astragalus membranaceus [huáng qí],
Panax ginseng [ginseng products] and Cordyceps 
sinensis. A. membranaceus [ghost moth caterpillar 
fungus])d
10 days
Note: Benzodiazepines are not exclusionary.
a
Subjects who are on medications that have the potential to prolong the QTc interval may be enrolled 
provided the dose has remained stable for at least 3 months prior to Screening, the subject meets all of the 
ECG inclusion criteria and none of the ECG exclusion criteria and if, in the opinion of the investigator, 
there are no safety concerns for the subject to participate in the study. Initiation of medications with the 
potential to significantly prolong the QT interval is prohibited throughout the study. Note: Short courses 
( 4 weeks) of antibiotics with the potential to prolong the QT interval (e.g. azithromycin, clarithromycin) 
are permitted.
b
Antipsychotic agents and tricyclic antidepressants used for previously diagnosed underlying medical 
conditions are allowed if, in the opinion of the Investigator, there are no concerns regarding patient safety, 
and if the patient has been on a stable dose for at least 6 weeks.
c
If systemic anticholinergics are used for treatment of overactive bladder and the treatment has been 
constant for at least 1 month, they are allowed.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 56 of 194
Table 4.
Prohibited Medications
Prohibited Medications
Minimum Cessation Period Prior to 
Screening (Visit 1)
d
Requires case-by-case review by the Investigator to determine appropriate wash-out period, if needed.
5.5
Other Restrictions, Illicit Drugs, or Drugs of Abuse
5.5.1
Illicit Drugs 
Illicit drugs or drugs of abuse will not be allowed from the start of Screening (Visit 1) to the 
end of the Follow-up TC or to whenever the subject withdraws from the study. If any illicit 
drugs or drugs of abuse are used by the subject during the study, the dates of use and the 
amount will be documented, and the subject will be discontinued at the discretion of the 
investigator.  Medical marijuana is not an exclusionary drug if used for medical purposes, 
and there is no change in the dose or frequency of consumption.
5.5.2
Dietary Restrictions
Subjects must not ingest xanthine and/or xanthine analogue (caffeine)-containing foods, 
beverages or caffeine containing medications for at least 6 hours prior to each study visit and 
for the duration of each study visit.  Examples of such products include coffee, tea, 
chocolate, and cola.  Decaffeinated beverages are acceptable.
5.6
Smoking Status
Changes in a subject’s smoking status (i.e., stopping or restarting smoking) may have an 
impact on the efficacy outcome measures.  At Visits 1, 2, 3, 4, 5, 7, 10, 12, and 14, the 
subject will be asked about any recent change in their smoking status (i.e., whether a 
subject’s status has changed from smoker to nonsmoker or vice versa).  Any change in 
smoking status during the Screening Period (Visit 1 to Visit 4) will result in a screen failure.  
Smoking status changes during the 52-week Treatment Period will be captured in the eCRF, 
but the subject will be permitted to continue in the study.  Subjects enrolled in the PFT sub-
study will be required to refrain from smoking (including medical marijuana and electronic 
cigarettes) for at least 4 hours prior to each study visit and throughout the duration of each 
study visit.  Study participants may utilize various nicotine replacement treatments such as 
chewing gum and patches as needed, in accordance with recommendations from the 
Investigator during the entire study visit.
Note: For this study, the use of electronic cigarettes will be treated in the same manner as 
smoking.
5.7
Reasons for Treatment Discontinuation or Study Withdrawal 
Subjects may be withdrawn from the study at any time at their own request, upon request of 
the Investigator, or by Pearl at any time or for any reason. A subject who withdraws consent 
will always be asked about the reason(s) and the presence of any adverse events (AE). For all 
subjects who withdraw from the study for any reason they, their family or healthcare 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 57 of 194
providers, will be contacted 52 weeks post randomization to determine vital status, and if 
appropriate, cause of death (Section 8.13). The subject may voluntarily discontinue treatment 
at any time without prejudice to further treatment.  
If a subject experiences any of the changes of concern listed below, a repeat assessment 
should be obtained, and if confirmed, the subject should be discontinued from randomized 
treatment but encouraged to continue in the study and complete all remaining study visits 
(See Section 8.9). The changes of concern include:
x
Calculated QTcF intervals >500 msec and have increased by 60 msec or more over test day 
baseline value.
Note: Applicable to EU-specific regions only - Calculated QTcF intervals 500 msec OR  
60 msec over test day baseline.
•
Hepatic impairment defined as abnormal liver function test of AST, ALT or total bilirubin 
3 times upper limit of normal on repeat testing.
•
Subjects participating in the 24-hour Holter Monitoring sub-study who experience any 
clinically significant abnormal findings during the Holter Monitoring recording as 
described in Section 5.2.1
If a subject experiences any of the changes of concern listed below, a repeat assessment 
should be obtained, and if confirmed, the Investigator or designee needs to make a 
determination as to the suitability of continuing the subject on randomized treatment. The 
changes of concern include:
•
Following dosing, a heart rate increase of >40 bpm from the pre-dose value obtained on 
that specific test day and the measured value is also >120 bpm.
Note: Applicable to EU-specific regions only - Following dosing, a heart rate increase of 
> 25 bpm from the pre-dose value obtained on that specific test day, without any 
threshold.
•
Following dosing, a systolic blood pressure increase of >40 mmHg from the 
pre-dose value obtained on that specific test day and the measured value is also 
>160 mmHg.
Note: Applicable to EU-specific regions only - Following dosing, a systolic BP (SBP) 
increase of > 30 mmHg from the pre-dose value obtained on that specific test day, 
without any threshold, or a clinically relevant change from baseline as determined by the 
Investigator.
• Decrease in creatinine clearance to a value 30 mL/minute using CKD-EPI formula or a 
clinically relevant change from baseline as determined by the Investigator.
Note: Applicable to EU-specific regions only - A decrease of 33% in calculated 
creatinine clearance from baseline using CKD-EPI without any threshold.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 58 of 194
If a subject requires any of the following prohibited medications (other than study-provided 
medication or COPD medications used during the treatment of a severe COPD exacerbation 
as described in Section 5.4.1), they should be discontinued from randomized treatment but 
encouraged to continue in the study and complete all remaining study visits (See Section 
8.9):
• Initiation of maintenance therapy with any prohibited medications as listed in Section 
5.4.3.
• Initiation of maintenance therapy with a LABA (e.g., salmeterol, formoterol, indacaterol, 
vilanterol, olodaterol) administered alone or in combination with an ICS or a LAMA 
(e.g., tiotropium, aclidinium, glycopyrronium, umeclidinium).
• Change inhaled maintenance therapy during the course of the study.
NOTE:  Subjects who suffer an exacerbation (regardless of severity) will remain in the 
study and continue to take their assigned study drug unless the Investigator decides that it is 
in the best interest of the subject to discontinue randomized treatment and/or withdraw from 
the study (See Section 8.9).
If a female subject becomes pregnant during the course of the study, the subject will be 
withdrawn from the study and the pregnancy will be followed through delivery or final 
outcome (see Section 7.3.12).
Subjects who prematurely discontinue treatment from the study drug should return to the 
study center and complete procedures described in Section 8.9. The reason for premature 
discontinuation of study drug should be documented in the source documentation and 
recorded in the eCRF.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 59 of 194
6
LABELING, PACKAGING, STORAGE, DISPENSING, AND 
RETURN OF CLINICAL SUPPLIES
6.1
Subject Information
Clinical supplies will be packaged to support enrollment of the study.  Study personnel will 
have access to an IWRS to allocate subjects, to assign study-related drug to subjects, and to 
manage the distribution of clinical supplies.  Clinical supplies will be packaged according to 
a component schedule generated by the Sponsor or their designee.  Each person accessing 
the IWRS system must be assigned an individual unique personal identification number 
(PIN).  They must use only their assigned PIN to access the system, and they must not share 
their assigned PIN with anyone.
6.2
Product Descriptions
Investigational materials will be provided by Pearl as summarized in Table 5 Atrovent HFA 
and Ventolin HFA will be supplied as open-label MDIs. 
US-sourced products are the preferred product for use during the study. In regions where it 
is not possible for the US-sourced products to be used, a locally available comparable 
product will be provided by the Sponsor.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 61 of 194
labeled with a single label. Labels will be printed with black ink and may include the 
following text: Labels will be printed with black ink and may include the following text:
Lot # (Packaging Lot Trace ID)
Space for entry of screening #
Component ID #
Space for entry of randomization #
Fill Count & Dosage Form
Visit # (Space for Entry of Interval ID)
Storage Conditions
Protocol #
Country regulatory requirements
Sponsor address Translation Key
ID = identification; # = number
6.4
Secondary Packaging and Labeling Information (Box)
Blinded investigational drug and open-label (Atrovent HFA and Ventolin HFA) supplies 
will be packaged in individual boxes as outlined in Table 6 . Box configuration is subject to 
change as a result of packaging constraints.
Table 6.
Description of Boxes
Drug Supplies
Individual Box Contents
Blinded
Atrovent(ipratropium bromide) HFAa
Ventolin (albuterol sulfate) HFAa
1 MDI
1 MDI
1 MDI
HFA=hydrofluoroalkane; MDI=metered dose inhaler
a
The US-sourced products are the preferred product for use during the study. In regions where it is not 
possible for US-sourced products to be used, a locally available comparable product will be provided by 
the Sponsor.
Each box will be labeled with a 2-part label printed with black ink and may include the 
following text:
Packaging Lot ID #
Space for entry of screening #
Component ID #
Space for entry of randomization #
Kit Contents (1 MDI)
Space for entry of Interval ID
Re-evaluation/Expiration date (if applicable)
Dosing Instructions (if applicable)
Storage Conditions
Compound ID - Protocol #
Country regulatory requirements
Sponsor address (if applicable)
Translation Key (if applicable)

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 62 of 194
6.5
Emergency Unblinding of Treatment Assignment
The IWRS should be used in order to unblind subjects and to unmask drug identity.  When 
the Investigator contacts the system to unblind a subject, he/she must provide the requested 
subject identifying information and confirm the necessity to unblind the subject.  Pearl will 
not provide a disclosure envelope with the clinical supplies.
The Investigator or treating physician may unblind a subject’s treatment assignment only in 
the case of an emergency, when knowledge of the study treatment is essential for the 
appropriate clinical management or welfare of the subject.
Whenever possible, the Investigator must first discuss options with the Medical Monitor or 
appropriate study personnel before unblinding the subject’s treatment assignment.  If this is 
impractical, the Investigator must notify Pearl as soon as possible, but without revealing the 
treatment assignment of the unblinded subject, unless that information is important for the 
safety of subjects currently in the study.  The date and reason for the unblinding must be 
recorded in the appropriate data collection tool.
6.6
Storage Requirements
Blinded supplies: BGF MDI, BFF MDI, and GFF MDI should be stored below 25°C 
(77°F) in a dry place. Excursions permitted up to 30°C (86°F).
Ventolin® HFA supplies: Store per Package Insert.  Store the inhaler with the mouthpiece 
down.  For best results, the inhaler should be at room temperature before use.  Do not use or 
store near heat or open flame.  Exposure to temperatures above 120°F (49°C) may cause 
bursting. Never throw into a fire or incinerator.
Atrovent® HFA supplies: Store per Package Insert.  For optimal results, the canister should 
be at room temperature before use.  Do not puncture.  Do not use or store near heat or open 
flame.  Exposure to temperatures above 120°F (49°C) may cause bursting.  Never throw the 
inhaler into a fire or incinerator.
The clinical supplies storage area at the site must be monitored by the site staff for 
temperature consistency with the acceptable storage temperature range specified in 
accordance with the product label.  Documentation of temperature monitoring should be 
maintained.
6.7
Instructions for Preparation of Treatments for Administration and 
Dispensing
6.7.1
BGF MDI, GFF MDI, and BFF MDI
Individual BGF MDI, GFF MDI, and BFF MDI inhalers will be packaged in a foil pouch 
and contained in an individual visit treatment box. Both the visit treatment box and the foil 
overwrap will have a label with a component ID number. Open label MDIs and DPIs will be 
packaged in a visit treatment box. The visit treatment box will have a label with a 
component ID number. Confirm that the identifier given by IWRS and the component ID 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 63 of 194
number written on the label are the same. The visit treatment box is labeled with a 2-part 
label. Write the subject number and treatment visit number on each of the 2-part labels. The 
‘tear-off’ part of the label is to be placed onto the IWRS confirmation report.
All MDIs must be primed before the first use.  Priming involves releasing a certain number 
of sprays (4) into the air before the first use of the inhaler.  Shaking and priming the inhaler 
fills a chamber inside the canister with the correct dose and mix of medication so that the 
inhaler is ready to use.
The MDI must be primed in a separate room from the subject treatment area.  Each dose 
will consist of 2 puffs from the MDI.  Subjects will be dispensed the MDI and instructed to 
continue taking study drug BID, two puffs in the morning and two puffs in the evening 
approximately 12 hours apart, until subject returns to the clinic.  Refer to Appendix 4 for 
instructions on the administration and cleaning of BGF MDI, GFF MDI, and BFF MDI.
6.7.2
Atrovent® HFA (Ipratropium Bromide)
Refer to Appendix 5 for instructions on the administration of Atrovent® HFA. 
6.7.3
Ventolin HFA® (Albuterol Sulfate)
Refer to Appendix 6 for instructions on the administration of Ventolin® HFA (Albuterol 
Sulfate).
6.8
Drug Accountability/Return of Clinical Supplies
Under no circumstances will the Investigator(s) allow the study drug to be used other than 
as directed by this protocol.
Investigational clinical supplies must be received by a designated person at the study site, 
handled and stored safely and properly, and kept in a secure location to which only the 
Investigator and designated study personnel have access.  Storage conditions for the clinical 
supplies should be observed, monitored, and documented.  Clinical supplies are to be 
dispensed only in accordance with the protocol.  The Investigator or designee is responsible 
for keeping accurate records of the clinical supplies received from Pearl, the amount 
dispensed to and returned by the subject, and the amount remaining at the conclusion of the 
study.  Study drug should be handled in accordance with Good Pharmacy Practices 
(e.g., gloves should always be worn by study personnel if directly handling study drug that 
is returned).  The Clinical Monitor should be contacted with any questions concerning 
investigational products where special or protective handling is indicated.  At the end of the 
study, all clinical supplies including partial and empty containers must be returned as 
directed by Pearl.
Sites should check with the Sponsor’s representative for appropriate documentation that
needs to be completed for drug accountability.
The Investigator or designated study personnel should not open individual clinical supply 
containers until all pre-dose assessments have been completed and the subject is eligible to 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 64 of 194
be randomized/continue with the study.  Any deviation from this must be discussed with the 
Clinical Monitor.
For each subject, all used study drug materials will be collected.  Used subject supplies will 
be kept at room temperature in a secure and locked cabinet until returned to Pearl or 
designee.  
Note: Used study drug must be stored separately from unused study drug.
All product complaints (including device malfunctions) must be reported to Pearl or the 
Sponsor’s representatives using the Product Complaints Form provided in each site’s 
regulatory binder.  Pearl or the Sponsor’s representatives will contact the site to evaluate the 
nature of the complaint and determine what further action is needed.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 65 of 194
7
STUDY PROCEDURES
A schedule of events is provided in Table 8. Other detailed schedules are provided for timed 
assessments for all post-randomization in-clinic visits for subjects participating in the PFT 
sub-study (Visits 4, 5, 7, 10, 12, and 14; Day 1, Weeks 4, 12, 24, 36, and 52) Table 8-1;
timed assessments for all post-randomization in-clinic visits for subjects NOT participating 
in the PFT sub-study (Visits 4, 5, 7, 10, 12, and 14; Day 1, Weeks 4, 12, 24, 36, and 52) 
Table 8-2; assessments to be collected at telephone visits (Visits 6, 8, 9,  11, and 13; Weeks 
8, 16, 20, 28, and 44) Table 8-3; timed assessment at Visit 3 (Screening Period) and Visit 8 
(Week 16) for 24-hour Holter Monitoring Sub-study, Table 8-4.
7.1
Efficacy Assessments
7.1.1
Pulmonary Function Tests
Forced expiratory spirometry maneuvers for derivation of FEV1, FVC, and PEFR will be 
assessed using a spirometer that meets or exceeds minimum performance recommendations 
of the ATS (see Appendix 2).
The volume accuracy of the spirometer is to be checked daily using a 3 L syringe across 
3 flow ranges (i.e., low, medium, and high flows), with temperature and barometric pressure 
correction.  The calibration syringe must meet ATS specifications and must not be used 
beyond the expiry date.  Required accuracy is ±3% (i.e., 3.09 L to 2.91 L) (ATS/ERS).  
The results will be printed and maintained in a calibration log, which will be monitored for 
compliance during the monitoring visits (refer to Appendix 2).
All PFTs including FEV1, FVC, and PEFR as defined in ATS/ERS guidelines will be 
performed in accordance with ATS criteria [Miller, 2005].
To standardize spirometry, all sites will be provided with identical spirometry systems 
(KoKo Spirometer, nSpire Health, Inc., Longmont, CO, US) with customized, 
study-specific software.  Every effort will be made to provide all sites with standardized 
spirometry equipment. In the event that it is not logistically possible to provide such 
equipment in a specific country, the use of local PFT equipment will be permitted merely 
for patient characterization purposes. These patients will not be eligible for participation in 
the PFT sub-study. Local equipment needs to be reviewed by the study monitor and must 
meet or exceed minimum performance recommendations of the ATS (see Appendix 2). The 
volume accuracy of the spirometer is to be checked daily with appropriate documentation in 
a calibration log prior to the conduct of PFT’s on each test day.
All study staff responsible for performing pulmonary function testing will receive 
standardized training at the Investigator Meetings.  All technicians are required to 
demonstrate proficiency in the use of the equipment and the ability to perform technically 
acceptable PFTs (ATS criteria), prior to performing testing on study subjects [Miller, 2005].  
After each test is performed, the spirometry software will provide immediate feedback to the 
technician indicating whether the effort meets ATS acceptability and repeatability standards 
[Miller, 2005].  All efforts will be stored electronically.  After completion of testing, the 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 66 of 194
study staff will electronically transmit the spirometric measurements for centralized quality 
assurance review 
  Feedback on the quality of the 
measurements will be provided to the investigational site and to Pearl or designee for central 
data management.
At Visit 1, a single spirometry assessment will be conducted.  
At Visit 2 and Visit 3, spirometry will be conducted 60 minutes and 30 minutes prior to
bronchodilator administration and at 30 min post-bronchodilator. 
Note: Spirometry must meet both acceptability and repeatability criteria. (Refer to 
Exclusion Criteria, Section 5.2).
For Subjects participating in the 4-Hour PFT sub-study, additional spirometry 
assessments will be conducted at Visits 4, 5, 7, 10, 12, and 14 (Day 1 and Weeks 4, 12, 24, 
36, and 52). At these visits, spirometry will be conducted at 60 minutes and 30 minutes 
prior to study drug administration and at 15 and 30 minutes, and 1, 2, and 4 hours after study
drug administration.  An additional spirometry assessment will be conducted at 5 minutes 
after study drug administration at Visit 4 (Day 1) only.  The mean of the -60 minute 
and -30 minute pre-dose spirometry assessments conducted at Visit 4 will be used to
establish baseline FEV1, FVC, PEFR, and FEF25-75.
Note: While the PFT sub-study was previously open to all eosinophil levels, subjects must 
now have a blood eosinophil count of  150 cells per mm3 at Visit 1 to participate in the 
PFT sub-study.
Subjects not participating in the 4-Hour PFT sub-study will be required to return to the 
clinic approximately the same time as Visit 4 for all treatment visits (± 2 hours) but not to 
exceed 12:00 PM and will be required to remain at the clinic until completion of all
protocol-defined assessments.
7.1.1.1
Characterization of Reversibility 
Reversibility to Ventolin HFA (SABA) will be evaluated at Visit 2 and to Atrovent HFA 
(SAMA) will be evaluated at Visit 3.  The procedures will be as follows:
•
Reversibility testing to Ventolin HFA (Visit 2 only):
ƕ
Perform pre-bronchodilator PFTs (-60 minute and -30 minute) prior to 
administration of Ventolin HFA.
ƕ
Administer 4 puffs of Ventolin HFA.
ƕ
Perform post-bronchodilator PFTs 30 minutes after the administration of 
Ventolin HFA.
• Reversibility testing to Atrovent HFA (Visit 3 Only):
ƕ
Perform pre-bronchodilator PFTs (-60 minute and -30 minute) prior to 
administration of Atrovent HFA.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 67 of 194
ƕ
Administer 4 puffs of Atrovent HFA. 
ƕ
Perform post-bronchodilator PFTs 30 minutes after the administration of 
Atrovent HFA.
Reversibility will be a comparison of the average best FEV1 effort obtained at -60 minute 
and -30 minute pre-bronchodilator to the best FEV1 effort obtained at 30 minutes 
post-bronchodilator following administration of Ventolin HFA or Atrovent HFA. A subject 
is determined to be responsive to Ventolin HFA if the improvement in FEV1 approximately 
30 minutes following administration of 4 puffs of Ventolin HFA is 12% and 200 mL. 
Reversibility to Atrovent HFA is used for characterization purposes only.
7.1.1.2
FEV1 Baseline Stability Criteria 
For Subjects participating in the 4-Hour PFT sub-study, all FEV1 comparisons will be 
made to the baseline (mean of 60 and 30 minutes prior to dosing) values obtained at Visit 4,
thus it is important to ensure that the baseline FEV1 is stable and reflective of the subject’s 
COPD severity prior to being randomized into the study. The baseline FEV1 at Visit 4 must 
be within ±20% or 200 mL of the mean of the pre-dose FEV1 obtained at the two preceding 
visits (average of pre-dose FEV1 obtained at Visit 2 and Visit 3).
Subjects who are unable to meet FEV1 Baseline Stability, will not be included in the PFT 
sub-study, but will be allowed to be randomized and continue into the study.
At Visit 4 (Randomization), if the pre-dose FEV1 average is outside of the ±20% or 200 mL 
range, but the -30 minute assessment is within ±22% or 220 mL, then another assessment 
may be conducted 30 minutes later. If the last two assessments meet the FEV1 baseline 
stability criteria (i.e., within ±20% or 200 mL), the initial 60-minute pre-dose assessment 
will not be used and the last two assessments will be used to establish the eligibility criteria.  
If the test day FEV1 is not within ± 20% or 200 mL, the subject will no longer be eligible to 
participate in the PFT sub-study but may be randomized into the main study providing all 
other eligibility criteria are met.
Note:  For Subjects not participating in the 4-Hour PFT sub-study, spirometry will only 
be conducted during screening and therefore, the FEV1 baseline stability criteria 
requirement does not apply
7.1.2
Subject Electronic Diary Data Collection
Subjects will be provided with an electronic Diary (eDiary) at screening to be completed 
twice daily to record time of study medication administration, daily symptoms using the 
Exacerbations of Chronic pulmonary disease Tool (EXACT) scale (see Section 7.1.4.5), and 
the use of rescue albuterol (Ventolin HFA) throughout their study participation. The dose 
indicator reading will be recorded from Visit 4 onwards once daily for subject on blinded 
study drug.  Before issuing the eDiary to the subject, site personnel will be responsible for 
programming the eDiary and training the subject on its use.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 68 of 194
During the screening period (between Visit 1 and Visit 4), subjects will be required to 
demonstrate acceptable eDiary collections and compliance in order to be eligible for 
randomization.
Electronic Diary Compliance Requirement:  Subject participation may be terminated at 
any time during the study for the following reasons:
•
Chronic failure, in the judgment of the Investigator, to comply with eDiary compliance, 
despite documentation at the site of repeated efforts to reinforce compliance. As defined 
for this study, compliance requires >70% subject completion of eDiary assessments for 
the duration of the study.  The Sponsor may also instruct a site to discontinue a subject 
based on consistent noncompliance.
•
Subjects who are unable to meet the compliance requirement (>70% subject completion 
of eDiary assessments) in the last 7 days preceding the Randomization Visit (Visit 4)
will be considered a screen failure.
The eDiary data report will be available to site personnel through the vendor's server.  The 
eDiary data report should be reviewed by the study personnel at each visit.  The review 
should verify that morning and evening eDiary entries have been recorded by the subject for 
compliance requirements.  The EXACT responses will be reviewed at each visit as part of 
the subject diary review.  The subject should be reinstructed, as appropriate, on the 
importance of recording BID entries if missing entries are observed.
7.1.2.1
Rescue Medication Use 
The subject will record the total number of “puffs” of rescue medication (i.e., albuterol 
sulfate or locally available equivalent product) used on a daily basis in the eDiary.  The 
number of “puffs” of rescue product will be recorded as the number of actuations on the 
canister.  For example, when rescue product is required, and 2 actuations are inhaled, this 
should be recorded as 2 “puffs.”  In the event the subject requires 4 actuations, this should 
be recorded as 4 “puffs”.  Subjects requiring more than 8 puffs per day on 3 consecutive 
days with worsening symptoms should contact the site.
7.1.2.2
Medication Compliance 
Time of dosing with study drug will be recorded in the subject’s eDiary for each day of 
treatment (except the in-clinic dosing time).  Study drug compliance will be checked at all 
visits, and any issues identified will be documented in the appropriate study files.
7.1.2.3
Major/minor Symptom Worsening Assessment and Alert System
All major and minor symptoms of a worsening event will be captured for the purposes of a 
symptom worsening alert. The purpose of this alert is to notify both the subject and the site 
of a potential symptom worsening event that warrants contact between the subject and site 
for further evaluation.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 69 of 194
All questions will have a 24-hour recall period.  Questions pertaining to the severity of 
symptoms versus their usual state will have 3 response options (e.g., How breathless have 
you been in the last 24 hours? Less breathlessness than usual, Usual level of breathlessness, 
More breathless than usual) whereas questions related to the presence or absence of a 
symptom will have a dichotomous response (e.g., Have you had a sore throat in the last 24 
hours? No, Yes, I had a sore throat).
An alert will be triggered if 2 or more major symptoms (dyspnea, sputum volume, and 
sputum color) worsen for 2 consecutive days or if 1 major symptom and 1 minor symptom 
(sore throat, cold, fever without other cause, cough, and wheeze) worsen for at least 
2 consecutive days.  When either of these criteria is met, the subject will be alerted via the 
eDiary to contact the site as soon as possible for further evaluation.  Likewise, the study site 
will be alerted to contact the subject within approximately 24 to 72 hours if he/she has not 
yet contacted the study site for further evaluation.
7.1.3
COPD Exacerbation 
A COPD exacerbation will be defined as a change in the subject’s usual COPD symptoms 
that lasts 2 or more days, is beyond normal day-to-day variation, is acute in onset, and may 
warrant a change in regular medication.  The change in symptoms must include at least one 
major COPD symptom and at least one other major or minor symptom from the list below:
• Major COPD symptoms: dyspnea, sputum volume, and sputum color
• Minor COPD symptoms: cough, wheeze, sore throat, cold symptoms (rhinorrhea or 
nasal congestion), and fever without other cause
If symptoms are acute or have progressed rapidly and require treatment less than two days 
from onset of symptoms, the investigator will have to justify the decision for defining the 
event as an exacerbation and record it in the eCRF. 
If a subject’s symptoms and the overall clinical findings support the diagnosis of a COPD 
exacerbation, but the subject has not experienced a worsening of at least one major COPD 
symptom and at least one other major or minor symptom, the investigator will have to 
justify the decision for defining the event as an exacerbation and record it in the eCRF.
7.1.3.1
Severity of COPD Exacerbation
COPD exacerbations will be classified as mild, moderate or severe based on the following 
criteria:
Exacerbations will be considered moderate if they result in: 
• Use of systemic corticosteroids and/or antibiotics for at least 3 days; a single depot 
injectable dose of corticosteroids will be considered equivalent to a 3-day course of 
systemic corticosteroids

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 70 of 194
Exacerbations will be considered severe if they result in: 
• An inpatient COPD-related hospitalization (documentation stating that the subject was 
hospitalized for the COPD exacerbation or a record of the subject being admitted for 
24 hours to an observation area, the emergency department, or other equivalent 
healthcare facility depending on the country and healthcare system)
• COPD-related death
Exacerbations will be considered mild if they do not meet the requirements to be classified 
as moderate or severe but otherwise fulfill the definition of COPD exacerbation.
7.1.3.2
Duration of COPD Exacerbation
For moderate or severe exacerbations, the duration is defined by the length of prescribed 
treatment, whereas for mild exacerbations, the duration is defined by the length of 
symptoms.
For moderate or severe COPD exacerbations, the start date will be defined as the start date 
of prescribed treatment with a systemic corticosteroid or systemic antibiotic and the stop 
date will be defined as the last day of prescribed treatment with a systemic corticosteroid or 
systemic antibiotic. In order to ensure that the same event is not counted twice, concurrent 
moderate or severe COPD exacerbations with start and stop dates equal to or less than 7 
days apart will be considered the same event and assigned the maximum severity between 
the two.
For mild COPD exacerbations, start date will be defined as the onset of worsened symptoms 
as recorded by the subject in the eDiary, and the stop date will be defined as the last day of 
worsened symptoms.  In order to ensure that the same event is not counted twice, mild 
COPD exacerbations with start and stop dates equal to or less than 7 days apart will be 
considered the same event.
7.1.3.3
Approach for Capturing COPD Exacerbations
All moderate or severe COPD exacerbations must be captured using the COPD 
Exacerbation eCRF.  Mild COPD exacerbations will be captured based on symptoms as 
recorded by the subject in the eDiary.  COPD exacerbations of any severity will be 
considered expected study endpoints and will not be reported as adverse events (AEs) unless 
considered a serious AE (SAE).
7.1.3.4
Other Information
An electronic diary (eDiary) will be used to capture daily symptom reporting.  If symptoms 
meet a specific threshold (i.e., one major COPD symptom and at least one other major or 
minor symptom for 2 consecutive days), the eDiary generates alerts to the subject and the 
clinical site.  This alert is intended to generate a contact between the subject and the clinical 
investigator.  The clinical investigator makes the decision to escalate or initiate treatment 
(steroids and/or antibiotics and/or hospitalization).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 71 of 194
Circumstances will occur where symptoms are not captured in the eDiary (e.g. technical 
difficulties, rapid deterioration, or sudden death).  In these cases, the investigator or designee, 
will enter the information into the eCRF to capture the symptoms related to a COPD 
exacerbation.
7.1.3.5
Investigator-Judged COPD Exacerbations
For events which do not meet the outlined symptom criteria and/or when symptoms have a 
shorter duration, the investigator can justify the decision for considering the event an 
exacerbation.  Exacerbations could be defined by an investigator when symptoms of COPD 
warranted urgent treatment due to rapid onset or rapidly progressive symptoms.  Such a 
situation does not allow enough time to strictly fulfill the criteria for symptom duration (2 
consecutive days).  In these cases, the investigator may define such an event as a COPD 
exacerbation.  As clinical presentations may vary among patients with COPD, exacerbations 
defined by an investigator can be supported by respiratory symptoms that may not strictly 
fulfill all symptom requirements defined above.  Since the investigator will need to document 
the symptoms that justify his or her decision to begin treatment defining a COPD 
exacerbation event, all exacerbations in the study will have documented symptoms justifying 
their clinical relevance.
7.1.4
Subject Questionnaires
The following subject questionnaires will be completed by subjects using the study-supplied 
electronic questionnaire devices at specified visits throughout the study: CAT, SGRQ, 
BDI/TDI, EQ-5D-5L. The EXACT questionnaire will be captured via the subject eDiary 
(see Section 7.1.2). Whenever BDI/TDI, SGRQ, and/or EQ-5D-5L are obtained at the same 
visit, it is recommended that the BDI/TDI be collected first followed immediately by the 
SGRQ and then the EQ-5D-5L. 
7.1.4.1
Chronic Obstructive Pulmonary Disease Assessment Test (CAT)
The CAT is a self-administered questionnaire designed to assess the condition of subjects 
and overall impact of COPD [Jones, 2009].  It has been proven that the CAT has good 
repeatability and discriminative properties, which suggest that it is sensitive to treatment 
effects at a group level.  Since the CAT is designed to assess the impact of COPD on the 
subject by measuring overall impairment, it has moderate correlations with other 
instruments, such as the Modified Medical Research Council Dyspnea Scale, SGRQ, and 
the 6-minute walk test.  
Subjects will complete the CAT (see Appendix 7 at Screening (Visit 1) and this assessment 
will be used as an entry criterion. Subjects will also complete the CAT at Randomization 
(Visit 4) to characterize the population on maximal therapy. The CAT score will describe 
the burden and symptomatic impact of COPD in subjects enrolled in the study and will be 
used to determine subject eligibility to participate in the study.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 72 of 194
7.1.4.2
Baseline and Transition Dyspnea Indices
Dyspnea is the primary symptom of COPD and its relief is an important goal of therapy.  In 
the evaluation of pharmacotherapy for COPD, several instruments are available to provide a 
discriminative and evaluative assessment of dyspnea.  Among these are the BDI and TDI 
indices, which assess breathlessness in components related to functional impairment, 
magnitude of task and magnitude of effort.  The reliability and validity of the BDI have 
been reported [Mahler, 1984].  The validity of the BDI/TDI based on its association with 
other related measures has also been demonstrated [Witek, 2003].  The BDI/TDI 
questionnaire should always be completed before any other assessments are made to avoid 
influencing the responses.  The Interviewer-administered rating of severity of dyspnea at a 
single state provides a multidimensional measurement of dyspnea based on 3 components 
that evoke dyspnea in activities of daily living, in symptomatic individuals. The BDI score 
ranges from 0 (very severe impairment) to 4 (no impairment) for each domain and are 
summed to determine the BDI focal score (0 to 12) (i.e., the lower the score, the worse the
severity of dyspnea). The appropriate language version of the questionnaires will be used.  
The questionnaire can be found in Appendix 9.
The TDI measures changes in dyspnea severity from the baseline as established by the 
BDI. TDI components are: Change in Functional Impairment, Change in Magnitude of 
Task, and Change in Magnitude of Effort.  The TDI score ranges from 
-3 (major deterioration) to +3 (major improvement) for each component.  The sum of all 
components yields the TDI focal score (-9 to +9) (i.e., the lower the score, the more 
deterioration in severity of dyspnea).  The BDI will be completed at Visit 4 (Day 1, prior to 
study drug administration).  The TDI will be completed at each in-clinic post-randomization 
visit including the Treatment Discontinuation/Withdrawal Visit.
The BDI/TDI should be completed prior to study drug administration and before 
administration of SGRQ Questionnaire.
7.1.4.3
St. George’s Respiratory Questionnaire 
The SGRQ 4-week recall tool will be used to provide the health status/health-related Quality 
of Life (QoL) measurements in this study (see Appendix 8).  The appropriate language 
version of the questionnaires will be available in each participating country.  The subject 
should complete the questionnaires in a quiet area and be allowed to ask questions; 
however, site staff should take care not to influence the subject’s responses.  The subject 
will be instructed to provide the most accurate and best individualized response about they 
how felt regarding their health status/health-related Quality of Life in the last four weeks 
from the study visit day.  The questionnaire will be checked for completeness and collected 
before the subject leaves the center.  At later visits, subjects are not allowed to review their 
previous responses. 
The SGRQ contains 50 items divided into 3 domains: "Symptoms" concerned with 
respiratory symptoms, their frequency and severity; "Activity" concerned with activities that 
cause or are limited by breathlessness; and "Impacts" which covers a range of aspects 
concerned with social functioning and psychological disturbances resulting from airway 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 73 of 194
disease.  A “Total” score combining each domain will be calculated.  In each case the lowest 
possible value is zero and the highest is 100.  Higher values correspond to greater 
impairment of quality of life.  Completed questionnaires will be reviewed and examined by 
the Investigator or designee, before the clinical examination, for responses which may 
indicate potential AEs or SAEs.  The Investigator should review not only the responses to 
the questions in the questionnaire but also for any unsolicited comments written by the 
subject.  Investigators should not encourage the subjects to change the responses reported in 
the questionnaire.
The SGRQ will be completed by the subject prior to study drug administration at Visit 4
(Day 1) and at each in-clinic post-randomization visit including the Treatment 
Discontinuation/Withdrawal Visit.
7.1.4.4
European Quality-of-Life-5 Dimensions Questionnaire
The EQ-5D-5L is a 5-level standardized instrument for use as a measure of health outcome.  
Applicable to a wide range of health conditions and treatments, it provides a simple 
descriptive profile and a single index value for health status [EuroQol Group, 2014].  The 
EQ-5D-5L consists of 2 assessments, a descriptive system and a visual analogue scale 
(VAS).  The descriptive system comprises of the following 5 dimensions: mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression.  Each dimension has 5 
severity levels: no problems, slight problems, moderate problems, severe problems, and 
extreme problems.  
The VAS records the respondent’s self-rated health on a 20-cm, 0-100 vertical scale with 
endpoints labeled “the best health you can imagine” and “the worst health you can 
imagine”, with higher scores corresponding to a better health state.  This information is used 
as a quantitative measure of health as judged by the individual respondents.
The EQ-5D-5L (see Appendix 10) will be completed by the subject prior to study drug 
administration at Visit 4 (Day 1, Randomization) and at each post-randomization visit 
including the Treatment Discontinuation/Withdrawal Visit. The EQ-5D-5L will be captured 
on the Sponsor-provided tablet, and not in the eDiary.
7.1.4.5
Exacerbations of Chronic Pulmonary Disease Tool (EXACT) 
The EXACT is a 14-item instrument developed to assess the frequency, severity and 
duration of COPD exacerbations (Jones, 2011).  The instrument was developed for daily, at 
home, administration using a handheld electronic device.  Respondents are instructed to 
complete the diary each evening just prior to bedtime and to answer the questions while 
considering their experiences “today”.  The instrument includes assessments of 
breathlessness (5 items), cough and sputum (2 items), chest symptoms (3 items), and 4 
additional items (difficulty with sputum, tired or weak, sleep disturbance, and psychological 
state).  
The daily EXACT total score is computed across the 14 items and has a range of 0-100 with 
higher scores indicative of greater severity.  Total score changes are used to identify the 
onset and recovery from an EXACT-defined exacerbation event.  In identifying event onset 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 74 of 194
and recovery, the EXACT can provide information on event frequency and duration as well 
as event severity.
The E-RS is an 11-item sub-set of the 14- question EXACT to evaluate the severity of 
respiratory symptoms of COPD (Jones, 2011). The E-RS was designed to be captured as 
part of the daily EXACT assessment. On 07 March 2016, the EXACT-Respiratory 
Symptoms Scale was renamed the Evaluating Respiratory Symptoms (E-RS) measure. 
When referring specifically to its use in COPD, the proposed context of use for 
qualification, the full name is now “Evaluating Respiratory Symptoms in COPD (E-RS™: 
COPD). Summation of E-RS item responses produces a total score ranging from 0 to 40, 
with higher scores indicating greater severity. In addition to the total score, symptom 
domain scores can be calculated for breathlessness (5 items; score range: 0–17), cough and 
sputum (3 items; score range: 0–11) and chest symptoms (3 items; score range: 0–11) by 
summing the responses of items within a respective domain. As with the total score, higher 
domain scores indicate greater severity.
The EXACT (see Appendix 11) will be completed daily by the subject as part of the eDiary 
assessments.
7.2
Safety Assessments
The safety assessments include physical examination findings, vital signs, ECGs, and 
clinical laboratory tests in addition to recording of AEs and SAEs. 
7.2.1
Medical/Surgical History and Physical Examination
Medical history, including specific cardiovascular history details, will be collected at 
Screening (Visit 1) and updated during the Screening Period (Visit 1 to Visit 4).  The 
number of COPD exacerbations requiring oral steroids and/or oral antibiotics, or 
hospitalization within 12 months of Screening (Visit 1) will be collected.  A complete 
physical examination will be performed at Visit 1 (Screening) and at Visit 14 (Final Visit) 
or the Treatment Discontinuation/Withdrawal Visit.  A complete physical examination will 
include evaluation of the following:  general appearance, skin, head, eyes, ears, nose, throat, 
neck (including thyroid), lymph nodes, chest, heart, abdomen, extremities, and nervous 
system.  Weight, assessed in ordinary indoor clothing with shoes removed, will be recorded 
at Visit 1 (Screening) and Visit 14 (Final Visit) only.  Height will be recorded at Visit 1
(Screening) only.
7.2.2
Vital Sign Measurements
Vital signs, including HR, SBP, diastolic blood pressure (DBP), and temperature, will be 
assessed as outlined below; assessments may be obtained while the subject is resting for 
5 minutes in either the supine or seated position.
A single set of vital signs will be obtained at Visit 1 (Screening) and the Premature 
Discontinuation Visit.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 75 of 194
Vital signs will be obtained at Visit 2 and Visit 3 within 60 minutes pre-bronchodilator and at 
30 minutes post-bronchodilator. 
At Visit 4 (Randomization) only, pre-dose vital signs will be obtained twice at least 
5 minutes apart within 1 hour prior to dosing. Post-dose vital signs will be obtained at 
30 minutes.  For 4- Hour PFT sub-study subjects only vital signs will be obtained at 2 
hours post study drug dosing.  
• At post-randomization Visits 5, 7, 10, 12, and 14 (Weeks 4, 12, 24, 36, and 52):
-
Pre-dose vital signs will be obtained once within 1 hour prior to dosing
-
Post-dose vital signs will be obtained at 30 minutes.  
-
For PFT sub-study subjects only vital signs will be obtained at 2 hours post study 
drug dosing
Note:  Temperature will be obtained at Visit 1 (Screening) and pre-dose at all visits 
and will not be repeated post-dose at subsequent time points unless clinically 
indicated.
7.2.3
12-Lead Electrocardiogram
A single ECG will be obtained At Visit 1 (Screening) and the Treatment 
Discontinuation/Withdrawal Visit.
Timed ECGs will be obtained as follows:
• At Visit 4 (Randomization Visit) only, Pre-dose ECGs will be obtained twice at least 
5 minutes apart within 1 hour prior to dosing.  
• At post randomization in-clinic visits [Visits 5, 10, and 14 (Weeks 4, 24, and 52)]:
-
Pre-dose ECGs will be obtained once within 1 hour prior to dosing
• For 4-Hour PFT sub-study subjects only, post-dose ECGs will be obtained at 
30 minutes and 2 hours post-dosing at [Visit 4 (Randomization), and Visits 5, 10, and 14 
(Weeks 4, 24, and 52)].
To standardize ECG collection, all sites will be provided with identical ECG equipment 
 with customized study-specific software. 
All study staff responsible for performing ECG collection will receive identical, detailed 
training at the Investigator meetings as well as site phone training sessions.  Each site is 
required to demonstrate proficiency in the use of the equipment and the ability to perform 
technically acceptable ECGs prior to performing testing on study subjects.  After each test is 
performed, the ECG data will be transmitted electronically for centralized quality assurance 
review 
  Feedback on the quality of the 
ECGs will be provided to the investigational site via a site qualification form.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 76 of 194
The ECG parameters that will be assessed include HR, PR interval, QRS axis, QRS interval, 
and QT/QTcF interval.
QT intervals and calculated QTcF intervals will be reviewed and checked for gross 
inaccuracies by the Investigator or designated ECG reviewer.  If the calculated QTcF 
intervals are >500 msec and have increased by 60 msec or more over test day baseline 
value, the Investigator will make a determination on the suitability of continuing the subject 
in the study.  If QTcF interval prolongation exceeding these limits is verified during 
treatment, the subject’s medical history should be examined closely for risk factors that may 
have contributed to the event, including evidence of prior genotyping for hereditary long QT 
syndromes, if appropriate.
Any sign of arrhythmia should be noted.  During treatment, any indication of Torsade de 
Pointes, a polymorphic ventricular tachyarrhythmia that appears on the ECG as continuous 
twisting of the vector of the QRS complex around the isoelectric baseline, must be recorded 
as an AE and reported to the Pearl Medical Monitor. 
All such subjects, including subjects with cardiac arrhythmias, should be monitored closely.  
If appropriate, ECG monitoring should be performed until the QT and QTcF interval and 
waveform morphology have returned to normal. If the prolongation or abnormal rhythm 
persists, the Pearl Medical Monitor must be contacted immediately.
7.2.4
Clinical Laboratory Tests
Clinical safety laboratory tests will be analyzed by a central laboratory according to
standardized, validated assays (see Section 10.4).  The laboratory will supply detailed
instructions and all containers for blood and urine investigations.  Blood sample volumes
will meet the laboratory’s specification.  The central laboratory will supply procedures for 
the preparation and collection of these samples.
All clinical laboratory tests (hematology, clinical chemistry, and urinalysis) will be obtained 
at Visit 1 (Screening) and prior to dosing at Visit 4 (Day 1), Visit 5 (Week 4), Visit 10 
(Week 24), and Visit 14 (Week 52) and the Treatment Discontinuation/Withdrawal Visit.
For subjects participating in the PFT sub-study, a Basic Metabolic Panel (BMP) will be 
obtained at 2 hours post-dosing at Visit 4 (Day 1), Visit 5 (Week 4), Visit 10 (Week 24), 
and Visit 14 (Week 52) or the Treatment Discontinuation/Withdrawal Visit.
7.2.4.1
Hematology 
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, 
eosinophils and platelet count will be measured at Visit 1 (Screening) and prior to dosing at 
Visit 4 (Day 1), Visit 5 (Week 4), Visit 10 (Week 24), and Visit 14 (Week 52) and the 
Treatment Discontinuation/Withdrawal Visit.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 77 of 194
7.2.4.2
Clinical Chemistry
Albumin, alkaline phosphatase, total bilirubin, blood urea nitrogen (BUN), calcium, total 
cholesterol, magnesium, phosphate, sodium, potassium, chloride, creatinine, gamma-
glutamyl transferase, blood glucose, total protein, triglycerides, bicarbonate, aspartate 
aminotransferase (AST), and alanine aminotransferase (ALT) will be measured at Visit 1 
(Screening) and prior to dosing at Visit 4 (Day 1), Visit 5 (Week 4), Visit 10 (Week 24), and 
Visit 14 (Week 52) and the Treatment Discontinuation/Withdrawal Visit.
For subject participating in the PFT sub-study, a Basic Metabolic Panel (BMP) will be 
obtained at 2 hours post-dosing at Visit 4 (Day 1), Visit 5 (Week 4), Visit 10 (Week 24), 
and Visit 14 (Week 52) or the Treatment Discontinuation/Withdrawal Visit.
Refer to Table 7 for a list of study-associated laboratory tests.  The central laboratory will 
supply procedures for the preparation and collection of these samples.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 78 of 194
Table 7.
Clinical Laboratory Tests
Hematology
Hemoglobin 
Mean corpuscular 
hemoglobin 
Hematocrit 
Mean corpuscular hemoglobin 
concentration 
White blood cell count with differential 
Mean corpuscular volume 
Red blood cell count 
Eosinophils
Platelet count 
Clinical Blood Chemistry
Liver Enzyme and Other Liver Function Tests
Other Clinical Blood 
Chemistry
Alanine aminotransferase 
Albumin
Aspartate aminotransferase 
Blood Urea Nitrogen (BUN)
Alkaline phosphatase 
Calciuma
Bilirubin, total 
Chloridea
Gamma-glutamyl transferase 
Cholesterol 
Bicarbonate
Creatininea
Glucosea
Magnesium 
Potassiuma
Phosphate
Protein, total 
Sodiuma
Triglycerides 
Urinalysis
Macroscopic examination including specific gravity, pH, protein, glucose, ketones, blood, and 
urobilinogen.
Other Tests:
Pregnancy test (women of childbearing potential only):  serum hCG at Visit 1 (Screening) and Visit 14 or 
Treatment Discontinuation 
Creatinine clearance will be estimated by the CKD-EPI formula [Levey, 2009].
Abbreviations: CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration; hCG=human chorionic 
gonadotropin
a
Parameters included in the Basic Metabolic Panel.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 79 of 194
7.2.4.3
Urinalysis
Routine macroscopic urinalysis for specific gravity, pH, protein, glucose, ketones, blood, 
and urobilinogen will be measured.  A microscopic examination will be performed if 
warranted based on macroscopic results.
7.2.4.4
Pregnancy Test
A serum pregnancy test will be performed at the central laboratory in pre-menopausal 
women who are not surgically sterile at Visit 1 (Screening) and Visit 14 (Week 52) or the 
Treatment Discontinuation/Withdrawal Visit.  A urine hCG pregnancy test will be 
performed on-site at in-clinic visits (Visits 4, 5, 7, 10, and 12 [Day 1, Weeks 4, 12, 24, and 
36]) (Table 8).
7.2.5
Holter Monitoring 24-Hour Continuous Electrocardiography
The following information applies only to subjects participating in the 24-Hour Holter
Monitoring Sub-study.
The designated service provider for Holter monitoring will be iCardiac Technologies, Inc, 
150 Allens Creek Road, Rochester, NY 14618. All Holter monitor recordings will be 
assessed for cardiac arrhythmias by an independent cardiologist appointed by iCardiac.
Continuous 12-lead ECGs (Holter monitor assessment) will be obtained at Visit 3 (baseline) 
and Visit 8 (Week 16). The Visit 3 and Visit 8 Holter monitor recordings are to be initiated 
in the morning at approximately the same time (+/- 2 hours).
Continuous Holter monitor recording will be collected for a minimum of 24 hours. Holter 
monitor recordings should contain a minimum of 18 hours of acceptable quality recording in 
a 24-hour period to be deemed an acceptable Holter monitor assessment.
The Visit 3 (Screening) Holter monitoring will be initiated subsequent to the post-dose 
spirometry assessments. The Holter recording obtained at Visit 3 will be used to determine 
the subject’s eligibility for participation in the 24-Hour Holter Monitor sub-study and will 
serve as the baseline for all comparisons. If the initial Holter monitor assessment at Visit 3 
is unacceptable, the Holter monitor will be reconnected for another 24 hours using a new 
Holter monitor hook-up kit. The subject will be instructed to continue his/her medications as 
per study protocol. The subject will return the following day for removal of the Holter 
monitor.
If the Holter monitoring quality remains unacceptable on the second attempt, no further 
attempts will be made and the subject will be permitted to enroll in the study but will be 
excluded from the Holter monitor sub-study. If clinically significant findings are noted on 
any of the Holter monitor recordings as defined in Section 5.2.1, the subject will be 
considered a screen failure and will not be eligible to enroll in the study.
At Visit 8 (Week 16) Holter monitoring will be initiated 15-30 minutes prior to the 
administration of the morning dose of study medication. Subjects will take their morning

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 80 of 194
dose of study medication at the clinic. Subjects will be instructed to return to the clinic the 
following day for removal of the Holter monitor.
When the subject returns to the clinic the following day, the quality of the Holter monitor 
recordings will be assessed at the site. If the Holter monitor recordings fail to meet adequate 
quality criteria (acceptable tracings for a minimum of 18 hours) on the first attempt, a 
second attempt will be made for another 24 hours using a new Holter monitor hook-up kit.
The subject will be instructed to continue his/her medications as per study protocol. The 
subject will return the following day for removal of the second Holter Monitor. No further 
attempts are allowed if the second attempt is unacceptable.
Following Holter monitoring at Visit 8 (Week 16), subjects continue on treatment provided
no clinically significant findings (as defined in Section 5.2.1) are reported by iCardiac 
following review of the Holter monitor recordings.
Data for analysis will include:
• General trends including heart rate
• Hourly rhythm comments
• Ventricular ectopy summary
• Ventricular run summary
• Supraventricular ectopy summary
• Supraventricular run summary
• Any other clinically relevant arrhythmias, including atrial fibrillation and pronounced 
bradycardia.
Manual summary interpretation of the data is sent as a report to the site and to Pearl 
Therapeutics.
7.3
Adverse Events
7.3.1
Performing Adverse Event Assessments
The Investigator is responsible for promptly documenting and reporting all AEs observed 
during the study in the subject’s eCRF and on the AE Reporting Form.  If the AE is 
“unexpected,” the Investigator must report the AE immediately to Pearl.  In addition, certain 
AEs (as described in Section 7.3.10) are classified as "serious" and must be reported no later 
than 24 hours after the Investigator recognizes/classifies the event as an SAE to Pearl or its 
designee.
In the case of SAEs, after discussing the details of the event, the Investigator and the Medical 
Monitor may discontinue the subject from treatment prematurely.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 81 of 194
7.3.2
Adverse Event Definitions
The following definitions of terms are guided by the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH), the US Code of Federal Regulations (21 CFR 312.32) and EU Directive 
2001/83/EC and are included herein.
An AE is any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related.  An AE (also referred to as an adverse experience) 
can be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, 
or disease temporally associated with the use of a drug, without any judgment about 
causality.  An AE can arise from any use of the drug (e.g., off-label use, use in combination 
with another drug) and from any route of administration, formulation, or dose, including an 
overdose.
Adverse events include, but are not limited to:
•
Any symptom or condition not previously reported by the subject (medical history)
•
An exacerbation of a pre-existing symptom or condition
•
A significant increase in frequency or intensity of a pre-existing episodic event or 
condition
•
A drug interaction
•
A condition first detected or diagnosed after study drug administration even though it 
may have been present prior to the start of the study
An AE does not include:
•
Medical or surgical procedures (e.g., surgery, endoscopy, tooth extraction, blood 
transfusion); the condition that leads to the procedure is an AE (e.g., bleeding esophageal 
varices, dental caries)
•
Overdose of either study drug or concurrent medication without any clinical signs or 
symptoms
•
Non-clinically significant abnormal laboratory values.  (If accompanied by 
signs/symptoms, the signs or symptoms are considered an AE.)
7.3.3
Pre-Randomization Adverse Events
Adverse events that occur between the time subject signs the informed consent form for the 
study and the time when that subject is randomized will be summarized as medical history 
and not as an adverse event unless the event meets the definition of an SAE as defined in 
Section 7.3.10.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 82 of 194
7.3.4
Severity
The Investigator must categorize the severity of each AE according to the following 
guidelines:
Mild:  Associated with no limitation of usual activities or only slight discomfort; generally,
not requiring alteration or cessation of study drug administration; and/or not needing 
therapeutic intervention.
Moderate:  Associated with limitation of usual activities or significant discomfort; generally 
requiring alteration or cessation of study drug administration; and/or requiring therapeutic 
intervention.
Severe:  Associated with inability of subject to carry out usual activities or very marked 
discomfort; considered to be life-threatening; resulting in significant disability or incapacity; 
and requiring therapeutic intervention.
7.3.5
Relationship
The relationship of each adverse event to the study drug administration will be assessed by 
the Investigator after careful consideration, and according to the following guidelines:
Definitely:  A reaction that follows a reasonable temporal sequence from administration of 
study drug; that follows a known or expected response pattern to the study drug; it disappears 
or decreases on cessation or reduction in study drug dose; and/or it reappears or worsens 
when the study drug is administered.
Probably:  A reaction that follows a reasonable temporal sequence from administration of 
study drug; that follows a known or expected response pattern to the study drug; and/or that 
could not be reasonably explained by other factors such as underlying disease, complications, 
concomitant drugs, or concurrent treatments.
Possibly:  A reaction that follows a reasonable temporal sequence from administration of 
study drug; that follows a known or expected response pattern to the study drug, but that 
could reasonably have been produced by a number of other factors including underlying 
disease, complications, concomitant drugs, or concurrent treatments.
Not Related:  A reaction for which sufficient data exist to indicate that the etiology is 
unrelated to the study drug.
7.3.6
Chronic Obstructive Pulmonary Disease Exacerbations
All moderate or severe COPD exacerbations must be captured using the COPD Exacerbation 
eCRF.  Mild COPD exacerbations will be captured based on symptoms as recorded by the 
subject in the eDiary.  COPD exacerbations of any severity will be considered expected study 
endpoints and will not be reported as adverse events (AEs) unless considered a serious AE 
(SAE).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 83 of 194
Exacerbation(s) of COPD is expected to occur as a progression of disease despite 
standardized drug treatment, or treatment(s) with combination therapies. As a result, the 
Sponsor has classified this event as a protocol specified criteria expected event. Any 
individual case safety reports received related to exacerbation of COPD will not be submitted 
on an expedited basis as a Suspected Unexpected Serious Adverse Reaction (SUSAR) unless 
otherwise required as per the Sponsor’s medical assessment.
7.3.7
Adverse Events of Special Interest
Certain AEs have been identified as adverse events of special interest (AESIs) due to the 
class of drugs being studied. These adverse events will be captured through spontaneous 
reporting and the reporting of these AESIs will be described in the SAP. Some events are 
described below but this is not a comprehensive list of all AESIs.
7.3.7.1
LABA and LAMA Effects
Known effects of LAMAs and LABAs include cardiovascular effects, ocular disorders, 
urinary retention, gastrointestinal disorders, and anticholinergic effects for LAMAs and 
cardiovascular and tremor effects for LABAs. 
7.3.7.2
Local Steroid Effects 
Local steroid effects include oral candidiasis, hoarseness candidiasis, oropharyngeal 
candidiasis, dysphonia, and throat irritation. 
7.3.7.3
Pneumonia
In order to adequately assess and characterize the risk of pneumonia in patients in a non-
biased manner, an external, clinical endpoint committee (CEC) will review all adverse events 
reported as pneumonia to ensure appropriate pre-defined and clinically consistent pneumonia 
criteria are met.
To standardize the diagnosis of pneumonia, a clinically consistent definition of pneumonia 
will be implemented, which will require the following: 
1. Clinical diagnosis of pneumonia by the investigator
2. Documentation of chest imaging obtained within 14 days of the diagnosis of pneumonia 
that is compatible with the diagnosis of pneumonia
3. Treatment with antibiotics (and/or if appropriate antiviral and/or antifungal agents)
4. At least 2 of the following clinical signs, symptoms, or laboratory findings:
•
Increased cough 
•
Increased sputum purulence or production 
•
Adventitious breath sounds on auscultation 
•
Dyspnea or tachypnea
•
Fever

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 84 of 194
•
Elevated white blood cell counts
•
Hypoxemia
The CEC will be empowered to request any additional information, including copies of chest 
X-rays or CT scans if needed, to confirm the pneumonia diagnosis.  
Radiographs will be evaluated locally and the results (infiltrate compatible with pneumonia) 
will be documented within the source document at the sites.  If the investigator becomes 
aware that a diagnosis of pneumonia was made without a chest image having been 
performed, he or she should obtain a chest x-ray (frontal and lateral) up to 10 to 14 days after 
the date of pneumonia diagnosis. 
7.3.7.4
Paradoxical Bronchospasm
Monitoring for paradoxical bronchospasm will occur at each in-clinic visit during the 
Treatment Period (Visits 4 through 14) at 15 and 30 minutes post-dose.  In this study, 
paradoxical bronchospasm is defined as a reduction in FEV1 of >20% from baseline (i.e., the 
mean FEV1 values obtained 60 and 30 minutes prior to study drug administration) that occurs 
within 30 minutes post-dosing with associated symptoms of wheezing, shortness of breath, or 
cough.
7.3.8
Major Adverse Cardiovascular Events
Due to the prevalence of cardiovascular diseases in patients with COPD, MACE will be 
evaluated according to pre-defined criteria as described in the Clinical Endpoint Adjudication 
Charters. The CEC will review potential clinical endpoints to determine if the events meet
the following MACE criteria.
•
Cardiovascular death
•
Non-fatal myocardial infarction (MI)
•
Non-fatal stroke
The Clinical Endpoint Adjudication Charters will be established to govern these processes as 
described in Section 7.3.16. 
7.3.9
Clinical Laboratory Adverse Events
Many laboratory abnormalities observed during the course of a study will be included under 
a reported AE describing a clinical syndrome (e.g., elevated blood urea nitrogen and 
creatinine in the setting of an AE of renal failure, or decreased hemoglobin in a case of 
bleeding esophageal varices).  Isolated laboratory abnormalities should be reported as AEs if 
they are considered to be clinically significant by the Investigator.
Criteria for a "clinically significant" laboratory abnormality are:

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 85 of 194
•
A laboratory abnormality that leads to a dose-limiting toxicity (eg, an abnormality that 
results in study drug dose reduction, suspension, or treatment discontinuation)
•
A laboratory abnormality that results in any therapeutic intervention (ie, concomitant 
medication or therapy)
•
Other laboratory abnormality judged by the Investigator to be of any particular clinical 
concern (e.g., significant fall in hemoglobin not requiring transfusion)
•
For laboratory abnormalities that do not meet the above criteria, but are outside of normal 
range (e.g., < or > normal reference range), the Investigator should indicate whether the 
value is clinically significant or not clinically significant for the subject.
7.3.10
Serious Adverse Events
An AE is considered “serious” if, in the view of the Investigator or Sponsor, it results in any 
of the following outcomes:
•
Death
•
A life-threatening AE
•
In-patient hospitalization or prolongation of existing hospitalization 
•
A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions
•
A congenital anomaly/birth defect
Important medical events that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based upon appropriate judgment, they may 
jeopardize the subject or subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in the definition.  Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in subject hospitalization, or the development of 
drug dependency or drug abuse.
Hospitalization for a pre-existing condition, including elective procedures, which has not 
worsened, does not constitute an SAE.
An adverse reaction or suspected adverse reaction is considered “life-threatening’ if, in the 
view of the Investigator or Sponsor, its occurrence places the subject or subjects at 
immediate risk of death.  It does not include an adverse reaction or suspected adverse 
reaction that, had it occurred in a more severe form, might have caused death.
An adverse reaction or suspected adverse reaction is considered unexpected if it is not listed 
in the current Investigator Brochure (IB) or is not listed at the specificity or severity that has 
been observed. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 86 of 194
7.3.10.1
Reporting of Serious Adverse Events
In agreeing to the provisions of this protocol, the Investigator accepts all legal responsibilities 
for AE identification, documentation, grading, assignment of causality, and prompt notification 
of SAEs to Pearl Pharmacovigilance or designee. All SAEs must be reported to Pearl 
Pharmacovigilance or designee no later than 24 hours after the Investigator 
recognizes/classifies the event as an SAE. All SAEs should be documented and reported 
using the eCRF. At a minimum, a description of the event and the Investigator’s judgment of 
causality must be provided at the time of the initial report using the appropriate form (e.g., 
SAE Report Form). After the initial report, as necessary, the Investigator must provide any 
additional information on an SAE to Pearl Pharmacovigilance or designee within two 
working days after he/she receives that information. This follow-up information will be a 
detailed written report that may include copies of hospital records, case reports, autopsy 
reports, and other pertinent documents.
Post-study SAEs following the last dose of study drug must be reported to Pearl 
Pharmacovigilance as described in Section 7.3.10.4.
The Investigator is responsible for continuing to report any new or relevant follow-up
information that he/she learns about the SAE.
7.3.10.2
Supplemental Investigations of SAEs
The Investigator and supporting personnel responsible for subject care should discuss with 
the Medical Monitor or designee any need for supplemental investigations of SAEs. The 
results of these additional assessments conducted must be reported to Pearl. If a subject dies 
during participation in the study and a post-mortem examination is performed, a copy of the
autopsy report must be submitted to Pearl.
7.3.10.3
Post-Study Follow Up of Adverse Events
Any AEs that are unresolved at the subject’s last AE assessment in the study are followed up 
by the Investigator for as long as medically indicated, but without further recording in the 
eCRF. Pearl retains the right to request additional information for any subject with ongoing 
AE(s)/SAE(s) at the end of the study, if judged necessary.
7.3.10.4
Notification of Post-Study Serious Adverse Events
Investigators are not obligated to actively follow subjects after the completion of the study.  
However, if the Investigator becomes aware of a post-study SAE occurring within the 
14 days following the last dose of study drug, the SAE must be reported to Pearl, whether or 
not the event is attributable to study drug.  All SAEs must be reported to Pearl no later than 
24 hours after the Investigator recognizes/classifies the event as an SAE.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 87 of 194
7.3.10.5
Investigational Research Board/Independent Ethics Committee Notification of 
Serious Adverse Events
The Investigator is responsible for promptly notifying her/his Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) of all SAEs, including any follow-up
information, occurring at his or her site and any SAE regulatory report, including any 
follow-up reports, that he or she receives from Pearl. Documentation of the submission to the 
IRB/IEC must be retained for each safety report. The Investigator is also responsible for 
notifying Pearl if their IRB/IEC requires revisions to the ICF or other measures based on its 
review of an SAE Report.
7.3.10.6
Health Authority Safety Reports
Pearl or its representatives will submit a safety report to the appropriate regulatory agencies 
for any suspected adverse reaction that is both serious and unexpected within the appropriate
time frame.  
Pearl or its representatives will send copies of each safety report submitted to the regulatory 
agencies to the Investigators who are actively participating in Pearl-sponsored clinical 
studies.  Safety reports must also be submitted to the appropriate IRB/IEC as soon as 
possible.  Documentation of the submission to the IRB/IEC must be retained for each safety 
report.
7.3.11
Overdose
An overdose is defined as a dose greater than the high dose level evaluated in this study 
described in Section 6.2 (Product Descriptions) that results in clinical signs and symptoms. In 
the event of an overdose of study drug, the Investigator should use clinical judgment in 
treating the overdose and contact the Medical Monitor. The Investigator should refer to the 
relevant document(s) for detailed information regarding warnings, precautions, 
contraindications, AEs, and other significant data pertaining to the study drug(s) being used 
in this study. Such document(s) may include, but not be limited to; the Investigator’s 
Brochure for BGF MDI, BFF MDI, and GFF MDI and approved product labeling for open-
label products.
7.3.12
Pregnancy
To ensure subject safety, each pregnancy in a female subject from Visit 1 (Screening) until 
study completion must be reported to Pearl within 24 hours of learning of its occurrence.  
The pregnancy should be followed up to determine outcome, including spontaneous or 
voluntary termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications.  Pregnancy should be 
recorded on a Paper Pregnancy Report Form and reported by the Investigator to Pearl 
Pharmacovigilance or designee.  Pregnancy follow-up should be recorded on the same form 
and should include an assessment of the possible relationship to the Pearl study drug of any 
pregnancy outcome.  Any SAE experienced during pregnancy must be reported on the SAE 
Report Form.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 88 of 194
7.3.13
Paternal Exposure
Male subjects who are sexually active must agree to use a double barrier method of 
contraception (condom with spermicide) from the first dose of randomized treatment until 2 
weeks after their last dose and must not donate sperm during their study participation period.  
If a male subject's partner becomes pregnant during the course of the study, it must be 
reported to the Sponsor within 24 hours of the investigator learning of its occurrence.
7.3.14
Hy’s Law
Cases where a subject shows an AST or ALT  3x Upper Limit of Normal (ULN) with Total 
Bilirubin (TBL)  2x ULN may need to be reported as SAEs.  Please refer to Appendix 13
for further instructions in cases of combined increase of aminotransferase and TBL.
7.3.15
Use of Steroids during the Study
At each visit, subjects will be asked whether they have been administered oral, intramuscular, 
or intravenous corticosteroids since their last visit.  Use of oral, intramuscular, or intravenous 
corticosteroids for the management of COPD exacerbations or other conditions is not a 
reason for early treatment discontinuation or study withdrawal.  Use of corticosteroids, 
however, should be documented.  Subjects who are being treated for a COPD exacerbation 
with OCS or have been treated for a COPD exacerbation with OCS within 14 days of a 
scheduled visit will be allowed to perform PFTs under close medical supervision.  The 
Investigator can decide to stop PFTs if subject safety is at risk or symptoms make it difficult 
for the subject to continue.
Subjects treated with oral, IM, or IV corticosteroids for other indications will follow their 
visit schedule.  If a subject requires intraocular corticosteroids, this use should be fully 
documented and the Investigator should make a determination as to the suitability of the 
subject continuing on randomized treatment.
7.3.16
Clinical Endpoint Committee
An external CEC will be established for this study. The committee will provide systematic
and unbiased assessment of pre-defined, Investigator reported AEs. The committee will 
consist of experts who will provide a centralized review functioning independently of Pearl. 
Three Clinical Endpoint Adjudication Charters will outline the clinical endpoints for 
adjudication.
•
Cardiovascular and Cerebrovascular (CCV) Clinical Endpoint Adjudication Charter
•
Cause-Specific Mortality Clinical Endpoint Adjudication Charter
•
Pneumonia Clinical Endpoint Adjudication Charter 
Further details are provided in the Adjudication Committee Charters.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 89 of 194
7.3.16.1
Cardiovascular and Cerebrovascular Clinical Endpoint Adjudication Charter
A Cardiovascular and Cerebrovascular Clinical Endpoint Adjudication Charter will be 
referenced for the review and assessment of non-fatal serious CCV events and classification 
of Major Adverse Cardiovascular Event (MACE). The CEC will review potential clinical 
endpoints to determine if the event meets MACE criteria.
7.3.16.2
Cause-Specific Mortality Clinical Endpoint Adjudication Charter
A Cause-Specific Mortality Clinical Endpoint Adjudication Charter will be referenced for the 
review and assessment of the cause of deaths. The CEC will review fatal reports to determine 
if the event meets MACE criteria. Cardiovascular deaths will be classified as MACE.
7.3.16.3
Pneumonia Clinical Endpoint Adjudication Charter
A Pneumonia Clinical Endpoint Adjudication Charter will be referenced for the review and 
assessment of all pneumonia-related events to ensure appropriate pre-defined and clinically 
consistent pneumonia criteria are met.
7.3.17
Data Monitoring Committee
An external Data Monitoring Committee (DMC) will be set up to provide systematic and 
unbiased assessment of safety for Study PT010005. Members of the DMC will review data at 
predetermined intervals. If significant safety issues arise in between scheduled meetings, ad 
hoc meetings will be scheduled to review the data. Based on the safety implications of the 
data, the DMC may recommend modification or termination of the study.
7.4
Health Care Resource Utilization
The number of days missed from work, days that primary caregivers of subjects missed work 
as a result of the subjects COPD, telephone calls to health care providers, visits to health care 
providers, Emergency Room (ER) visits,   days in the hospital, days in Intensive Care Units
(ICU), days in Coronary Care Units (CCU), , use of ambulance transport, will be captured at 
Visit 5 (Week 4), Visit 6 (Week 8), Visit 7 (Week 12), Visit 8 (Week 16), Visit 9 (Week 20), 
Visit 10 (Week 24), Visit 11 (Week 28), Visit 12 (Week 36), Visit 13 (Week 44),  Visit 14 
(Week 52), and telephone follow up call or Treatment Discontinuation/Withdrawal Visit.
7.5
Termination of the Study
An Investigator may choose to discontinue study participation at any time with sufficient 
notice by the Investigator for any reason as per the terms of the contract with Pearl.  
Pearl reserves the right to discontinue the study at any time for clinical or administrative 
reasons.  Such a termination must be implemented by the Investigator, if instructed to do so 
by Pearl, in a time frame that is compatible with the subjects’ wellbeing.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 90 of 194
8
STUDY ACTIVITIES
A time and events schedule is provided in Table 8. Other detailed schedules are provided for 
timed assessments for all post-randomization in-clinic visits for subjects participating in the 
PFT sub-study (Visits 4, 5, 7, 10, 12, and 14; Day 1, Weeks 4, 12, 24, 36, and 52) Table 8-1;
timed assessments for all post-randomization in-clinic visits for subjects NOT participating 
in the PFT sub-study (Visits 4, 5, 7, 10, 12, and 14; Day 1, Weeks 4, 12, 24, 36, and 52)
Table 8-2; assessments to be collected at telephone visits (Visits 6, 8, 9,  11, and 13; Weeks 
8, 16, 20, 28, and 44) Table 8-3; timed assessment at Visit 3 (Screening Period) and Visit 8 
(Week 16) for 24-hour Holter Monitoring Sub-study, Table 8-4.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 91 of 194
Table 8. Schedule of Events
Procedures
Screening
52-Week Treatment Period
Follow-
up
TC
Visit
1
Visit
2
Visit
3
Visit 4
(Rand)
Visit 5
Week 4
Visit 6
Week 8
Visit 7
Week 12
Visit 8
Week 16
Visit 9
Week 20
Visit 10
Week 24
Visit 11
Week 28
Visit 12
Week 36
Visit 13
Week 44
Visit 14
Week 52
Study Daya
Day
-28 to -
12
Day
-16 to -
2
Day
-15 to -
1
Day
1
Day
29±2
Day
57±5
Day
85±5
Day
113±5
Day
141±5
Day
169±5
Day
197±5
Day
253±5
Day
309±5
Day
366±5
Day
380
IN-CLINIC
X
X
X
X
X
X
X
X
X
TELEPHONE 
CONTACT
X
X
X
X
X
X
Informed Consent
X
Eligibility Criteria
X
X
X
X
Verify Continued 
Eligibility 
X
X
X
X
X
Reversibility Testingb
X
X
Demographics and 
Medical/Surgical 
History
X
Smoking Status
X
X
X
X
X
X
X
X
X
Chest Imaging
Xq
CATc
X
X
Prior/Concomitant 
Medicationsd
X
X
X
X
X
X
X
X
X
X
X
X
X
Xp
X
Spirometry (All 
subjects)e
X
X
X
Spirometry (PFT Sub-
study) e
X
X
X
X
X
X
Physical Examinationf
X
Xp
Vital Signs
X
X
X
X
X
X
X
X
Xp
12-Lead ECGg
X
X
X
X
Xp
Pregnancy Testh
X
X
X
X
X
X
Xp
Clinical Laboratory 
Testingi
X
X
X
X
Xp
Adjust COPD 
Medicationsj
X
Xp
Adverse Events/COPD 
Exacerbations.
X
X
X
X
X
X
X
X
X
X
X
X
X
Xp
X

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 92 of 194
Procedures
Screening
52-Week Treatment Period
Follow-
up
TC
Visit
1
Visit
2
Visit
3
Visit 4
(Rand)
Visit 5
Week 4
Visit 6
Week 8
Visit 7
Week 12
Visit 8
Week 16
Visit 9
Week 20
Visit 10
Week 24
Visit 11
Week 28
Visit 12
Week 36
Visit 13
Week 44
Visit 14
Week 52
Study Daya
Day
-28 to -
12
Day
-16 to -
2
Day
-15 to -
1
Day
1
Day
29±2
Day
57±5
Day
85±5
Day
113±5
Day
141±5
Day
169±5
Day
197±5
Day
253±5
Day
309±5
Day
366±5
Day
380
IN-CLINIC
X
X
X
X
X
X
X
X
X
TELEPHONE 
CONTACT
X
X
X
X
X
X
Inhalation Device and 
Dose Indicator Training
X
X
X
X
Study Drug Dispensingj
XJ
X
X
X
X
X
X
24-hour Holter 
Monitoring k
X
X
Study Drug Collection
X
X
X
X
X
Xp
Study Drug 
Administrationl
X
X
X
X
X
X
BDI/TDIm
X
X
X
X
X
Xp
SGRQm
X
X
X
X
X
Xp
EQ-5D-5Lm
X
X
X
X
X
Xp
HCRU
X
X
X
X
X
X
X
X
X
Xp
X
eDiary 
Dispensing/Collection
X
Xp
eDiary Trainingn
X
eDiary Reviewo
X
X
X
X
X
X
X
X
Vital Status Check
X
Abbreviations: BDI/TDI=Baseline Dyspnea Index/Transition Dyspnea Index; CAT=COPD Assessment Test; COPD=chronic obstructive pulmonary disease; 
eDiary=electronic diary; ECG=electrocardiogram; EQ-5D=EuroQol 5 Dimensions Questionnaire; Exac.=exacerbations; EXACT =Exacerbations of Chronic Pulmonary 
Disease Tool; hCG=human chorionic gonadotropin; HCRU=health care resource utilization; MDI=metered dose inhaler; PFT=pulmonary function test; Rand=randomization; 
SGRQ=St. George’s Respiratory Questionnaire; TC=Telephone Call
a
Scheduling Visits: The minimum Screening Period is between 1 to 4 weeks in duration (can be extended to a maximum of 10 weeks in case of an exacerbation during the 
Screening Period). Sites should make every effort to maintain subjects within the scheduled visit window.  Subjects who fall outside the visit window will be placed in 
the appropriate visit window at the next scheduled visit.
b
Subjects will be tested for reversibility within 30 minutes following 4 puffs of albuterol (Visit 2) and ipratropium bromide (Visit 3).
c
Subjects will complete the CAT at Screening (Visit 1) as an entry criterion. Subjects will also complete the CAT at Randomization (Visit 4) to characterize the 
population on maximal therapy.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 93 of 194
d
At all in-clinic visits beyond Visit 1 (Screening), note time of last dose of short-acting bronchodilator and other COPD medications (if < 6 hours, visit should be 
rescheduled)
e
Refer to Section 7.1.1 for spirometry assessments and specific time points required for Screening, and for the PFT sub-study. Table 8-1 also provides the timed assessments 
for the PFT sub-study. While the PFT sub-study was previously open to all eosinophil levels, subjects must now have a blood eosinophil count of  150 cells per mm3 at 
Visit 1 to participate in the PFT sub-study. NOTE: Subjects, who have met all of the inclusion criteria but have failed to meet acceptability or repeatability criteria at Visit 1, 
may continue to Visit 2.  Provided these subjects meet all spirometry criteria at Visit 2, including acceptability and repeatability, they are eligible for inclusion in the main 
study but they are excluded from participating in the PFT sub-study.  Subjects who fail to meet acceptability and repeatability criteria at Visit 2 must be screen failed.
f
Physical examination includes evaluation of weight at Visit 1 (Screening) and Visit 14 (Final Visit) and height at Visit 1 (Screening) only.
g
Refer to Section 7.2.3 for ECG assessments and specific time points.
h
Females of childbearing potential: A serum pregnancy test will be performed at the central laboratory in pre-menopausal women who are not surgically sterile at Visit 1
(Screening) and Visit 14 (Week 52) or at the Treatment Discontinuation/Withdrawal Visit.  A urine hCG pregnancy test will be performed on-site at in-clinic visits 
(Visits 4, 5, 7, 10, and 12 [Day 1, Weeks 4, 12, 24, and 36])  If any of these tests are positive, the subject must be discontinued from the study.
i
Refer to Section 7.2.4 for clinical laboratory assessments and specific time points.
j
At Visit 1 (Screening), stop prohibited COPD medications and change COPD medications as specified in Section 5.4.3 (i.e., ipratropium bromide for use between Visits 
1 to 4, and albuterol for rescue use throughout the study).  Sponsor-provided run-in medication will be dispensed only after a subject is determined to be eligible to 
proceed to Visit 2 (i.e., only if a subject meets COPD definition following spirometry assessments at Screening) and will be collected prior to Randomization at Visit 4.  
At the end of Visit 14, return subject to pre-study or other appropriate inhaled maintenance COPD medications.
k
Refer to Section 7.2.5 for further information on 24-Hour Holter Monitoring. Table 8-4 also provides the timed assessments for the 24-Hour Holter Monitoring sub-
study.  Visit 8 (Week 16) is an in-clinic visit for subjects participating in the 24-Hour Holter Monitoring Sub-study
l
In-clinic dosing time is recorded as time of the 2nd puff/inhalation.  The in-clinic dosing time should occur within 12±2 hours of the prior evening dosing time.
m
When BDI/TDI, SGRQ, and/or EQ-5D-5L are obtained at the same visit, BDI/TDI will be collected first followed immediately by SGRQ, then EQ-5D-5L.  These 
questionnaires must be completed by the subject prior to any other visit procedures.
n
Subjects will be issued and trained on eDiary use only after they are determined to qualify to proceed to Visit 2.
o
Subjects will be asked to maintain a daily record of their study drug dosing and rescue medication use.  EXACT will be reviewed at each visit as part of the subject diary 
review.  Refer to Section 7.1.2 for details on subject diary review.
p
These are the minimum procedures that should be completed at a Treatment Discontinuation/Withdrawal Visit, refer to Section 8.9.
q
Obtain a new chest x-ray if image was not obtained within the 6 months prior to Visit 1 (Screening). In countries with restrictive radiology assessment practices, subjects 
who have had a chest x-ray or CT scan (thorax) performed outside of the study in the last 6 months are allowed to be enrolled. Alternatively, in these countries, an MRI 
may be used instead of a CT scan or chest x-ray as per local practice assessment.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 94 of 194
Table 8-1.
Timed Assessments for all Post-randomization In-clinic Visits for Subjects Participating in the PFT 
Sub-study (Visits 4, 5, 7, 10, 12, and 14; Day 1, Weeks 4, 12, 24, 36, and 52)
Clinical Variable
Pre-dose
Post-dose
-1 hour
-30
minutes
5
minutes
15
minutes
30
minutes
1
hour
2
hours
4
hours
Review of Electronic Diarya
X
Vital Signsb,c
X
X
X
Spirometry (FEV1, FVC, PEFR, 
FEF25-75)f
X
X
Xf
X
X
X
X
X
Study Drug Collection/Dispensingg,h
X†
TDIi
X†
SGRQi
X†
EQ-5D-5Li
X†
Assessments to be performed at Visits 4, 5, 10, and 14 (Day 1, Weeks 4, 24, and 52)
12-Lead ECGb,d
X
X
X
Clinical Laboratory Testingb,e
X†
X
Abbreviations:  BDI/TDI=Baseline Dyspnea Index/Transition Dyspnea Index; COPD=chronic obstructive pulmonary disease; ECG=electrocardiogram; EQ-5D-
5L=EuroQol 5 Dimensions Questionnaire; EXACT =Exacerbations of Chronic Pulmonary Disease Tool; FEF25-75=forced expiratory flow between 25% to 75% of FVC; 
FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity; hCG=human chorionic gonadotropin; PEFR=peak expiratory flow rate;  PFT=pulmonary function 
test; SGRQ=St. George’s Respiratory Questionnaire
Note: While the PFT sub-study was previously open to all eosinophil levels, subjects must now have a blood eosinophil count of  150 cells per mm3 at Visit 1 to 
participate in the PFT sub-study.
Note: The time point at which dosing is to occur is regarded as “0 minutes”. When data collection time-points are concurrent, it is recommended that variables be collected 
in the following order: BDI/TDI, SGRQ, EQ-5D-5L, vital signs, ECG, clinical laboratory assessments, and spirometry.
†
This is not a timed assessment. Sites should plan to perform these activities so as not to interfere with collection of timed assessments such as spirometry.
a
EXACT will be reviewed at each visit as part of the subject diary review.  Refer to Section 7.1.2 for details on subject diary review. 
b
Safety assessments (vital signs, clinical laboratory assessments, ECGs) should be started approximately 5 to 10 minutes ahead of the specified time point to ensure that 
spirometry for FEV1, FVC, PEFR, and FEF25-75 determination will be conducted as close to the specified time points as possible (i.e., FEV1, FVC, PEFR, and FEF25-75
assessments need to be conducted within ±15 minutes of specified time prior to study drug administration; ±5 minutes of specified time for the first 60 minutes after 
study drug administration; and  ±15 minutes of specified time point for assessments obtained thereafter).  

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 95 of 194
c
At Visit 4 only, pre-dose vital signs (heart rate, blood pressure) will be collected twice, at least 5 minutes apart.  Temperature will be obtained pre-dose at all visits and 
will not be repeated post-dose at subsequent time points unless clinically indicated.  Refer to Section 7.2.2 for vital signs assessments and specific time points.
d
At Visit 4 only, pre-dose ECG will be collected at least twice, 5 minutes apart.  Refer to Section 7.2.3 for ECG assessments and specific time points
e
All clinical laboratory tests (hematology, chemistry, and urinalysis) will be assessed within 60 minutes prior to dosing at these visits.  The 2-hour post-dose collection 
will be a basic metabolic panel only.  Females of childbearing potential: Serum pregnancy test will be performed at Visit 1 (Screening) and Visit 14 (Final Visit) or at 
the Treatment Discontinuation/Withdrawal Visit; urine hCG screening will be performed at in-clinic visits (Visits 4, 5, 7, 10, and 12 [Day 1, Weeks 4, 12, 24, and 
36]).  Refer to Section 7.2.4 for clinical laboratory assessments and specific time points. 
f
Spirometry assessments will be obtained in those subjects participating in the PFT sub-study.  Post-dose spirometry will be collected at 5 minutes on Visit 4 (Day 1) 
only.  Refer to Section 7.1.1 for spirometry assessments and specific time points.
g
At the start of each treatment visit, subjects must withhold all COPD medications, including study medication and rescue Ventolin HFA for at least 6 hours prior to 
start of test day procedures.  
h
Dispense study drug to subject for at-home use following the completion of all post-dose assessments.  See Section 6.7 for Instructions for Preparation of Treatments 
for Administration and Dispensing. Study drug will not be dispensed at Visit 14 (Week 52).
i
When BDI/TDI, SGRQ, and/or EQ-5D-5L are obtained at the same visit, BDI/TDI will be collected first followed immediately by SGRQ, then EQ-5D-5L. These 
questionnaires must be completed by the subject prior to any other visit procedures.  BDI/TDI will be obtained at all in clinic post randomization visits.  SGRQ will be 
obtained at Visits 4, 5, 7, 10, 12 and 14 (Day 1 and Weeks 4, 12, 24, 36 and 52).  EQ5D-5L will be obtained at Visits 4, 5, 7, 10, 12 and 14 (Day 1 and Weeks 4, 12, 
24, 36 and 52).  Refer to Section 7.1.4 for subject questionnaires and time points.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 96 of 194
Table 8-2.
Timed Assessments for all Post-randomization In-clinic Visits for Subjects not Participating in the 
PFT Sub-study (Visits 4, 5, 7, 10, 12, and 14; Day 1, Weeks 4, 12, 24, 36, and 52)
Clinical Variable
Pre-dose
Post-dose
-1 hour
30 minutes
Review of Electronic Diarya
X
Vital Signsb
X
X
12-Lead ECGc
X
Clinical Laboratory Testingd
X†
Study Drug Collectione
X†
Study Drug Dispensingf
BDI/TDIg
X†
SGRQg
X†
EQ-5D-5Lg
X†
Abbreviations:  BDI/TDI=Baseline Dyspnea Index/Transition Dyspnea Index; COPD=chronic obstructive pulmonary disease; ECG=electrocardiogram; EQ-5D-
5L=EuroQol 5 Dimensions Questionnaire; EXACT =Exacerbations of Chronic Pulmonary Disease Tool; hCG=human chorionic gonadotropin; SGRQ=St. George’s 
Respiratory Questionnaire
Note: The time point at which dosing is to occur is regarded as “0 minutes”. When data collection time-points are concurrent, it is recommended that variables be 
collected in the following order: BDI/TDI, SGRQ, EQ-5D-5L, vital signs, ECG, and clinical laboratory assessments. 
†
This is not a timed assessment. Sites should plan to perform these activities so as not to interfere with collection of timed assessments such as vital signs and ECGs.
a
EXACT will be reviewed at each visit as part of the subject diary review. Refer to Section 7.1.2 for details on subject diary review.
b
Temperature will be obtained pre-dose at all visits and will not be repeated post-dose at subsequent time points unless clinically indicated.  Refer to Section 7.2.2 for 
vital signs assessments and specific time points.
c
ECGs will be performed at Visits 4, 5, 10, and 14 only (Day 1, and Weeks 4, 24, and 52; see Table 8. Refer to Section 7.2.3 for ECG assessments and specific time 
points
d
Clinical laboratory tests will be performed at Visits 4, 5, 10, and 14 only (Day 1, and Weeks 4, 24, and 52); see Table 8.  All clinical laboratory tests 
(hematology, chemistry, and urinalysis) will be assessed within 60 minutes prior to dosing at these visits.  Females of childbearing potential will undergo a urine 
hCG screening at in-clinic visits (Visits 4, 5, 7, 10, and 12,[Day 1, Weeks 4, 12, 24, and 36]).  Refer to Section 7.2.4 for clinical laboratory assessments and specific 
time points
e
At the start of each treatment visit, subjects must withhold all COPD medications, including study medication and rescue Ventolin HFA for at least 6 hours prior to 
start of test day procedures
f
Dispense study drug to subject for at-home use following the completion of all post-dose assessments.  See Section 6.7 for Instructions for Preparation of Treatments 
for Administration and Dispensing. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 97 of 194
g
When BDI/TDI, SGRQ, and/or EQ-5D-5L are obtained at the same visit, BDI/TDI will be collected first followed immediately by SGRQ, then EQ-5D-5L. These 
questionnaires must be completed by the subject prior to any other visit procedures.  BDI/TDI will be obtained at all in clinic post randomization visits.  SGRQ will 
be obtained at Visits 4, 5, 7, 10, 12 and 14 (Day 1 and Weeks 4, 12, 24, 36 and 52).  EQ5D-5L will be obtained at Visits 4, 5, 7, 10, 12 and 14 (Day 1 and Weeks 4, 
12, 24, 36 and 52).  Refer to Section 7.1.4 for subject questionnaires and time points.
Table 8-3.
Assessments to be collected at Post-randomization Telephone Visits (Visits 6, 8, 9, 11, and 13; 
Weeks 8, 16, 20, 28, and 44)
Clinical Variable
Review of Electronic Diary
X
AEs/Exacerbations
X
Concomitant Medications
X
HCRU
X
Abbreviations: AEs = Adverse Events; HCRU = Health Care Resource Utilization

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 98 of 194
Table 8-4.
Schedule of Events at Visit 3 (Screening Period) and Visit 8 (Week 16) for 24-Hour Holter Monitoring 
Sub-study
Screening Period
Treatment Period
Procedures
Visit 3
Visit 3b
Visit 3c
Visit 8
Visit 8b
Visit 8c
24-Hour Holter Monitoring (1st Attempt)
Xa
Xb
Removal of 24-Hour Holter Monitor (1st
Attempt)c
X
X
24-Hour Holter Monitoring (2nd Attempt)d
Xd
Xd
Removal of 24-Hour Holter Monitor (2nd
Attempt)e
Xe
Xe
a.
Attach Holter monitoring device and initiate 24-hour Holter Monitor recording following the post-dose spirometry assessments.
b.
Attach Holter monitoring device and initiate 24-hour Holter Monitor recording following the pre-dose spirometry assessments but 15-30 minutes prior to the administration of the morning dose of 
study medication.
c.
Site personnel will determine the acceptability of Holter monitor recording.   
d.
If the Holter monitor recordings fail to meet adequate quality criteria (acceptable tracings for a minimum of 18 hours) on the first attempt, a second attempt will be made for another 24 hours using a 
new Holter monitor hook-up kit.
e.
No further attempts will be allowed if the second attempt is unacceptable.
Note: Subjects can proceed to Visit 4 (Randomization) or Visit 8 (Week 16) provided no clinically significant findings (as defined in Section 5.2.1) are reported by iCardiac 
following review of the Holter monitor recordings.
Note: Subjects who discontinue treatment before Week 12 will NOT be eligible for Holter assessments.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 99 of 194
8.1
Visit 1 (Screening)
•
Obtain informed consent.
•
Register the subject in IWRS to obtain subject screening number. 
•
Obtain demographic data, including age, race, smoking history/status, medical/surgical 
history (including cardiovascular risk factors and history), and age of onset of COPD.
•
Review inclusion/exclusion criteria.
•
Obtain medication history, including COPD medications.
•
Conduct a serum pregnancy test for all female subjects unless it is documented in the 
medical history that the subject has been irreversibly surgically sterilized (hysterectomy, 
oophorectomy, or bilateral tubal ligation) or they are at least 2 years post-menopausal.
•
Conduct a complete physical examination (general appearance, skin, head, eyes, ears, 
nose, throat, neck [including thyroid], lymph nodes, chest, heart, abdomen, extremities, 
and nervous system).
-
Record COPD exacerbations and AEs (if any). 
Note: Adverse events that occur during the Screening Period (Visit 1 to Visit 4, 
before study drug dosing) will be summarized as medical history and not as a study 
AE, unless the event meets the definition of an SAE. 
•
Obtain height, weight, and vital signs (HR and blood pressure after being supine or seated 
for 5 minutes, and temperature).
•
Obtain a 12-lead ECG.
•
Obtain CAT
•
Conduct spirometry assessments.
•
Confirm subject’s ability to use MDI correctly (provide coaching as needed).
•
If subject qualifies to continue to Visit 2 perform the following:

Obtain laboratory samples (hematology, chemistry, and urinalysis).

If Chest x-ray or CT within 6 months of Visit 1 (Screening) is not available, 
obtain a new Chest x-ray except in countries with restrictive radiology 
assessment practice (e.g. Germany) where only subjects who have had a chest 
x-ray or CT scan (thorax) performed outside of the study in the last 6 months 
are allowed to be enrolled. Alternatively, in these countries, an MRI may be 
used instead of a CT scan or chest x-ray as per local practice assessment.

Stop prohibited COPD medications and change concurrent COPD 
medications, as specified in protocol (refer to Section 5.4).

Obtain subject assignment information of Atrovent HFA and Ventolin HFA 
from IWRS.

Provide subjects with study drug as assigned by IWRS.

Dispense and train subject on eDiary use.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 100 of 194

During the screening period, subjects that are receiving an ICS/LABA will 
discontinue the ICS/LABA, but will continue the ICS component for the 
remainder of the screening period. Similarly, subjects treated with an ICS as 
part of their inhaled maintenance therapy will also be permitted to continue 
their ICS for the remainder of the screening period. All subjects will receive 
open-label Atrovent® hydrofluoroalkane (HFA; ipratropium bromide 
inhalation aerosol) administered QID for maintenance during Screening. 
Ventolin® HFA (albuterol sulfate inhalation aerosol) will be provided for 
rescue use throughout the study. All ICS use will be stopped at 
randomization.

In order to allow for adequate washout of previous maintenance medications, 
subjects will undergo a Washout Period of at least 1 week (at least 2 weeks if
taking Spiriva), but not greater than 26 days in duration prior to returning to
the clinic for Visit 2. In instances where an exacerbation has occurred during 
the Screening Period, the Screening Period may be extended to a maximum of 
10 weeks (to account for a course of OCS of up to 2 weeks in duration and a 
4-week period after treatment for exacerbation).
•
Schedule Visit 2
-
Adverse events and COPD exacerbations must be recorded during the Screening 
Period, that is, from the time of consent to the start of study treatment. 
-
It is recommended that sites call subjects on the day before their scheduled Visit 2 
and remind them of these expectations for the upcoming visit.
-
Subjects will be instructed to bring their eDiary, Sponsor-provided Ventolin HFA and 
Atrovent HFA to the next scheduled clinic visit.
8.2
Visit 2
•
Review subject diary entries and retrain subject if subject has not met diary compliance 
requirement of >70% subject completion of diary assessments.
•
Determine time of last dose of short-acting bronchodilator and other COPD medications 
(if <6 hours, Visit 2 must be rescheduled).
•
Review inclusion/exclusion criteria and confirm subject eligibility to continue.
•
Review smoking status
•
Record COPD exacerbations and AEs (if any).
Note: Adverse events that occur during the Screening Period (Visit 1 to Visit 4, pre study 
drug dosing) will be summarized as medical history and not as a study AEs unless the 
event meets the definition of an SAE.
•
Review all prior medications and ensure adherence to COPD regimen.
•
Obtain vital signs 60 minutes pre-bronchodilator and 30 minutes post-bronchodilator.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 101 of 194
•
Perform reversibility test to Ventolin HFA (sees Section 7.1.1.1 for instructions) and 
confirm if subject continues to meet entry criteria based on pre- and post-dose spirometry 
quality (see Exclusion Criteria 5.2 #3l), and post-dose spirometry values.
•
Obtain spirometry pre-bronchodilator 60 and 30 minutes and 30 minutes post 
bronchodilator.
•
Schedule Visit 3.
Note: Visit 3 can be scheduled a minimum of 1 day after Visit 2 and no later than 
27 days after Visit 1 (Screening). In instances where an exacerbation has occurred during 
the Screening Period, the Screening Period may be extended to a maximum of 10 weeks 
(to account for a course of oral corticosteroids of up to 2 weeks in duration and a 4-week 
period after treatment of the exacerbation).
•
Ensure subject has adequate supply of Sponsor-provided Atrovent HF, and rescue 
Ventolin HFA.
•
Provide subjects with study drug as assigned by IWRS.
•
Subjects will be instructed to bring their eDiary, and Sponsor-provided Atrovent HFA 
and Ventolin HFA to the next scheduled clinic visit.
8.3
Visit 3
•
Review subject diary entries and retrain subject if subject has not met diary compliance 
requirement of >70% subject completion of diary assessments.
•
Review all prior medications and ensure adherence to COPD regimen.
•
Determine time of last dose of short-acting bronchodilator and other COPD medications 
(if <6 hours, Visit 3 must be rescheduled).
•
Review inclusion/exclusion criteria and confirm subject eligibility to continue.
•
Review smoking status
•
Record COPD exacerbations and AEs (if any). 
Note: Adverse events that occur during the Screening Period (Visit 1 to Visit 4, pre-study 
drug dosing) will be summarized as medical history and not as a study AEs unless the 
event meets the definition of an SAE.
•
Obtain vital signs 60 minutes pre-bronchodilator and 30 minutes post-bronchodilator.
•
Perform reversibility test to Sponsor-provided Atrovent HFA (see Section 7.1.1.1 for 
instructions).
•
Obtain spirometry pre-bronchodilator 60 and 30 minutes and 30 minutes post 
bronchodilator.
•
If a subject is participating in the 24 –hour Holter Monitoring Sub-Study, attach 
Holter monitor and initiate 24-hour Holter monitor recording following the post-dose 
spirometry assessments (see Section 7.2.5 and Table 8-4 for further instructions).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 102 of 194
•
Subjects will be instructed to return the following day (Visit 3b) for the removal of 
the Holter monitor.
•
Schedule Visit 4 (Randomization Visit, Day 1).
Note: Visit 4 (Randomization Visit, Day 1) can be scheduled at minimum 1 day after 
Visit 3 and no later than 28 days after Visit 1 (Screening).
Ensure subject has adequate supply of sponsor-provided Atrovent HFA and sponsor-
provided rescue Ventolin HFA.
•
Provide subjects with study drug as assigned by IWRS.
•
Subjects will be instructed to bring their eDiary, Atrovent HFA, and sponsor-provided 
Ventolin HFA to the next scheduled clinic visit.
8.4
Visit 4 (Randomization, Day 1)
•
Review subject diary entries and screen fail subject if subject has not met diary 
compliance requirement of >70% subject completion of diary assessments in the last 
7 days preceding Visit 4.
•
If a subject is participating in the PFT sub-study, determine time of last dose of short-
acting bronchodilator and other COPD medications (if <6 hours, Visit 4 must be 
rescheduled).
Note: While the PFT sub-study was previously open to all eosinophil levels, subjects 
must now have a blood eosinophil count of  150 cells per mm3 at Visit 1 to participate in 
the PFT sub-study.
•
Have subject complete BDI questionnaire followed by SGRQ questionnaire, and EQ-5D-
5L, before any other study procedures are performed.
•
Obtain CAT (only to characterize the population on maximal therapy)
•
Record COPD exacerbations and AEs (if any).
•
Review smoking status
•
A urine pregnancy test will be performed for women of childbearing potential at each of 
the in-clinic visits.
•
Review all concomitant medications and ensure adherence to COPD regimen.
•
Subjects treated with an ICS during screening must discontinue ICS use prior to 
randomization and throughout the study.
•
Collect Sponsor-provided Atrovent HFA and Ventolin HFA dispensed during the 
Screening Period.

Discontinue all ICS throughout the study

Ventolin HFA will be provided for rescue use throughout the study
•
Review inclusion/exclusion criteria and confirm subject eligibility for randomization.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 103 of 194
•
Obtain subject randomization number and treatment assignment information from IWRS.
Note: The subject is to be considered randomized after receiving a randomization 
number.
•
Complete all pre-dose assessments (refer to Table 8-2).
o
Obtain central laboratory tests 
o
Obtain vital signs and ECGs twice at least five minutes apart 60 minutes pre-dose
x
For Subjects participating in the 4-Hour PFT sub-study, perform spirometry 
assessments 60 and 30 minutes pre-dose (see Table 8-1).
Note: To be randomized, subjects in the PFT sub-study must meet the reproducibility 
criteria (see Section 7.1.1.2 for additional details).  If the FEV1 Baseline Stability criteria 
are not met at Visit 4 (Randomization) the subject will not be eligible to be participate in 
the PFT sub-study but may be randomized and included in the overall study.
Note: While the PFT sub-study was previously open to all eosinophil levels, subjects 
must now have a blood eosinophil count of  150 cells per mm3 at Visit 1 to participate in 
the PFT sub-study.
•
To allow for proper preparation of study drug, it is recommended that the seal around the 
study day treatment box is opened 15 to 30 minutes prior to dosing and the instructions 
for administration of study drug followed:
-
Refer to Appendix 4 for detailed instructions for preparation of treatments for 
administration.  These instructions are to be adhered to and are relevant to all study 
treatment visits.
-
Record/document the dose indicator reading (see Appendix 12).  The dose indicator 
count recorded by the site staff will be dose indicator count observed after priming 
but prior to subject dosing.  For new MDIs, the recorded count will be the count 
following the priming of the device but before the subject dose.
•
Subject will administer first dose of randomized study drug at the clinic.
•
Perform all post-dosing assessments (see Table 8-3).
o Obtain vital signs 30 minutes post-dose
•
For Subjects participating in the 4-Hour PFT sub-study:
o
Perform spirometry assessments 5, 15, 30 minutes and 1, 2, and 4 hours post-dose 
(see Table 8-1).
o
Central Laboratory Test (BMP) will be collected 2 hours post-dose
o
Obtain vital signs and ECGs 30 minutes and 2 hours post- dose
•
Return eDiary to subjects and provide retraining if appropriate.
•
Subjects will be instructed to bring their eDiary and all issued study drug (including used 
study drug and rescue Ventolin HFA) to the next scheduled clinic visit.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 104 of 194
•
Provide subjects with study drug as assigned by IWRS.
•
Schedule Visit 5 and ensure subject has adequate supply of study drug including rescue 
Ventolin HFA.
8.5
In-Clinic Visits 5, 7, 10, and 12 (Weeks 4, 12, 24, 36)
•
Review subject eDiary (including EXACT etc.) for data collection compliance.
•
Determine time of last dose of short-acting bronchodilator and other COPD medications 
(if <6 hours, visit must be rescheduled).
•
Review smoking status
•
A urine pregnancy test will be performed for women of childbearing potential at each in-
clinic visits.
•
Confirm subject eligibility to continue.
•
At each in-clinic post-randomization visit, have subject complete TDI questionnaire 
followed by SGRQ, and EQ-5D-5L questionnaires, if applicable, before any other study 
procedures are performed.
•
Collect HCRU information.
•
Record COPD exacerbations and AEs (if any).
•
Review all concomitant medications and ensure adherence to COPD regimen.
•
Perform all pre-dose assessments (see Table 8-3).
o
Obtain central laboratory tests at Visit 5 and Visit 10 only
o
Obtain vital signs 60 minutes pre-dose at Visit 5, 7, 10 and 12 
o
Obtain ECGs 60 minutes pre-dose at Visit 5 and 10 only
•
For Subjects participating in the 4-Hour PFT sub-study, perform spirometry 
assessments 60 and 30 minutes pre-dose (see Table 8-1)
•
Return eDiary to subjects and provide retraining if appropriate.
•
Prior to dosing, site personnel will use IWRS to assign subjects adequate supply of study 
drug for in-clinic dosing and to continue dosing at home until the next scheduled visit.
o
See Section 6.7 for detailed instructions for preparation of treatments for 
administration.  These instructions are to be adhered to and are relevant to all study 
treatment visits.
o
Record/document the dose indicator readings of the used MDI and the replacement 
MDI.  
o
For new MDIs, the recorded count will be the count following the priming of the 
device but before the subject doses
•
Administer in-clinic study drug dose from the new kit assigned at the visit

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 105 of 194
•
Perform all post-dosing assessments (refer to Table 8-2).
o Obtain vital signs 30 minutes post-dose
•
For Subjects participating in the 4-Hour PFT sub-study:
o
Perform spirometry assessments at 15, 30 minutes and 1, 2, and 4 hours post-dose 
(see Table 8-1)
o
Central Laboratory Test (BMP) will be collected 2 hours post-dose at Visit 5 and 
Visit 10 only
o
Obtain vital signs 30 minutes and 2 hours post-dose at Visit 5, 7, 10 and 12
o
Obtain ECGs 30 minutes and 2 hours at Visit 5 and 10 only
•
Subjects will be instructed to track study drug dosing in their eDiary between study clinic 
visits
•
Subjects will be instructed to dose while at home from the site-primed MDI only, until all 
of the following replacement conditions are met:
o
Dose indicator is in the red zone (See Appendix 12 for dose indicator reading 
instructions)
o
The dose indicator registers 10 puffs remaining, and their next scheduled study 
clinic visit is not the following day.
•
If these conditions are met, subjects will be instructed to open their supplemental kit, 
prime the MDI and start using it for at home dosing until the next scheduled study clinic 
visit.
•
Provide subjects with study drug as assigned by IWRS.
•
Subjects will be instructed to bring their eDiary and all study drug (including used study 
drug and Sponsor-provided rescue Ventolin HFA) to the next scheduled clinic visit.
•
Schedule next visit and ensure subject has adequate supply of study drug including a 
Sponsor-provided rescue Ventolin HFA. Note: At Visit 7 (Week 12), if a subject is 
participating in the 24 –hour Holter Monitoring Sub-Study, they will be scheduled to 
return to the clinic at Visit 8 (Week 16)
•
For the subject who discontinues study treatment (randomized study medication) and 
continue in the study, the scheduled study visit, data collection, and procedures will be 
done according to the study protocol see Section 8.9.
8.6
In-Clinic Visit 8 (Weeks 16) For 24 –Hour Holter Monitoring Sub-
Study Subjects Only
•
If a subject is participating in the 24 –hour Holter Monitoring Sub-Study, they will need 
to return to the clinic at Visit 8 (Week 16).
•
Attach Holter monitor and initiate 24-hour Holter monitor 15-30 minutes prior to the 
administration of the morning dose of study medication. (see Section 7.2.5 and Table 8-4
for further  instructions).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 106 of 194
•
Subjects will take their morning dose of study medication at the clinic following 
initiation of Holter monitoring.
•
Subjects will be instructed to return the following day (Visit 8b) for the removal of the 
Holter monitor.
•
Note: At Visit 8b if the Holter monitor recordings fail to meet adequate quality criteria 
(acceptable tracings for a minimum of 18 hours) on the first attempt, a second attempt 
will be made for another 24 hours using a new Holter monitor hook-up kit (See Section 
7.2.5 for further instructions).
8.7
Telephone Visits 6, 8, 9, 11, and 13 (Weeks 8, 16, 20, 28, and 44)
•
Review subject eDiary for data collection compliance.
•
Collect HCRU information.
•
Record COPD exacerbations and AEs (if any).
•
Review all concomitant medications and ensure adherence to COPD regimen.
•
Subjects will be instructed to track study drug dosing in their eDiary between study clinic 
visits.
•
Subjects will be instructed to bring their eDiary and all study drug (including used study 
drug and Sponsor-provided rescue Ventolin HFA) to the next scheduled clinic visit.
•
Schedule next visit and ensure subject has adequate supply of study drug including a 
Sponsor-provided rescue Ventolin HFA.
For subjects who discontinue treatment (randomized study medication) and continue in the 
study, the scheduled study visit, data collection, and procedures will be completed according 
to the study protocol see Section 8.9.
8.8
Final Visit (Visit 14; Week 52)
•
Review subject eDiary for data collection compliance.
•
Determine time of last dose of short-acting bronchodilator and other COPD medications 
(if <6 hours, the visit must be rescheduled). 
•
Review smoking status
•
Perform all pre-dose assessments (see Table 8-1 and Table 8-2).
o
Obtain central laboratory tests and serum pregnancy test for women of childbearing 
potential
o
Obtain vital signs and ECGs 60 minutes pre-dose
•
For Subjects participating in the 4-Hour PFT sub-study, perform spirometry 
assessments 60 and 30 minutes pre-dose (see Table 8-1)

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 107 of 194
•
Confirm the subject took their last dose of randomized study drug as scheduled the prior 
evening.  If the time of dosing was not in accordance with the protocol, then the visit 
must be rescheduled.  
•
Conduct a physical examination
•
Have subject complete TDI questionnaire followed by SGRQ and EQ-5D questionnaires 
before any other study procedures are performed.
•
Collect HCRU information.
•
Record COPD exacerbations and AEs (if any).
•
Review all concomitant medications and ensure adherence to COPD regimen.
•
Prior to dosing, site personnel will use IWRS to assign subjects a new kit of study drug 
for in-clinic dosing.
o
See Section 6.7 for detailed instructions for preparation of treatments for 
administration.  These instructions are to be adhered to and are relevant to all study 
treatment visits.
o
Record/document the dose indicator readings of the used MDI and the replacement 
MDI.  
o
For the new MDI, the recorded count will be the count following the priming of the 
device but before the subject doses.
•
Administer in-clinic study drug dose from the new kit assigned at the visit.
•
Perform all post-dosing assessments (refer to Table 8-2).
o Obtain vital signs 30 minutes post-dose
•
For Subjects participating in the 4-Hour PFT sub-study:
o
Perform spirometry assessments at 15, 30 minutes and 1, 2, and 4 hours post-dose 
(see Table 8-1)
o
Central Laboratory Test (BMP) will be collected 2 hours post-dose
o
Obtain vital signs and ECGs 30 minutes and 2 hours post- dose
•
Collect subject eDiary.
•
Collect all study drugs including Sponsor-provided Ventolin HFA.
•
At completion of all Visit 14 assessments, return subject to pre-study or appropriate 
maintenance COPD medications.
•
Inform subject about reporting all SAEs up to 14 days following the last dose of study 
drug.
•
Schedule the follow-up TC at least 14 days from Visit 14.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 108 of 194
8.9
Procedures for Treatment Discontinuation and Study Withdrawal 
Subjects
Subjects who discontinue study treatment prior to Week 52 (Visit 14) will be encouraged to 
remain in the study to complete all remaining study visits during the 52 week treatment 
period. Subjects who agree to continue to be followed post treatment discontinuation will 
sign an ICF addendum. All subjects who agree to continue study participation beyond 
treatment discontinuation will complete a Treatment Discontinuation/Withdrawal Visit (refer 
to Section 8.10) prior to transitioning back to regularly scheduled study visits. Subjects 
participating in the Holter Monitoring sub-study who discontinue from treatment will only 
complete regular scheduled visits and not complete any remaining Holter sub-study 
assessments. Subjects participating in the PFT sub-study who discontinue from treatment 
will continue to complete spirometry assessments.  Treatment discontinuation subjects will 
return to appropriate maintenance COPD medications, per the investigator’s discretion.
For subjects who discontinue study treatment but continue to participate in the study to 
complete all remaining study visits, all AEs/SAEs will be collected through the 14-day follow-
up telephone call
For subjects recorded as Treatment Discontinuations that do not complete at least one post-
treatment data collection a telephone follow-up call is required at least 14 days after last
study drug dose.  All AEs/SAEs will be collected through the 14-day follow-up telephone call
If a subject chooses not to continue with study assessments, at a minimum the subject will 
complete the Treatment Discontinuation/Withdrawal Visit (refer to Table 8). These subjects 
will return to appropriate maintenance COPD medications, per the investigators discretion. A
follow-up telephone call will be performed at least 14 days after the last study drug dose. All 
AEs/SAEs will be collected through the 14-day follow-up telephone call. In the event the 
Treatment Discontinuation/Withdrawal Visit is performed >14 days post last study drug 
dosing; a follow-up TC will not be required. These subjects will be followed for vital status 
at 52 weeks post randomization in accordance with the informed consent.
8.10
Unscheduled Visit and Treatment Discontinuation/Withdrawal Visit 
Repeat assessments, if needed, will be captured in unscheduled visits.
The following minimum procedures will be completed for Treatment 
Discontinuation/Withdrawal Visits:
•
Complete TDI questionnaire first; followed by SGRQ questionnaire and EQ-5D-5L 
before any other study procedures are performed.
•
Collect HCRU information.
•
Record COPD exacerbations and AEs (if any).
•
Review concomitant medications.
•
Conduct a physical examination, including vital signs.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 109 of 194
•
Perform ECG and collect blood samples for hematology, chemistry and urinalysis.
•
Collect a blood sample for pregnancy test for women of child-bearing potential.
•
Collect subject eDiary.
Note: Subjects who have discontinued treatment but continue in the study will have their 
eDiary re-dispensed
•
Collect all study drugs, including rescue medications. 
•
Return subject to pre-study or appropriate maintenance COPD medications.
•
Inform subjects all AEs/SAEs will be collected through the 14-day follow-up telephone call.
•
Inform subject about reporting all SAEs up to 14 days following the last dose of study 
drug.
•
Capture the reason for treatment discontinuation.
8.11
Follow-up Telephone Call
Subjects will be followed up through a TC at least 14 days after the last study drug dosing.  
The following information will be requested:
•
Collect HCRU information.
•
Review previously on-going COPD exacerbations 
•
Review and record AEs /SAEs (if any).
•
Review concomitant medications.
8.12
52-Week Post-Randomization Vital Status Confirmation
All subjects who discontinue study treatment prior to 52 weeks post- randomization will have 
their vital status confirmed at 52 weeks post-randomization.
To confirm the vital status and cause of death, if appropriate, the following attempts will be 
made:
•
The first and second attempts may be conducted as telephone follow-up call to the subject 
within 2 weeks after 52 weeks post-randomization 
•
The third attempt will be by certified mail to the subject’s address provided at the time of 
informed consent within 3 weeks after 52 weeks post-randomization.
•
The fourth attempt will be made as a telephone follow-up call to the next of
kin/emergency contact provided at the time of informed consent within 4 weeks after 52 
weeks post-randomization

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 110 of 194
•
A fifth attempt will be made through a certified letter to the next of kin/emergency 
contact provided at the time of informed consent within 5weeks after 52 weeks post-
randomization
•
After the fifth attempt, the study site will contact the national death registries (if available 
in that country) to confirm date and cause of death.
8.13
Completion of the Study
The Investigator will document the study completion or the reason for early treatment 
discontinuation or study withdrawal by a subject in the eCRF.  The following categories 
should be used to describe these events in the eCRF:
•
Subject discretion (document reason)
•
Investigator considers it to be in the best interest of the subject
•
AE(s)/SAEs
•
Administrative reasons (e.g., early termination of the study)
•
Subject lost to follow up
•
Lack of efficacy
•
Major protocol violation
•
Death
•
Completion of the study 
•
Protocol-specified criteria (see Section 5).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 111 of 194
9
PLANNED STATISTICAL METHODS
9.1
Introduction
The primary objective of this study is to assess the effect of BGF MDI relative to GFF MDI 
and BFF MDI on the rate of moderate or severe COPD exacerbations in subjects with a 
history of previous COPD exacerbations.  In addition, as secondary and other objectives, this 
study will assess the effects of BGF MDI relative to GFF MDI and BFF MDI on COPD 
symptoms, disease-related health status, pulmonary function, and long-term safety and 
tolerability, as well as HCRU.  This study will include a 52-week Treatment Period, preceded 
by a 2- to 4-week Screening Period and followed by a 2-week follow-up TC.
9.2
Protocol Variables
9.2.1
Efficacy Endpoints
All efficacy assessments are relative to pre-dose baseline obtained at or prior to Visit 4 and
are stated in Section 3.
9.2.2
Safety Endpoints
•
AEs
•
12-lead ECG
•
Clinical laboratory testing
•
Vital sign measurements
9.3
Study Populations
The following analysis populations are defined in this study:
•
The Intent-To-Treat (ITT) Population is defined as all subjects who are randomized to 
treatment and receive any amount of the study treatment.  Subjects will be analyzed 
according to randomized treatment group. Efficacy data obtained after discontinuation of 
treatment, but prior to withdrawal from the study, will be included.  The ITT population 
will be used for sensitivity analyses.
•
The Modified Intent-to-Treat (mITT) Population is a subset of the ITT Population 
defined as all subjects with post-randomization data obtained prior to discontinuation
from treatment.  Any data collected after completion of or discontinuation from 
randomized study medication will be excluded from the mITT analysis but will still be 
included in the ITT analysis. Subjects will be analyzed according to randomized 
treatment group. (Note that a subject who used a study treatment but took less than one 
full dose of treatment will qualify for this population). The mITT will be the primary 
population for all efficacy analyses except for the non-inferiority analyses. Note: The 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 112 of 194
knowledge that a subject did not have a COPD exacerbation constitutes an efficacy 
assessment.
•
The Per-Protocol (PP) Population is a subset of the mITT Population defined as all 
subjects with post-randomization data obtained prior to any major protocol deviations.  
Data obtained after any major protocol deviation or discontinuation from treatment will 
be excluded.  Since receiving the wrong treatment will be a major protocol deviation, 
subjects in the PP population will be analyzed as randomized (which for this population 
is identical to analysis by the actual treatment received).  Any evaluability criteria with a 
potential impact on efficacy results will be identified during blinded data review prior to 
database lock. Major protocol deviations (protocol violations), therefore, can result in 
exclusion of all data from a particular subject from the PP population or require exclusion 
of data from a specific time point and/or subsequent time points for an endpoint.
•
The Safety Population is similar to the mITT Population (all subjects who are 
randomized to treatment and receive any amount of the study treatment).  However, 
subjects will be analyzed according to treatment received rather than randomized.  If a 
subject received more than one randomized treatment, they will be analyzed and included 
in summaries according to the treatment they received the most. Subjects receiving no 
study treatment will be excluded, as will subjects who had no post-dose safety 
assessments. (Note that a subject who used a study treatment but took less than one full 
dose of treatment will qualify for this population). Note: The statement that a subject had 
no AEs also constitutes a safety assessment.
•
The Holter Monitoring Population is defined as all subjects in the Safety Population 
who had at least 18 hours of acceptable quality Holter monitoring data at both Visit 3 
(Holter Monitor Baseline) and Visit 8 (Week 16). Exclusions from this population may 
be identified by Pearl Therapeutics prior to database lock and unblinding.
Analyses will be performed as follows:
Demographics will be summarized for the mITT, PP, and Safety Populations as well as for 
subjects participating in the 4-hr PFT and Holter sub-studies.  Extent of exposure will be 
summarized for the Safety Population. The Safety Population will be used to summarize 
safety. Efficacy Analyses will be performed for the ITT, mITT, and PP Populations. A 
discussion of the various estimands follows below.
9.4
Efficacy Analysis
9.4.1
Estimands
The primary estimand of interest is called the efficacy estimand and is the effect of the 
randomized treatments in all subjects assuming continuation of randomized treatments for 
the duration of the study regardless of actual compliance. There are three additional 
estimands of interest. One is called the attributable estimand and is the effect of treatment in 
subjects attributable to the randomized treatment. For this estimand, discontinuation of 
randomized medication for reasons such as tolerability or lack of efficacy is considered a bad 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 113 of 194
outcome. Another estimand of interest is called the treatment policy estimand. This estimand 
is the effect of randomized treatment over the study period regardless of whether randomized 
treatment is continued. The final estimand of interest is called the per protocol estimand. This 
estimand is the effect of treatment on subjects who are compliant with the protocol (i.e. no 
major protocol deviations), including the use of randomized medication.
The primary analysis for the efficacy estimand will be conducted using the mITT Population 
where only data obtained prior to subjects discontinuing from randomized treatment will be 
utilized. This assumes that efficacy observed on treatment is reflective of what would have 
occurred after discontinuation of randomized treatment had they remained on treatment. 
The second estimand of interest is the attributable estimand. Analyses of the attributable 
estimand will be conducted in the mITT Population, but data that are missing due to 
treatment discontinuation will be imputed based on the 95th percentile of the reference arms’ 
distribution if the reason is reasonably attributable to tolerability or lack of efficacy. The 95th 
percentile applies to an endpoint for which a higher value is a worse outcome; however, the 
5th percentile applies to an endpoint for which a higher value is a better outcome. More 
detail about the computation of the attributable estimand will be provided in the SAP.
The third estimand of interest is the treatment policy estimand. Analyses of the treatment 
policy estimand will be conducted in the ITT Population, in which all observed data will be 
utilized regardless of whether subjects remain on randomized treatment. The treatment policy 
estimand will be provided as a supporting analysis for all primary and secondary endpoints.
Finally, the last estimand of interest is the per protocol estimand. Analysis of this estimand 
will use the PP Population. This estimand will serve as primary for the non-inferiority 
comparison of BGF MDI 160/14.4/9.6 g to GFF MDI. It will be supportive for other 
comparisons of interest.
The following efficacy comparisons will be made, in the following order:
•
BGF MDI 320/14.4/9.6 g versus GFF MDI 14.4/9.6 g
•
BGF MDI 320/14.4/9.6 g versus BFF MDI 320/9.6 g
•
BGF MDI 160/14.4/9.6 g versus GFF MDI 14.4/9.6 g
•
BGF MDI 160/14.4/9.6 g versus BFF MDI 320/9.6 g
All comparisons will be for superiority, with the exception of BGF MDI 160/14.4/9.6 g 
MDI to BFF MDI 320/9.6 g, which will be for non-inferiority first, followed by superiority.  
Details of multiplicity controls are found in Section 9.4.6.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 114 of 194
9.4.2
Primary Efficacy Analysis  
9.4.2.1
Rate of Moderate or Severe COPD Exacerbations
The rate of moderate or severe COPD exacerbations will be analyzed using negative 
binomial regression. COPD exacerbations will be considered separate events provided that 
more than 7 days are between the recorded stop date of the earlier event and start date of the 
later event. Time at risk of experiencing an exacerbation will be used as an offset variable in 
the model. Time during an exacerbation or in the 7 days following an exacerbation will not 
be included in the calculation of exposure. However, the start day of a COPD exacerbation 
will not be excluded from the time at risk. Treatments will be compared adjusting for 
baseline post-bronchodilator percent predicted FEV1, baseline COPD exacerbation history, 
log baseline blood eosinophil count, region, and ICS use at Screening. Baseline blood 
eosinophil count will be the average of all non-missing eosinophil counts obtained on the 
study prior to first dose of study medication.
The number and percentage of subjects with exacerbations in each treatment group will be 
tabulated.
The primary analysis will be for the efficacy estimand.  Secondary analyses will be produced 
for the attributable estimand.  Sensitivity analyses will be presented on the treatment policy 
estimand.
Duration of COPD Exacerbation
For moderate or severe exacerbations, the duration is based on information from the eCRF 
COPD exacerbation page, whereas for mild exacerbations, the duration is defined by the 
length of symptoms as recorded in the eDiary.
For moderate or severe COPD exacerbations (using the eCRF COPD exacerbation page), the 
start date of a moderate or severe COPD exacerbation is the earlier of the medication start 
date, hospitalization start date (if the exacerbation resulted in hospitalization) and date of 
death (if the exacerbation resulted in death). The end date of a moderate or severe COPD 
exacerbation is the later of the medication end date, hospitalization (for exacerbation) end 
date, and date of death (from the exacerbation). In order to ensure that the same event is not 
counted twice, concurrent moderate or severe COPD exacerbations with start and stop dates 
equal to or less than 7 days apart will be considered the same event and assigned the 
maximum severity between the two. 
For mild COPD exacerbations, start date will be defined as the onset of worsened symptoms 
as recorded by the subject in the eDiary, and the stop date will be defined as the last day of 
worsened symptoms.  In order to ensure that the same event is not counted twice, mild COPD 
exacerbations with start and stop dates equal to or less than 7 days apart will be considered 
the same event.
In addition, in order to not double count exacerbations that are moderate or severe, eDiary 
data from dates within 7 days of a moderate or severe exacerbation will not be included as 
additional mild COPD exacerbations.  This implies that continuing worsened symptoms that 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 115 of 194
meet the definition of a mild exacerbation would need to be present at least 2 days prior to 
the 7-day period immediately preceding the start date of a moderate or severe COPD 
exacerbation in order to be considered a separate event.  Similarly, worsened symptoms 
would need to be present for at least 2 days after the 7-day period immediately following a 
moderate or severe COPD exacerbation to be considered a separate event.
Analyses of each severity of exacerbation will account for the time that subjects are at risk of 
having an exacerbation of that severity or greater.  Time during or immediately following an 
exacerbation will not be considered as part of the time that the subject was at risk.  However, 
time during or immediately following an exacerbation of lower severity will be included 
since, for example, a subject experiencing a mild exacerbation is still at risk of the event 
increasing in severity and becoming a moderate exacerbation. 
9.4.3
Analysis of Secondary Endpoints
9.4.3.1
Time to First COPD Exacerbation: Moderate or Severe
The time to first COPD exacerbation will be analyzed using a Cox regression model. The 
model will include treatment; baseline post-bronchodilator percent predicted FEV1, baseline 
COPD exacerbation history, log baseline blood eosinophil count, region, and ICS use at 
Screening. Estimated adjusted hazard ratios relative to the comparator will be displayed 
along with the associated Wald two-sided 95% confidence interval (CI) and p-values for all 
four treatment comparisons. Time to first moderate or severe COPD exacerbation will be 
displayed graphically for each treatment group using a Kaplan-Meier curve and analyzed 
using a log-rank test to compare the curves between the treatments as a supportive analysis. 
Subjects who did not experience a COPD exacerbation and completed the study will be 
censored at Week 52 (Visit 14). Early treatment discontinuations who did not experience a 
COPD exacerbation will be censored at the date of discontinuation. 
9.4.3.2
Time to Death: All Cause, Respiratory
Time to death due to any cause will be summarized using a Kaplan-Meier curve. Subjects 
will be censored at the date of last contact. The time to death will be compared between 
treatments using a Cox regression model, adjusted for baseline percent predicted post 
bronchodilator FEV1 and baseline age as covariates. For this endpoint, the treatment policy 
estimand will be presented as primary. Hazard ratios with Wald 2-sided 95% CIs for these 
ratios will also be provided for all four treatment comparisons. Data permitting, these 
analyses will be repeated time to death from respiratory causes. Pearl and the CEC will agree 
on search terms (based on the prevailing version of the MedDRA dictionary) to identify 
mortalities due to possible respiratory causes. Only those deaths identified as being due to 
respiratory causes by the CEC will be considered as events for this analysis.
9.4.3.3
Transition Dyspnea Index 
Assessments of dyspnea will be obtained using the BDI/TDI.  The BDI/TDI questionnaire 
can be found in Appendix 9

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 116 of 194
At Randomization (Visit 4), the severity of dyspnea at baseline will be assessed using the 
BDI.  At subsequent visits, change from baseline will be assessed using the TDI.  Scoring 
and handling of missing items will be conducted in accordance with the user’s guide for the 
TDI score.  TDI will be analyzed using a RM linear model.  Data from all study treatments 
will be included in the modeling. 
The linear RM ANCOVA model will include treatment, visit, and the treatment by 
visit interaction, and ICS use at Screening as categorical covariates and log baseline blood 
eosinophil count, BDI, and baseline post bronchodilator percent predicted FEV1, and percent 
reversibility to Ventolin HFA as continuous covariates.  An unstructured correlation matrix 
will be used to model additional autocorrelation within subject.  If this model fails to 
converge, an AR(1) structure will be used instead; for this model, subject will be considered 
a random effect.  Contrasts will be used to obtain estimates of the treatment differences over 
the entire 52 weeks, and over 24 weeks (secondary for ex-US).  Two-sided p-values and 
point estimates with two-sided 95% CIs will be produced for each treatment difference.
As additional supportive analyses, the difference between treatments at each of the individual 
visits will also be evaluated and summarized.  Furthermore, as supportive analyses, 
responder analyses will be performed where responders are defined as a response of 1.0 
points or more on average over 24 weeks, and over 52 weeks.  Logistic regression will be 
used to compare the treatment groups with BDI and log baseline blood eosinophil count and 
percent reversibility to Ventolin HFA as continuous covariates and treatment, and ICS use at 
Screening as a categorical covariate.  P-values and odds ratios with 95% CIs will be 
produced for each of the 4 treatment comparisons.
9.4.3.4
Rescue Ventolin HFA Use
The number of puffs of rescue medication use (i.e. albuterol sulfate or locally available 
equivalent product) taken in the previous 12 hours will be recorded in the subject diary in the 
morning and evening.  Diary data recorded during the last 7 days of the Screening Period will 
be used to calculate the baseline.   The mean daily number of puffs of rescue medication use 
(i.e. albuterol sulfate or locally available equivalent product) will be calculated overall and 
for each of the 4-week intervals during the Treatment Period.  For every period of time for 
which the mean number of puffs of rescue will be calculated, missing values will be ignored 
in both the numerator and denominator.  As such, the denominator will be adjusted based on 
the number of days (including half days) with non-missing values.
The difference between treatment groups in the change from baseline in average daily rescue 
medication use (i.e. albuterol sulfate or locally available equivalent product) use over 52 
weeks will be evaluated using a similar RM approach as for TDI.  Instead of visit, the 
number of the relevant 4-week interval (1-13) will be used as a categorical covariate in the
model.
The linear repeated measures (RM) analysis of covariance (ANCOVA) model will include 
treatment, visit, the treatment by visit interaction, and ICS use at Screening as categorical 
covariates and baseline post-bronchodilator percent predicted FEV1, baseline rescue Ventolin 
HFA use, log baseline blood eosinophil count, and percent reversibility to Ventolin HFA (or 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 117 of 194
locally available equivalent product) as continuous covariates. An unstructured correlation 
matrix will be used to model additional autocorrelation within subject. If this model fails to 
converge, an autoregressive order 1 [AR(1)] structure will be used instead; for this model, 
subject will be considered a random effect. Contrasts will be used to obtain estimates of the 
treatment differences over 24 weeks (secondary endpoint), and over the entire 52 weeks. 
Two-sided p-values and point estimates with two-sided 95% CIs will be produced for each of
the 4 treatment differences. 
As supportive analyses, the treatment difference for each 4-week interval will be evaluated 
and summarized.  Additionally, as supportive analyses, daytime rescue Ventolin HFA use 
and nighttime rescue medication use (i.e. albuterol sulfate or locally available equivalent 
product) will be evaluated and summarized in a similar fashion.  Two-sided p-values and 
point estimates with 2-sided 95% CIs will be produced for each treatment difference.
9.4.3.5
St. George’s Respiratory Questionnaire 
The difference between treatment groups in the change from baseline in SGRQ over 
52 weeks of treatment will be evaluated using a similar RM approach as for TDI but using 
baseline SGRQ score instead of the BDI.  Scoring and handling of missing items will be 
conducted in accordance with the user’s guide for the SGRQ.  Each response is to be given a 
unique empirically derived weight between 0 and 100, the weights of all responses are then 
summed up and divided by the maximum possible score and expressed as a percentage.  
Missing SGRQ total scores will not be imputed.  Two-sided p-values and point estimates 
with 2-sided 95% CIs will be produced for each treatment difference.
Responder analyses will be performed, where responders are defined as an improvement
from baseline of 4.0 points in the SGRQ Score.  The proportion of responders at Week 24 
(Secondary for US) will be compared between treatment groups using a logistic regression 
with baseline SGRQ Score, log baseline blood eosinophil count, and baseline post 
bronchodilator percent predicted FEV1 and percent reversibility to Ventolin HFA as 
continuous covariates and treatment, and ICS use at Screening as categorical covariates.
P-values and odds ratios with 95% CIs will be produced for each treatment comparison. The 
analysis will be repeated for responders at Week 24 (Secondary for ex-US), at Week 52, over 
24 weeks, and over 52 weeks.
As supportive analyses, the difference between treatments at each of the individual visits will 
also be evaluated and summarized.
9.4.3.6
Exacerbations of Chronic Pulmonary Disease Tool (EXACT)
The EXACT is a 14-item patient reported outcome (PRO) daily diary which will be used to 
measure the effect of treatment on exacerbations, and on the severity of respiratory 
symptoms. Mean change from baseline in the daily EXACT Total Score, and the 11-item 
EXACT Respiratory Symptoms total score (RS-Total Score), will be calculated over 52 
weeks and over each 4-week interval of the 52-week Treatment Period. The last 7 days of the 
10 to 14 day Screening Period will be used to calculate the baseline. The mean change from 
baseline in RS-Total Score over each 4-week interval will be analyzed using a similar RM 
model as for TDI to estimate treatment effects over 52 weeks and over 24 weeks, but using 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 118 of 194
the corresponding baseline mean score instead of the BDI as a covariate. Instead of visit, the 
number of the relevant 4-week interval (1-13) will be used as a categorical covariate in the 
model.
9.4.3.7
Rate of Severe COPD Exacerbations 
The rate of severe COPD exacerbations will be analyzed in a manner similar to the primary 
efficacy variable, the rate of moderate or severe COPD exacerbations.
The logarithm of time at risk of experiencing a severe (see explanation below) COPD 
exacerbation will be used as an offset variable in the model for the rate of severe COPD 
exacerbations. Time during a severe exacerbation or in the 7 days following a severe 
exacerbation will not be included in the calculation of exposure (i.e. time at risk). However, 
the start day of a severe COPD exacerbation will not be excluded from the time at risk. 
Sensitivity analyses will be presented on the treatment policy estimand.
9.4.4
Analysis of Other Endpoints 
9.4.4.1
Time to First COPD Exacerbation: of Any Severity
All of the above variables will be analyzed in a manner similar to the time to first moderate 
or severe COPD exacerbation as defined under secondary variables.
9.4.4.2
Rate of COPD Exacerbations: of Any Severity
The following efficacy variables will be analyzed in a manner similar to the primary efficacy 
variable, the rate of moderate or severe COPD exacerbations:
•
Rate of COPD exacerbations of any severity
9.4.4.3
Time to Treatment Failure
Treatment failure is defined as a moderate or severe COPD exacerbation or discontinuation 
from treatment for any reason or death.  Time to treatment failure will be will be analyzed in 
a manner similar to the time to first moderate or severe COPD exacerbation as defined under 
secondary variables.  Subjects who do not experience a treatment failure will be censored at 
their Week 52 Visit or Day 365, whichever comes first.
9.4.4.4
Percentage of Days with “No Rescue Ventolin HFA Use” Over the Treatment 
Period
As a supportive analysis, percentage of days with “no rescue Ventolin HFA use” over 
52 weeks will be analyzed. A “day with no rescue use” is defined using rescue 
Ventolin HFA usage data from days where rescue Ventolin HFA usage data is non-missing 
as any day where the subject reported no puffs of rescue Ventolin HFA.  The percentage of 
days with “no rescue use” will be summarized by treatment and analyzed using ANCOVA 
with baseline average daily rescue Ventolin HFA use, log baseline blood eosinophil count , 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 119 of 194
post-bronchodilator percent predicted FEV1, and percent reversibility to Ventolin HFA as 
continuous covariates and ICS use at Screening as a categorical covariate.
9.4.4.5
European Quality-of-Life-5 Dimension-5 Level Questionnaire
The EQ-5D-5L data will be scored to calculate an index score based upon subjects’ responses 
to the 5 dimensions. The visual analogue scale will be scored from 0 (worst imaginable 
health state) through 100 (best imaginable health state) to represent the subject’s self-report 
concerning how bad or how good their health was during that day. The percentage of 
subject’s categorical responses to each of the 5-dimensions will be summarized. Descriptive 
statistics for the index score and VAS will be presented by treatment group. VAS scores over 
52 weeks may be analyzed using RM ANCOVA with age and baseline score as continuous 
covariates and region, gender, and treatment as categorical covariates. .
9.4.5
Analysis of PFT Sub Study
Pulmonary function testing will be conducted in a subset of subjects at the randomization 
visit and at Weeks 12, 24, 36, and 52.
9.4.5.1
Change from Baseline in Morning Pre-dose Trough FEV1 at Week 24 (US) and 
Over 24 Weeks (ex US) for the comparison of BGF MDI to GFF MDI
The change from baseline in morning pre-dose trough FEV1 will be analyzed using an RM 
linear model.  The ANCOVA model will include baseline FEV1, log baseline blood
eosinophil count, and percent reversibility to Ventolin HFA as continuous covariates and 
visit, treatment, the treatment by visit interaction, and ICS use at Screening as categorical 
covariates.  Baseline is defined as the average of the non-missing -60 minute and -30 minute 
values obtained prior to dosing at Day 1 (Visit 4).  An unstructured correlation model will be 
used to model additional autocorrelation within subject.  If this model fit fails to converge, an 
AR(1) structure will be used to model correlation between time points from the same subject; 
for this model, subject will be included as a random effect.  Contrasts will be used to obtain 
estimates of the treatment differences at Week 24, over 24 weeks, as well as at each visit.  
Two-sided p-values and point estimates with two-sided 95% CIs will be produced for each 
treatment difference.  
Additional sensitivity analyses will be implemented based on a cumulative responder 
approach as described in Farrar 2006 for the change from baseline in morning pre-dose
trough FEV1 at Week 24. A cumulative distribution plot by treatment arm (Farrar et al., 
2006) will also be produced.  The cumulative responder curves for each treatment will then 
be compared pairwise using Kolmogorov-Smirnov tests.
9.4.5.2
FEV1 AUC0-4 at Week 24 (US) and Over 24 Weeks (ex-US)
FEV1 AUC0-4 will be calculated using the trapezoidal rule and transformed into a weighted 
average by dividing by the time in hours from dosing of the last measurement included 
(typically 4 hours).  Only one non-missing post-dose value is required for the calculation of 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 120 of 194
AUC.  Actual time from dosing will be used if available; otherwise scheduled time will be 
used.  The differences between treatment groups in FEV1 AUC0-4 at Week 24 and over 24 
weeks will be evaluated using a linear mixed RM ANCOVA model with baseline FEV1, log 
baseline blood eosinophil count, and percent reversibility to Ventolin HFA as continuous 
covariates and treatment, ICS use at Screening as a categorical covariate.  Two-sided p-
values and point estimates with two-sided 95% CIs will be produced for each treatment 
difference.
9.4.5.3
Other PFT Sub-study Analyses
In addition to the two primary PFT endpoints discussed above (Sections 9.4.5.1 and 9.4.5.2),
the change from baseline in morning pre-dose trough FEV1 over 24 weeks, over Weeks 12 to 
24, and over 52 weeks, FEV1 AUC0-4, and peak change from baseline in FEV1 over 52 weeks 
and at each visit will be estimated and compared between treatment groups using the same 
linear mixed RM model as pre-dose trough FEV1.  Similar analyses will be conducted for 
FVC, PEFR, and FEF25-75 over 52 weeks and at each post-randomization visit.
9.4.5.4
Rate of decline in pre-dose FEV1 and FEV1 AUC0-4 over 52 weeks
The rate of decline in pre-dose FEV1 will be analyzed as follows.  Pre-dose FEV1 will be 
analyzed with a linear mixed model with random subject slopes of FEV1 versus time and 
random subject intercepts.  An unstructured covariance matrix will be employed for these 
two random effects.  The model will fit a distinct fixed mean for each treatment and a distinct 
fixed slope (of FEV1 versus time) for each treatment. The model will include the interaction 
between treatment (as a categorical covariate) and time (as a continuous covariate), and the 
interaction between screening smoking status and time and the interaction between baseline 
FEV1 and time. Other covariates in the model will be percentage reversibility to Ventolin 
HFA, baseline FEV1, and log baseline blood eosinophil count as continuous covariates, and 
treatment, smoking status at screening, and ICS use at Screening as a categorical covariate. 
The rate of decline (the negative of the slope) will be estimated and compared between 
treatments
The rate of decline in FEV1 AUC0-4 over 52 weeks will be analyzed in a similar manner.
9.4.5.5
Time to Onset on Day 1
The onset of action will be determined for each treatment using the 5 minutes and 15 minutes 
post-dosing FEV1 assessments from Day 1. The onset of action for each product will be defined 
as the median time point to 100 ml improvement in FEV1 from baseline.
9.4.6
Control of Type I Error 
All comparisons will be for superiority, with the exception of BGF MDI 160/14.4/9.6 g 
MDI to BFF. The comparisons of BGF MDI 160/14.4/9.6 g to BFF MDI 320/9.6 g on 
COPD exacerbations will be for non-inferiority (NI) with an NI margin of 1.1, followed by 
superiority; however, attaining statistical significance in the superiority comparison is not a 
pre-requisite to proceeding down the testing hierarchy.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 121 of 194
If BGF MDI 320/14.4/9.6 g significantly reduces the rate of moderate or severe COPD 
exacerbations compared to both GFF MDI 14.4/9.6 g and BFF MDI 320/9.6 g (using first 
the efficacy estimand and then the attributable estimand as the first secondary), then primary 
endpoints from the lung function sub-study will be assessed. For the US approaches, these 
are first FEV1 AUC0-4 at Week 24 for the comparison of BGF MDI 320/14.4/9.6 g to BFF 
MDI 320/9.6 g and then the change from baseline in morning pre-dose trough FEV1 at 
Week 24 for the comparison of BGF MDI 320/14.4/9.6 g to GFF MDI 14.4/9.6 g. For ex-
US Approaches, these are first FEV1 AUC0-4 over 24 weeks for the comparison of BGF MDI 
320/14.4/9.6 g to BFF MDI 320/9.6 g and then the change from baseline in morning pre-
dose trough FEV1 over 24 weeks for the comparison of BGF MDI 320/14.4/9.6 g to GFF 
MDI 14.4/9.6 g. If these comparisons are statistically significant, then for both the US and 
Ex-US approaches, the rate of moderate or severe exacerbations in the subgroup of subjects 
with a history of  2 exacerbations at baseline will be compared between BGF MDI 
320/14.4/9.6 g and GFF MDI 14.4/9.6 g and between BGF MDI 320/14.4/9.6 g and BFF 
MDI 320/9.6 g, as will the other secondary endpoints. BGF MDI 160/14.4/9.6 g will 
follow a similar approach, except that the comparison to BFF 320/9.6 g will be for non-
inferiority first. Non-inferiority margins for secondary endpoints are specified in the SAP. If 
BGF MDI 160/14.4/9.6 g significantly reduces the rate of moderate or severe COPD 
exacerbations compared to GFF MDI 14.4/9.6 g and is non-inferior to BFF MDI 320/9.6 
g, then primary endpoints from the lung function sub-study will be assessed as outlined 
above. 
For both registration approaches, US and ex-US, and for each dose of BGF MDI, if the 
primary and first secondary measures are statistically significant for all comparisons, then 
Type I error for the remainder of the secondary measures with the exception of time to death 
(all cause) will be controlled by using Hochberg within each comparison [Hochberg 1988]. If 
all of the secondary measures are significant, then time to death (all cause) will be tested 
within each comparison.
The family-wise Type I error rate is maintained throughout the trial, including the interim 
analysis by one-sided group sequential testing. Further details about maintaining the Type I 
error throughout multiple tests may be found in the SAP.
9.4.7
Safety Analysis
9.4.7.1
Adverse Events
The version of the Medical Dictionary for Regulatory Activities (MedDRA) that is current at 
the time of database lock will be used to code verbatim terms for AEs for final analysis of the 
data. The number and incidence of adverse events, serious adverse events, adverse events of 
special interest by category, confirmed AEs of pneumonia, and study drug discontinuations 
due to adverse events will be summarized by treatment group. They will be tabulated at the 
level of the Medical Dictionary for Regulatory Activities (MedDRA) preferred term and the 
MedDRA system organ class. Tabulations will be broken down by severity, by relationship 
to study drug, and AEs leading to treatment discontinuation. No hypothesis tests will be 
performed.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 122 of 194
9.4.7.2
MACE Events Determined by Clinical Endpoint Committee
The CEC will review and adjudicate serious CCV events as MACE. MACE events are 
defined as the following:
•
Cardiovascular death
•
Non-fatal myocardial infarction (MI)
•
Non-fatal stroke
The CEC will review and assess these non-fatal serious CCV events and all deaths as to 
whether or not they fulfill criteria (based on CEC working practices) for MACE. MACE
events will be summarized by treatment group.  
9.4.7.3
Pneumonia Events Determined by CEC
All AEs/SAEs with preferred terms that could relate to pneumonia will be adjudicated to 
provide a more complete assessment of all physician-reported pneumonias. The assessment 
of pneumonia events will include the overall rates of pneumonia.
In order to account for specific patient risk factors, data permitting, time to first pneumonia 
will be compared between treatments using Cox proportional hazards. Specific patient risk 
factors that have will be evaluated for inclusion.
9.4.8
Clinical Laboratory Measurements
Summary statistics (n, mean, median, standard deviation [SD], minimum, and maximum) for 
the baseline assessment (Day 1) and for the pre-dose value and change from baseline at 
pre-dose value of post-baseline visits with scheduled lab assessments of continuous 
laboratory variables, including serum potassium and glucose, will be tabulated.
Shift tables relative to the normal reference ranges will be produced using the categories 
defined by the Common Terminology Criteria for Adverse Events (CTCAE) grades.  For 
these shift tables, for each treatment, the subject’s pre-dose grade will cross-tabulated by the 
subject’s maximum post-baseline grade during the treatment; also, the subject’s maximum 
post-baseline grade during treatment will be tabulated for all baseline grades combined.
The number and percent of subjects with potentially clinically significant (PCS) laboratory 
values will be summarized.  The PCS values for serum potassium are <3.0 mmol/L or >6.0 
mmol/L and for blood glucose <2.2 mmol/L, or >13.9 mmol/L if no history of diabetes,
>27.8 mmol/L regardless of baseline. PCS values for additional labs will be defined in the 
Statistical Analysis Plan (SAP). No hypothesis tests will be performed.
9.4.9
Vital Signs
Summary statistics (mean, median, SD, and range) for absolute values and change from 
baseline values in SBP, DBP, HR, and temperature will be tabulated for each treatment and 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 123 of 194
assessment time.  Baseline values for vital signs will be defined as the average of the values 
prior to dosing at the Randomization Visit (Visit 4).  The PCS values for vital signs will be 
defined in the SAP and the percentage of subjects with PCS values will be summarized. No
hypothesis tests will be performed.
9.4.10
ECGs
Summary statistics (mean, median, SD, and range) for raw values and change from baseline 
values in HR, RR interval, PR interval, QRS axis, QRS interval, QT interval, and QTcF 
interval will be calculated, where baseline is defined as the average of the pre-dose 
measurements taken prior to the start of treatment at the Randomization Visit (Visit 4).  The 
QTcF (Fridericia corrected QT) is defined as (QT/[RR1/3]).  The RR Interval (msec) is 
estimated as 60000/HR.  These assessments will be tabulated for each treatment and 
assessment time.  The PCS values for ECG parameters will be defined in the SAP, and the 
percentage and number of subjects with PCS ECG values will be tabulated.  No hypothesis 
tests will be performed. 
9.4.11
Health Care Resource Utilization
All COPD-related and non-COPD-related HCRU endpoints will be summarized by treatment 
group.
9.4.12
24-Hour Holter Monitoring
Holter monitoring will be conducted over 24 hours in a subset of approximately 800 
randomized subjects (200 subjects from each treatment arm) at Visit 3 (Holter Monitor 
Baseline) and Visit 8 (Week 16). If there is not at least 18 hours of acceptable quality 
monitoring for a given assessment, then the assessment is to be repeated. In these cases, the 
second assessment will be used whether for baseline and/or for the Visit 8 (Week 16) value. 
However, any incidence of AEs indicated by the incomplete Holter monitor findings at Week 
4 will be captured.
Primary Holter Monitoring Endpoint: 
The change from baseline in mean 24-hour heart rate (HR) obtained using Holter monitoring 
at Week 16 will be analyzed using an ANCOVA model to evaluate treatment differences 
with baseline mean 24-hour HR (obtained during 24-hour Holter monitoring at screening) as 
a covariate. LS means and estimated treatment differences with 95% CIs will be provided. 
The raw mean values and change from baseline values will also be summarized by treatment 
group.
Secondary Holter Monitoring Endpoints:
The change from baseline at Week 16 (Visit 8) in the mean daytime (06:00 to 22:00) HR, 
mean nighttime (22:00 to 06:00) HR, maximum 24-hour HR, and minimum 24-hour HR will 
each be summarized and analyzed in a similar manner to the primary Holter monitoring 
endpoint.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 124 of 194
A frequency distribution of the following will be provided:
•
Proportion of subjects with maximum heart rate during treatment of >180, >160-180,
>140-160, >120-140, >100-120, and 100 bpm or less.
•
Proportion of subjects with minimum heart rate during treatment of >60, >50-60, >40-50,
and <40 bpm
The change from baseline in the number of Holter monitor events will be summarized 
descriptively. This analysis will be performed for change from baseline for the following 
parameters (calculated per hour): number of isolated ventricular events (PVCs), number of
ventricular couplets, and number of ventricular runs, number of isolated supraventricular 
events, number of supraventricular couplets, and number of supraventricular runs. The 
ventricular variables will each be analyzed using an ANCOVA to evaluate treatment
differences with baseline number of PVCs as a covariate. The supraventricular variables will 
each be analyzed using an ANCOVA to evaluate treatment differences with baseline number 
of supraventricular ectopic events as a covariate. LS means and estimated treatment 
differences with 95% CIs will be provided. The raw mean values and change from baseline 
values will also be summarized by treatment group. The distribution of the frequency of 
these events for baseline (Visit 3) and at Week 16 will be evaluated for each event and if 
necessary, a natural log transformation or ln (value +1) will be used to normalize (prior to 
calculating the change from baseline value which will be analyzed). If a log transformation is 
used, then both descriptive statistics as well as analysis results will be back-transformed to 
provide information about geometric means.
Additionally, the proportion of subjects in each category of change from baseline in the 
number of PVCs per hour (no change, increase of >0-<60, 60-<120, and 120, and decrease 
of >0-<60, 60-<120, and 120) will be tabulated.
9.5
Randomization
Subjects will be randomized to one of the four treatment arms using an IWRS in a 1:1:1:1 
ratio.  Randomization will be stratified by: exacerbation history (1 or 2 moderate or severe 
exacerbations), post-bronchodilator FEV1 (25% to <50% or 50% to 65% predicted), blood 
eosinophil count (<150 cells per mm3 or 150 cells per mm3), and country. Center will not be 
used as a stratification factor given the impracticality of enrolling a large enough number of 
subjects to ensure balance in each of the eight strata formed by combining, exacerbation 
history, FEV1, and eosinophil categories use within each center.  
9.6
Experimental Design 
This study is a multi-center, double-blind, parallel-group design. All study treatments are 
given in addition to permitted COPD background therapy. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 125 of 194
9.7
Sample Size
9.8
Data Validation and Transformation
In general, the distribution of spirometry measures is well-approximated by a normal 
distribution.  Under some circumstances, however, (for example during a COPD 
exacerbation, unrelated to treatment) extreme and atypical values can arise.  Such values 
have high influence on estimation of variance parameters and on standard errors of fixed 
effect estimates.  The distribution and potential influence of outliers will be evaluated and 
additional sensitivity analyses will be conducted if warranted to demonstrate the robustness 
of the primary and secondary results.
9.9
Interim Analysis
There will be an interim efficacy analysis at which an independent Data Monitoring 
Committee will review unblinded efficacy data and determine if the study can be stopped 
early for unequivocal efficacy.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 126 of 194
Should the study continue until all subjects complete, the one-sided alpha criteria for the final 
analysis will be adjusted based on the percent of information available at the prior interim 
analyses using an appropriate spending function such that the overall Type I error is 
controlled at one-sided 0.025.  
Should the study be stopped for unequivocal efficacy, the data used for the analysis of 
moderate or severe exacerbations in that analysis will be considered the primary data set so 
that the primary result will not change. An additional analysis including all data collected 
after the interim snapshot data will be included in the CSR as supportive.   Regardless of the 
efficacy interim analysis decision, enrolled subjects from China will continue all efficacy and 
safety assessments until approximately 52 weeks after Randomization. 
Further details will be provided in the DMC charter and in the Statistical Analysis Plan 
(SAP).
9.10
Analysis Plan
All final analyses will be specified in a detailed SAP that will be accompanied by table and 
data listing shells with mock graphical representations.  The analysis plan will be approved 
by signature before database lock and unblinding.  A separate SAP was approved prior to the 
conduct of the planned 
 and if insufficient details are included in the DMC Charter, a 
separate SAP will also be used to describe the interim analysis.  
9.11
Handling of Missing Data
All observed values prior to study withdrawal will be included in the treatment policy 
estimand.  All observed values recorded prior to treatment discontinuation will be included in 
the efficacy estimand and the attributable estimand.  The impact of missing data caused by 
subjects withdrawing from the study (not just the randomized treatment) will be evaluated.  
These robustness analyses will use data imputed under varying assumptions about what the 
relative treatment effects would have been in the unobserved data. Further details will be 
specified in the SAP.
For the subset of subjects included in the PFT spirometry assessment, the efficacy estimand 
will use all available data prior to treatment discontinuation. Change from baseline in 
morning pre-dose trough FEV1 at each visit is defined as the average of the 60 and 30 minute 
pre-dose values minus baseline. In subjects missing either of these pre-dose assessments, the 
value will be calculated from the single measurement. In subjects missing both pre-dose 
values, morning pre-dose trough FEV1 at that visit will not be calculated. Peak FEV1 and 
FEV1 AUC0-4 will be included in the efficacy, attributable, treatment policy, and per-protocol 
estimands as long as there is one non-missing post-dose value.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 127 of 194
9.12
Statistical Software
Data processing, statistical screening, descriptive reporting and analysis of the efficacy and 
safety data will be performed using 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 128 of 194
10 ADMINISTRATIVE CONSIDERATIONS
10.1
Regulatory Authority Approval
Pearl will obtain approval to conduct the study from the appropriate regulatory agency in 
accordance with any applicable country-specific regulatory requirements prior to a site 
initiating the study in that country.
10.2
Ethical Conduct of the Study and Institutional Review Board or 
Independent Ethics Committee Approval
The study will be conducted in accordance with Good Clinical Practice (GCP).  These 
standards respect the following guidelines:
•
Guideline for Good Clinical Practice E6 (R1):  Consolidated Guideline (International 
Conference on Harmonization of Technical Requirements for the Registration of 
Pharmaceuticals for Human Use, May 1996).
•
US CFR dealing with clinical studies (21 CFR parts 50, 54, 56, and 312).
•
Declaration of Helsinki, concerning medical research in humans (Ethical Principles for 
Medical Research Involving Human Subjects) [http://www.wma.net/en/10home/index.html].
•
Any additional regulatory requirements.
The Investigator (or Pearl, where applicable) is responsible for ensuring that this protocol, 
the site’s ICF, and any other information that will be presented to potential subjects (eg, 
advertisements or information that supports or supplements the ICF) are reviewed and 
approved by the appropriate IRB/IEC.  The Investigator agrees to allow the IRB/IEC direct 
access to all relevant documents.  The IRB/IEC must be constituted in accordance with all 
applicable regulatory requirements.  
Pearl will provide the Investigator with relevant document(s)/data that are needed for 
IRB/IEC review and approval of the study.  If the protocol, the ICF, or any other information 
that the IRB/IEC has approved for presentation to potential subjects is amended during the 
study, the Investigator is responsible for ensuring the IRB/IEC reviews and approves, where 
applicable, these amended documents.  The Investigator must follow all applicable regulatory 
requirements pertaining to the use of an amended ICF including obtaining IRB/IEC approval 
of the amended form before new subjects consent to take part in the study using this version 
of the form.  The IRB/IEC approval of the amended ICF/other information and the approved 
amended ICF/other information must be forwarded to Pearl promptly.
10.3
Subject Information and Consent
The study will be conducted in accordance with applicable subject privacy requirements.  
The proposed ICF, which must be in compliance with applicable regulations, must be 
reviewed and approved by the IRB and Pearl prior to initiation of the study.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 129 of 194
The Investigator will be responsible for obtaining written informed consent from potential 
subjects prior to any study-specific screening and entry into the study.  A copy of the signed 
ICF will be provided to the subject.  The original will be retained by the Investigator.
10.4
Laboratory Accreditation
Any laboratory facility intended to be used for analysis of clinical laboratory samples 
required by this protocol must provide evidence of adequate licensure or accreditation 
according to the prevailing regulations in that state and/or country.  Reference values and/or 
normal ranges for the test results must be provided to Pearl.  Pearl must be notified promptly 
in writing of any changes occurring in reference values during the course of the study.
10.5
Confidentiality
10.5.1
Confidentiality of Data
By signing this protocol, the Investigator affirms to Pearl that information furnished to the 
Investigator by Pearl will be maintained in confidence and such information will be divulged 
to the IRB/IEC, or similar or expert committee; affiliated institution; and employees only 
under an appropriate understanding of confidentiality with such board or committee, 
affiliated institution and employees.  Data generated by this study will be considered 
confidential by the Investigator, except to the extent that it is included in a publication.
10.5.2
Confidentiality of Subject/Patient Records
By signing this protocol, the Investigator agrees that Pearl (or representative), IRB/IEC, or 
Regulatory Agency representatives may consult and/or copy study documents in order to 
verify worksheet/case report form data.  By signing the ICF, the subject/patient agrees to this 
process.  If study documents will be photocopied during the process of verifying 
worksheet/case report form information, the subject/patient will be identified by unique code 
only; full names/initials will be masked prior to transmission to Pearl.  In addition, the 
Investigator agrees to treat all subject/patient data used and disclosed in connection with this 
study in accordance with all applicable privacy laws (ie, Health Insurance Portability and 
Accountability Act), rules, and regulations.
10.6
Quality Control and Assurance
Pearl is responsible for implementing and maintaining quality control and quality assurance
systems with written Standard Operating Procedures to ensure that studies are conducted and 
data are generated, documented, and reported in compliance with the protocol, accepted 
standards of GCP, and all applicable federal, state, and local laws, rules, and regulations 
relating to the conduct of the clinical study.
10.7
Data Management
Data management procedures and information for this protocol will be provided by Pearl.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 130 of 194
10.8
Study Monitoring
In accordance with applicable regulations, GCP, and Pearl procedures, clinical monitors will 
contact the site prior to subject enrollment to review the protocol and data collection 
procedures with site staff.  In addition, the clinical monitor will periodically contact the site, 
including conducting on-site visits.  The extent, nature, and frequency of on-site visits will be 
based on such considerations as the study objective and/or endpoints, the purpose of the 
study, study design complexity, and enrollment rate.
During these contacts, the monitor will:
•
Check the progress of the study
•
Review study data collected
•
Conduct source document verification
•
Identify any issues and address their resolution
This will be done in order to verify that the:
•
Data are authentic, accurate, and complete
•
Safety and rights of subjects are being protected
•
Study is conducted in accordance with the currently approved protocol (and any 
amendments), GCP, and all applicable regulatory requirements
The Investigator agrees to allow the monitor direct access to all relevant documents and to 
allocate his/her time and the time of his/her staff to the monitor to discuss findings and any 
relevant concerns.  
Upon completion of the study, the monitor will conduct the following activities in 
conjunction with the Investigator or site staff, as appropriate:
•
Return of all study data to Pearl 
•
Data queries
•
Accountability, reconciliation, and arrangements for unused investigational product(s)
•
Review of site study records for completeness
After the final review of the study files, the files should be secured for the appropriate time 
period as specified in Section 10.9.  The Investigator will also permit inspection of the study 
files by Pearl’s Quality Assurance auditors, and authorized representatives of the FDA or 
other applicable regulatory agencies.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 131 of 194
10.9
Retention of Data
Documents that individually and collectively permit evaluation of the conduct of the study 
and the quality of the data produced must be maintained for review by Pearl’s quality 
assurance auditors and by all applicable regulatory authorities.  The period of time these 
documents must be maintained is governed by applicable regulations.  Pearl or its designee 
will inform the Investigator when these documents may be destroyed.  Pearl or its designee 
must be notified in writing at least 6 months prior to the intended date of disposal of any 
study record related to this protocol to allow Pearl to make alternate storage arrangements
10.10 Financial Disclosure
The Principal Investigator or sub-Investigators named on the Form FDA 1572 or the locally 
accepted alternate Investigator Statement form will need to complete a financial disclosure 
form prior to study initiation, at any time during the study execution if new information 
needs to be disclosed, and for 1 year after study completion.  Investigators should make the 
IRB/IEC aware of any financial interests that the Investigator has in the study drug.
10.11 Investigator’s Final Report
Shortly after completion of the Investigator's participation in the study, the Investigator will 
submit a written report to Pearl.
10.12 Publication Policy
Pearl intends to publish the results of all of the clinical studies that it sponsors in compliance 
with the Declaration of Helsinki (http://www.wma.net/en/10home/index.html).  Consistent 
with the recommendations of the editors of several leading medical journals, the International 
Committee of Medical Journal Editors (ICMJE), authorship of publications resulting from 
Pearl -sponsored studies should fairly recognize the activities of those that have made a 
significant contribution to the study.  Thus, it is anticipated that authorship will reflect the 
contribution made by Pearl personnel, the Investigators and others involved, such as 
statisticians.
In recent years, issues about conflicts of interest and accuracy of the study data have been 
raised in the medical press.  Accordingly, Pearl has developed publication guidelines as 
described below:
1. Responsibility: Each Principal Investigator is responsible for the accuracy and 
completeness of all data from their site.  Pearl (or its representatives) is responsible for 
the accuracy of the data entered into the study databases and for the accuracy of the 
analyses conducted.
2. Sponsor Review of External Manuscripts: Consistent with the previous bullet point, 
drafts of any and all publications or presentations that may arise from this study must be 
submitted at least 30 days prior to submission for publication or presentation to Pearl for 
review, approval, and to ensure consistency with the policy in this protocol.  Pearl will 
have the right to request appropriate modification to correct facts and to represent its 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 132 of 194
opinions, or the opinions of the publication committee, if these differ with the proposed 
publication.
3. Confidentiality: Investigators will conduct all interactions with Pearl and with third 
parties consistent with the executed confidentiality agreements.  While publication, by 
intention, presents the critical scientific data in a public forum, some information (such as 
future plans, results of nonclinical studies, or chemical formulae) may still need to remain 
confidential.
4. Medical Journal Review: Consistent with the intention of Pearl to publish the study in a 
fair and accurate manner, Pearl supports diligence in the publication review process of 
medical journals.  Accordingly, upon request, all pertinent study data and information 
will be made available as supplemental information for journal editors and reviewers to 
evaluate and audit, e.g., protocol and amendments, data tabulations.  The journal and 
reviewers will need to make arrangements to maintain the confidentiality of such 
supplemental information, where relevant, and Pearl will make suitable arrangements to 
ensure that the identity of journal reviewers is kept confidential.  Records will be 
maintained of reviewers and the respective documents and datasets that were reviewed by 
each of them.
5. Reporting of Clinical Trial Results: To provide transparency in the conduct and 
reporting of randomized clinical trials, Pearl reports clinical findings based on the 
guidance of The CONSORT (Consolidated Standards of Reporting Trials) Statement 
(Moher 2010) and a 25-item checklist which is intended to improve the reporting of a 
randomized controlled Study, and to facilitate reader understanding of the Study design, 
conduct, analysis and interpretation, and to support their ability to assess the validity of 
its results.
6. Internet Clinical Trial Listing: In addition, also consistent with the recommendations of 
the ICMJE, Pearl will make available appropriate information regarding the study via the 
internet.  This will include registration and listing of the study on www.clinicaltrials.gov, 
the US National Institutes of Health listing of clinical trials, and other clinical trial 
listings as appropriate (e.g., EudraCT; https://eudract.ema.europa.eu)Per AstraZeneca 
policy, Pearl posts clinical study protocols for public viewing when a manuscript is 
published in a medical journal. Prior to being made public, the protocol is reviewed by 
AstraZeneca Intellectual Property.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 133 of 194
11 REFERENCE LIST
Celli B, MaNee W, Agusti A, et al. Standards for the diagnosis and treatment of subjects with 
COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946.
Centers for Disease Control (CDC guidelines 2013-2014). Summary Recommendations: 
Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory 
Committee on Immunization Practices, United States, 2013-2014. Centers for Disease 
Control and Prevention (CDC). Available from: URL:
http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm
Centers for Disease Control (CDC guidelines 2010). Updated Recommendations for 
Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent 
Pneumococcal Polysaccharide Vaccine (PPSV23). Centers for Disease Control and 
Prevention (CDC). Morbidity and Mortality Weekly Report .2010 / 59(34);1102-1106.
Available from: URL: http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-
specific/pneumo.html
EuroQol Group.  EQ-5D. Accessed at http://www.euroqol.org/about-eq-5d/how-to-use-eq-
5d.html (November, 2014).
Food and Drug Administration (FDA). Guidance for Industry: Chronic Obstructive 
Pulmonary Disease: Developing Drugs for Treatment. November, 2007.
From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 2016.  Available from: 
http://www.goldcopd.org/.
Global Initiative for Chronic Obstructive Lung Disease (GOLD).  Global Strategy for the 
Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease.  
Updated; 2014:1-102. Available from: 
http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf
Global Lung Initiative (GLI). Reference values for spirometry. 2012. 
http://www.lungfunction.org/files/GLI-2012_Reference_values.pdf
Hochberg Y, A sharper Bonferroni procedure for multiple tests of significance. Biometrika 
1988; 75, 4, pp. 800-802.
Japanese Respiratory Society (JRS).  Guidelines for the Diagnosis and Treatment of COPD, 
4th edition, 2013.
Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C,
Leibbrandt Y, Maier S, Miedinger D, Müller B, Scherr A, Schindler C, Stoeckli R, Viatte S,
von Garnier C, Tamm M, Rutishauser J. Short-term vs conventional glucocorticoid therapy 
in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized 
clinical trial. JAMA. 2013 Jun 5;309(21):2223-31.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 134 of 194
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration 
rate. Ann Intern Med. 2009;150(9):604-612.
Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. 
Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. 
Chest. 1984;85(6):751-758.
Miller MR, Hankinson J, Brusasco V, et al.  Standardisation of spirometry. Eur Respir J. 
2005;26(2):319-338.
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, 
Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for 
reporting parallel group randomised trials. BMJ 2010; 340:c869.
New York Heart Association NYHA 2011 NYHA Classification, the Stages of Heart Failure. 
Accessed on 14 July 2014.  Available online at Heart Failure Society of America: 
http://www.abouthf.org/questions_stages.htm.
Niewoehner DE, Rice K, Cote C, et al.  Prevention of exacerbations of chronic obstructive 
pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator:  a 
randomized trial.  Ann Intern Med.  2005;143:317-326.
http://www.renal.org/information-resources/the-uk-eckd-guide/ckd-
stages#sthash.u0MhYkto.dpbsRennard SI, Tashkin DP, McElhattan J, et al.  Efficacy and 
tolerability of budesonide/formoterol in one HFA pressurized metered-dose inhaler in 
patients with chronic obstructive pulmonary disease: results from a 1-year randomized 
controlled clinical trial.  Drugs. 2009;69(5):549-65.
Tashkin DP, Rennard SI, Martin P, et al.  Efficacy and safety of budesonide and formoterol 
in one pressurized metered-dose inhaler in patients with moderate to very severe chronic 
obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008; 
68(14):1975 2000. 
Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a 
multinational clinical trial. Eur Respir J. 2003;21(2):267-272.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 135 of 194
12 APPENDICES

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 136 of 194
Appendix 1
Spirometry Performance Recommendations
Spirometry data of the highest quality must be obtained for proper interpretation of the 
results of this protocol.  To these ends, a standard spirometer will be used (provided by 
Pearl), central training provided, qualification will be required, and specific operating 
instruction will also be provided.
The following instructions are supported by ATS/ERS defined criteria [Miller 2005].
FEV1 AND FVC MANEUVERS
Equipment Requirements
The spirometer must be capable of accumulating volume for 15 s (longer times are 
recommended) and measuring volumes of 8 L (body temperature (i.e., 37°C), ambient 
pressure, saturated with water vapor, body temperature and pressure saturated [BTPS]) with 
an accuracy of at least ±3% of reading or ±0.050 L, whichever is greater, with flows between 
0 and 14 L-s-1.  The total resistance to airflow at 14.0 L-s-1 must be <1.5 cmH2O L-1s-1
(0.15 kPa L-1s-1).  The total resistance must be measured with any tubing, valves, pre-filter, 
etc. included that may be inserted between the subject and the spirometer.  Some devices 
may exhibit changes in resistance due to water vapor condensation, and accuracy 
requirements must be met under BTPS conditions for up to eight successive FVC maneuvers 
performed in a 10-minute period without inspiration from the instrument.
Display
For optimal quality control, both flow-volume and volume-time displays are useful, and test 
operators should visually inspect the performance of each maneuver for quality assurance 
before proceeding with another maneuver.  This inspection requires tracings to meet the 
minimum size and resolution requirements set forth in this standard.  Displays of flow vs. 
volume provide more detail for the initial portion (first 1 s) of the FVC maneuver.  Since this 
portion of the maneuver, particularly the peak expiratory flow rate, is correlated with the 
pleural pressure during the maneuver, the flow–volume display is useful to assess the 
magnitude of effort during the initial portions of the maneuver.  The ability to overlay a 
series of flow–volume curves registered at the point of maximal inhalation may be helpful in 
evaluating repeatability and detecting sub-maximal efforts.  However, if the point of maximal 
inhalation varies between blows, then the interpretation of these results is difficult because 
the flows at identical measured volumes are being achieved at different absolute lung 
volumes.  In contrast, display of the FVC maneuver as a volume–time graph provides more 
detail for the latter part of the maneuver.  A volume–time tracing of sufficient size also 
allows independent measurement and calculation of parameters from the FVC maneuvers.  In 
a display of multiple trials, the sequencing of the blows should be apparent to the user.  For 
the start of test display, the volume–time display should include >0.25 s, and preferably 1 s,
before exhalation starts (zero volume).  This time period before there is any change in 
volume is needed to calculate the back extrapolated volume (EV) and to evaluate effort 
during the initial portion of the maneuver.  Time zero, as defined by EV, must be presented 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 137 of 194
as the zero point on the graphical output.  The last 2 s of the maneuver should be displayed to 
indicate a satisfactory end of test.
When a volume–time curve is plotted as hardcopy, the volume scale must be 10 mm L-1
(BTPS).  For a screen display, 5 mm L-1 is satisfactory (Table A1-1).
Table A1-1. Recommended Minimal Scale Factors for Time, Volume, and 
Flow on Graphical Output
Instrument Display
Hardcopy
Graphical Output
Parameter
Resolution 
Required
Scale Factor
Resolution 
Required
Volume a
0.050 L
5 mm-L-1
0.050 L
Flow a
0.200 L-s-1
2.5 mm L-1 s-1
0.200 L-s-1
Time
0.2 s
10 mm-s-1
0.2 s
a
The correct aspect ratio for flow versus volume display is 2 units of flow per 1 unit of volume.
The time scale should be 20 mm-s-1, and larger time scales are preferred (30 mm-s-1) when 
manual measurements are made.  When the volume–time plot is used in conjunction with a 
flow–volume curve (i.e., both display methods are provided for interpretations and no hand 
measurements are performed), the time scale requirement is reduced to 10 mm-s-1 from the 
usually required minimum of 20 mm-s-1 (Table A1-1).  The rationale for this exception is that 
the flow–volume curve can provide the means for quality assessment during the initial 
portion of the FVC maneuver.  The volume–time curve can be used to evaluate the latter part 
of the FVC maneuver, making the time scale less critical.
Validation
It is strongly recommended that spirometry systems should be evaluated using a 
computer-driven mechanical syringe or its equivalent, in order to test the range of exhalations 
that are likely to be encountered in the test population.  Testing the performance of 
equipment is not part of the usual laboratory procedures.
Quality Control
Attention to equipment quality control and calibration is an important part of Good 
Laboratory Practice.  At a minimum, the requirements are as follows:  1) a log of calibration 
results is maintained; 2) the documentation of repairs or other alterations which return the 
equipment to acceptable operation; 3) the dates of computer software and hardware updates 
or changes; and 4) if equipment is changed or relocated (e.g., industrial surveys), calibration 
checks and quality-control procedures must be repeated before further testing begins.
Key aspects of equipment quality control are summarized in Table A1-2.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 138 of 194
Table A1-2. Summary of Equipment Quality Control
Test
Minimal 
Interval
Action
Volume
Daily
Calibration check with a 3-L syringe
Leak
Daily
2 cmH2O (0.3 kPa) constant pressure for 1 minute
Volume 
Linearity
Quarterly
1-L increments with a calibrating syringe measured over 
the entire volume range
Flow
Linearity
Weekly
Test at least three different flow ranges
Time
Quarterly
Mechanical recorder check with stop watch
Software
New 
versions
Log installation date and perform test using “known” 
subject
Calibration is the procedure for establishing the relationship between sensor-determined 
values of flow or volume and the actual flow or volume.  A calibration check is different 
from calibration and is the procedure used to validate that the device is within calibration 
limits, e.g., ±3% of true.  If a device fails its calibration check, then new calibration 
procedure or equipment maintenance is required.  Calibration checks must be undertaken 
daily, or more frequently, if specified by the manufacturer.  The syringe used to check the 
volume calibration of spirometers must have an accuracy of ±15 mL or ±0.5% of the full 
scale (15 mL for a 3-L syringe), and the manufacturer must provide recommendations 
concerning appropriate intervals between syringe calibration checks.  Users should be aware 
that a syringe with an adjustable or variable stop may be out of calibration if the stop is reset 
or accidentally moved.  Calibration syringes should be periodically (e.g., monthly) leak 
tested at more than one volume up to their maximum; this can be done by attempting to 
empty them with the outlet corked.  A dropped or damaged syringe should be considered out 
of calibration until it is checked.
With regard to time, assessing mechanical recorder time scale accuracy with a stopwatch 
must be performed at least quarterly.  An accuracy of within 2% must be achieved.
Quality Control for Volume-Measuring Devices
The volume accuracy of the spirometer must be checked at least daily, with a single 
discharge of a 3-L calibrated syringe.  Daily calibration checking is highly recommended so 
that the onset of a problem can be determined within 1 day and also to help define day-to-day 
laboratory variability.  More frequent checks may be required in special circumstances, such 
as:  1) during industrial surveys or other studies in which a large number of subject 
maneuvers are carried out, the equipment’s calibration should be checked more frequently 
than daily; and 2) when the ambient temperature is changing (e.g., field studies), volume 
accuracy must be checked more frequently than daily and the BTPS correction factor 
appropriately updated.  

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 139 of 194
The accuracy of the syringe volume must be considered in determining whether the measured 
volume is within acceptable limits.  For example, if the syringe has an accuracy of 0.5%, a 
reading of ±3.5% is appropriate.
The calibration syringe should be stored and used in such a way as to maintain the same 
temperature and humidity of the testing site.  This is best accomplished by keeping the 
syringe in close proximity to the spirometer, but out of direct sunlight and away from heat 
sources.
Volume-type spirometer systems must be evaluated for leaks every day.  The importance of 
undertaking this daily test cannot be overstressed.  Leaks can be detected by applying a 
constant positive pressure of 3.0 cmH2O (0.3 kPa) with the spirometer outlet occluded 
(preferably at or including the mouthpiece).  Any observed volume loss of 0.30 mL after 
1 minute indicates a leak and needs to be corrected.
At least quarterly, volume spirometers must have their calibration checked over their entire 
volume range using a calibrated syringe or an equivalent volume standard.  The measured 
volume should be within ±3.5% of the reading or 65 mL, whichever is greater.  This limit 
includes the 0.5% accuracy limit for a 3-L syringe.  The linearity check procedure provided 
by the manufacturer can be used if it is equivalent to one of the following procedures:  
1) consecutive injections of 1-L volume increments while comparing observed volume with 
the corresponding cumulative measured volume (e.g., 0–1,1–2, 2–3,…6–7 and 7–8 L, for an 
8-L spirometer); and 2) injection of a 3-L volume starting at a minimal spirometer volume, 
then repeating this with a 1-L increment in the start position (e.g., 0–3, 1–4, 2–5, 3–6, 4–7,
and 5–8 L, for an 8-L spirometer).  The linearity check is considered acceptable if the 
spirometer meets the volume accuracy requirements for all volumes tested.
Quality Control for Flow-Measuring Devices
With regards to volume accuracy, calibration checks must be undertaken at least daily, using 
a 3-L syringe discharged at least three times to give a range of flows varying between 0.5 and 
12 L-s-1 (with 3-L injection times of 6 s and 0.5 s).  The volume at each flow should meet the 
accuracy requirement of ±3.5%.  For devices using disposable flow sensors, a new sensor 
from the supply used for subject tests should be tested each day.
For linearity, a volume calibration check should be performed weekly with a 3-L syringe to 
deliver three relatively constant flows at a low flow, then three at a mid-range flow and 
finally three at a high flow.  The volumes achieved at each of these flows should each meet
the accuracy requirement of ±3.5%.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 140 of 194
VITAL CAPACITY AND MANEUVERS
Equipment
For measurements of vital capacity (VC), the spirometer or flow meter must comply with the 
requirements for FVC (as described previously) and be capable of accumulating volume for 
>30 s.  Expiratory maneuvers or, ideally, both inspiratory and expiratory maneuvers should 
be included in the display of VC maneuver.  Regardless of whether the inspiratory or 
expiratory maneuver is used for deriving measurements, a display of the entire recorded VC 
maneuver must be provided.  The maximal expiratory volume must be assessed to determine 
whether the subject has obtained a plateau in the expiratory effort.  For display of the slow 
VC, the time scale may be reduced to 5 mm-s-1.
TECHNICAL CONSIDERATIONS
Minimal Recommendations for Spirometry Systems
Accurate results require accurate equipment.  Spirometer equipment recommendations apply 
to all spirometers and are minimal requirements.  In some circumstances, it may be 
appropriate to exceed these requirements (i.e., in some research/surveillance applications).  
Instrumentation recommendations should be followed to provide accurate spirometric data 
and information that is comparable from laboratory to laboratory and from one time period to 
another. The accuracy of a spirometry system depends on characteristics of the entire 
system, from the volume or flow transducer and the use of an in-line filter, to the recorder, 
display or processor.  Changes in any aspect of the equipment or errors at any step in the 
process can affect the accuracy of the results.  For example, if the BTPS correction factor is 
wrong, an accurately measured FVC will be incorrectly reported.  Spirometers are not 
required to measure all of the indices in Table A1-3, but must meet the recommendations for 
those that are measured.  Accuracy and repeatability recommendations apply over the entire 
volume range of the instrument. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 141 of 194
Table A1-3. Range and Accuracy Recommendations Specified for Forced 
Expiratory Maneuvers
Test
Range/Accuracy
(BTPS)
Flow
Range
(L-s-1)
Resistance 
and
Back 
Pressure
Test Signal
VC
0.5–8 L, ±3% of 
reading or +0.050 L, 
whichever is greater
0-14
3-L calibration 
syringe
FVC
0.5–8 L, +3% of 
reading or +0.050 L, 
whichever is greater
0-14
<1.5 cmH2O
L-1 s-1
(0.15 kPa 
L-1s-1)
24 ATS 
waveforms, 3-L
calibration syringe
FEV1
0.5–8 L, +3% of 
reading or +0.050 L, 
whichever is greater
0-14
<1.5 cmH2O
L-1 s-1
(0.15 kPa 
L-1s-1)
24 ATS 
waveforms
Time 
Zero
The timepoint from 
which all FEV1
measurements are 
taken
Back 
extrapolation
BTPS Correction
All spirometry values should be reported at BTPS by any method (measuring temperature 
and barometric pressure) proven effective by the manufacturer.  For volume-type 
spirometers, the temperature inside the spirometer should be measured for each breathing 
maneuver.  Regardless of the BTPS correction technique used, the ambient temperature must 
always be recorded with an accuracy of ±1°C.  In situations where the ambient air 
temperature is changing rapidly (>3°C in <30 minutes), continuous temperature corrections 
may be necessary.  Spirometer users should be aware of potential problems with testing 
performed at lower ambient temperatures:  17°C is the lower limit for ambient temperature, 
unless a manufacturer states that their spirometer will operate accurately at lower ambient 
temperatures.  If barometric pressure is not used in calculating the BTPS correction factor, 
the range of barometric pressures over which the BTPS correction factor is valid must be 
published.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 142 of 194
Appendix 2
Spirometry Assessment Criteria
Acceptable Versus Usable Tests
Acceptable tests must meet the following seven criteria:
Acceptable start of exhalation with brisk upstroke, no hesitation or false start, and back EV 
<5% of FVC or 0.150 L, whichever is the greater.  (See example in
1. Figure 2.
Example of a Usable Spirogram below).
2. No cough during the first second.
3. No valsalva maneuver.
4. No leak.
5. No obstruction of mouthpiece.
6. No extra breaths.
7. Plateau achieved, ie, the volume-time curve shows no change in volume (<0.025 L) for 1s, 
and the subject has tried to exhale for at least 6 seconds.
An acceptable test meets all seven criteria listed.  This is to be considered the “gold 
standard.”
Useable spirometry tracings are those that only meet criteria 1 and 2.  When this occurs, 
repeat testing up to eight attempts in an effort to obtain three acceptable spirograms.  If only 
usable tests are obtained, report results based on the three best usable trials with observed 
limitations.
Figure 2.
Example of a Usable Spirogram
Abbreviations:  EV=back extrapolated volume
The expanded version of the early part of a subject’s volume-time spirogram, illustrating 
back extrapolation through the steepest part of the curve, where flow is peak expiratory flow 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 143 of 194
rate, to determine the new “time zero.”  Forced vital capacity-4.291 L; EV-0.123 L
(2.9% FVC): back extrapolation line through peak expiratory flow rate.
Between-Maneuver Reproducibility Criteria
After three acceptable spirograms have been obtained, apply the following tests:
•
The two largest values of FVC must be within 0.150 L of each other
•
The two largest values of FEV1 must be within 0.150 L of each other
If these criteria are met, the spirometry testing for that time point may conclude.  The highest 
FEV1 and the highest FVC obtained at each testing time point (even if from different 
reproducible tracings), will be collected. 
If acceptability criteria are not met, continue testing until they are met or the subject cannot/ 
should not continue (maximum of eight attempts). 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 144 of 194
Appendix 3
Classification of COPD Severity - GOLD Guidelines 
(2014)
The GOLD staging system classifies people with COPD based on their degree of airflow 
limitation (obstruction).  The airflow limitation is measured during PFTs.
Because of lung damage, people with COPD take longer to blow air out.  This impairment is 
called obstruction or airflow limitation.  An FEV1 less than 70% of FVC can make the 
diagnosis of COPD in someone with compatible symptoms and history. 
In GOLD COPD, classifications are then used to describe the severity of the obstruction or 
airflow limitation based on post-bronchodilator FEV1 [GOLD, 2014].
Table A3-1. Classification of Severity of Airflow Limitation in COPD 
(Based on Post-bronchodilator FEV1)
Stage I
Mild COPD
FEV1/FVC<0.70
FEV1 80% normal
Stage II
Moderate COPD
FEV1/FVC<0.70
FEV1 50% to <80% 
normal
Stage III
Severe COPD
FEV1/FVC<0.70
FEV1 30% to <50% 
normal
Stage IV
Very Severe COPD
FEV1/FVC<0.70
FEV1 <30% normal 
Abbreviations:  COPD=chronic obstructive pulmonary disease; FEV1=forced expiratory volume in 
1 second; FVC=forced vital capacity

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 146 of 194
are 110 puffs of medicine left (see Figure 2b).  After 10 more puffs are 
used, the Dose indicator pointer will move to the number 100.  This means 
that there are 100 puffs of medicine left (see Figure 2c). 
•
The Dose indicator number will continue to change after every 20 
puffs. 
•
When the number in the Dose indicator window changes to 20 and 
the color behind the number changes to red, this means that there are 
only 20 puffs left in your inhaler.  See Figure 2d. 
Figure 2d 
 
Preparing the Inhaler for Use: 
The inhaler comes in a foil pouch that contains a drying packet (desiccant). 
•
Take the inhaler out of the foil pouch. 
•
Throw away the pouch and the drying packet.  Do not eat or inhale the 
contents of the drying packet.  
•
Remove the Cap from the Mouthpiece as shown in Figure 3.  
 
Figure 2b 
110 puffs 
Figure 2a 
120 puffs 
Figure 2c 
100 puffs 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 147 of 194
Figure 3 
Prime the inhaler before you use it for the first time. 
 
Priming the Inhaler: 
•
Check inside the Mouthpiece for objects before use. 
•
Hold the Actuator with the Mouthpiece pointing away from you and others 
as shown in Figure 4a. 
•
Shake the inhaler well before each puff. 
•
Push down fully on the center (not ‘off center’) of the Dose indicator on top 
of the Canister (see Figure 1) until the Canister stops moving in the 
Actuator to release a puff from the Mouthpiece as shown in Figure 4b.  
Note:  It is normal to hear a soft click from the dose indicator as it counts 
down during use. 
•
Repeat this priming step 3 more times for a total of 4 times, shaking the 
inhaler each time before you press it. 
•
After completing the 4 priming puffs, your inhaler is now primed ready to use 
for the first time. 
You must re-prime your inhaler again if you have not used it in more than 
7 days.  Take the cap off the mouthpiece and shake and spray the inhaler 2 
times into the air away from your face. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 148 of 194
Using the Inhaler: 
Your dose of medicine comes from 2 puffs from the inhaler. 
Refer to Figure 5 for Step 1 through Step 8. 
•
Step 1: Remove the Cap from the Mouthpiece. 
•
Step 2: Shake the inhaler well before each puff. 
•
Step 3: While holding the inhaler with the Mouthpiece pointing towards you 
breathe out through your mouth to empty as much air from your lungs as 
possible. 
•
Step 4:  Close your lips around the Mouthpiece and tilt your head back 
slightly to make sure your tongue is away from the Mouthpiece. 
•
Step 5: Take a deep breath in (inhale) slowly through your mouth while 
pressing down firmly on the center (not ‘off center’) of the Dose indicator 
until the Canister stops moving in the Actuator and a puff has been 
released. Then, stop pressing the Dose indicator.  
•
Step 6: When you have finished breathing in, remove the Mouthpiece from 
your mouth and hold your breath for 10 seconds or as long as comfortable.    
•
Step 7:  Then, breathe out normally.  
Take your second puff of medicine by repeating Step 2 through Step 7.  
•
Step 8:  Replace the Cap back on the Mouthpiece. 
Figure 4a 
Figure 4b 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 149 of 194
Figure 5  
How to clean the Inhaler: 
It is very important to keep your inhaler clean so medicines will not build-up and 
block the spray through the Mouthpiece.  See Figure 6. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 150 of 194
Figure 6 
 
The Canister should be gently pulled from the top of the Actuator once a week 
and the Actuator cleaned.  Do not clean the Canister or let it get wet. 
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 151 of 194
•
Step 1: Pull the Canister out of the Actuator as shown in Figure 7. 
Figure 7 
 
•
Step 2:  Set the Canister aside where it will not get wet. 
•
Step 3: Take the Cap off the Mouthpiece. 
•
Step 4:  Rinse the Actuator through the top with warm running water for 30 
seconds.  Then rinse the actuator again through the Mouthpiece (see Figure 
8). 
Figure 8 
 
•
Step 5:  Shake all of the water droplets out of the Actuator. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 152 of 194
•
Step 6: Look in the Actuator and the Mouthpiece to make sure it is clean 
and clear. 
Repeat Step 4 through Step 6, until the Actuator and the Mouthpiece are 
clean and clear. 
•
Step 7:  Let the Actuator dry completely, such as overnight as shown in 
Figure 9.  Do Not put the Canister back into the Actuator if it is still wet. 
Figure 9 
 
Reassembly of the Inhaler and Instructions for Use after Cleaning: 
•
After the Actuator is completely dry, gently press the Canister down in the 
Actuator as shown in Figure 10.  It is not necessary to press down on the 
Canister hard enough to cause a puff to be released. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 153 of 194
Figure 10 
 
•
Re-prime your inhaler 2 times after each cleaning. 
•
Hold the Actuator with the Mouthpiece pointing away from you and others 
as shown in Figure 4. 
•
Shake the inhaler well before each puff. 
•
Push down fully on the center (not ‘off center’) of the Dose indicator on top 
of the Canister until the Canister stops moving in the Actuator to release a 
puff from the Mouthpiece. 
•
Repeat this re-priming step 1 more time for a total of 2 times. 
•
After re-priming your inhaler 2 times, your inhaler is now ready to use. 
 
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 154 of 194
Appendix 5
Instructions for Use of Atrovent® HFA Inhalation 
Aerosol Device
INSTRUCTIONS FOR USE
Atrovent® HFA
(ipratropium bromide HFA)
Inhalation Aerosol
Read the Instructions for Use before using your ATROVENT HFA and each time you get a 
refill. There may be new information. This leaflet does not take the place of talking with your 
healthcare provider about your medical condition or your treatment.
Use ATROVENT HFA exactly as your healthcare provider tells you to. Do not change 
your dose or how often you use ATROVENT HFA without talking with your healthcare 
provider.
Tell your doctor about all the medicines you take. ATROVENT HFA may affect the way 
some other medicines work and some other medicines may affect the way ATROVENT HFA 
works.
Important information about using ATROVENT HFA
•
You do not have to shake ATROVENT HFA before using it.
•
ATROVENT HFA should be "primed" 2 times before you use the first dose of a new
ATROVENT HFA inhaler or when the inhaler has not been used for more than 3 days.
•
To prime, push the canister against the mouthpiece (See Figure 1), allowing the medicine 
to spray into the air.
•
Do not spray the medicine into your eyes while priming ATROVENT HFA.
Inhaler Description
ATROVENT HFA Inhalation Aerosol (Figure 1) consists of a metal canister containing the 
medicine and a mouthpiece that releases the medicine from the canister. The mouthpiece 
includes a clear colorless sleeve, a white plastic portion and a green protective dust cap.
The inhaler comes with a dose indicator you can see through a small window on the plastic 
mouthpiece (See Figure 1). A new inhaler first shows “200” in the dose indicator window. 
The dose indicator will show the approximate number of actuations (sprays) of medicine 
remaining in the inhaler. As you use the inhaler, the dose indicator will typically rotate 
during every 5 to 7 actuations (sprays) towards the next decreasing number (See Figure 2).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 155 of 194
Figure 1
Figure 2
Instructions for Use:
1. Insert the metal canister into the clear end of the mouthpiece (See Figure 1). Make sure the 
canister is fully and firmly inserted into the mouthpiece.
•
The ATROVENT HFA canister is to be used only with the ATROVENT HFA
mouthpiece.
•
Do not use the ATROVENT HFA mouthpiece with other inhaled medicines.
2. Remove the green protective dust cap. If the cap is not on the mouthpiece, make sure there is 
nothing in the mouthpiece before use. For best results, the canister should be at room 
temperature before use.
3. Breathe out (exhale) deeply through your mouth. Hold the inhaler upright (See Figure 3),
between your thumb and first 2 fingers. Put the mouthpiece in your mouth and close your lips.
•
Keep your eyes closed so that no medicine will be s prayed into your eyes . If sprayed into 
the eyes, ATROVENT HFA can cause blurry vision and other vision abnormalities, eye pain 
or discomfort, dilated pupils, or narrow-angle glaucoma or worsening of this condition. If any 
Combination of these symptoms develops, you should consult your physician immediately.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 156 of 194
Figure 3
4. Breathe in (inhale) slowly through your mouth and at the same time spray the 
ATROVENT HFA into your mouth.
•
To spray ATROVENT HFA firmly press the canister against the mouthpiece 1 time (See 
Figure 4). Keep breathing in deeply.
Figure 4
5. Hold your breath for ten seconds and then take the mouthpiece out of your mouth and
breathe out slowly (See Figure 5).

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 157 of 194
Figure 5
6. Wait at least 15 seconds and repeat steps 3 to 5 again.
7. Replace the green protective dust cap after use.
8. Keep the mouthpiece clean. At least once a week, wash the mouthpiece, shake it to remove 
excess water and let it air dry all the way (see Mouthpiece Cleaning Instructions).
Mouthpiece Cleaning Instructions:
Step A. Remove and set aside the canister and dust cap from the mouthpiece (See Figure 1).
Step B. Wash the mouthpiece through the top and bottom with warm running water for at least 30
seconds (See Figure 6). Do not use anything other than water to wash the mouthpiece.
Figure 6
Step C. Dry the mouthpiece by shaking off the excess water and allow it to air dry all the way.
Step D. When the mouthpiece is dry, replace the canister. Make sure the canister is fully and
firmly inserted into the mouthpiece.
Step E. Replace the green protective dust cap.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 158 of 194
If little or no medicine comes out of the mouthpiece, wash the mouthpiece as described in Steps 
A to E under the "Mouthpiece Cleaning Instructions".
9. When to get a new ATROVENT HFA inhaler.
There are approximately 40 actuations (sprays) left when the dose indicator displays “40,” 
where the background changes from green to red (See Figure 7a). This is when you need to 
refill your prescription or ask your doctor if you need another prescription for ATROVENT 
HFA inhalation aerosol.
The background color will be all red when the indicator approaches 20. The indicator will stop
moving at “0”. Discard the inhaler once the dose indicator displays “0” (See Figure 7b). Even
though the canister may not be empty, you cannot be sure of the amount of medicine in each
actuation (spray) once the dose indicator displays “0”.
Figure 7a
Figure 7b
This product does not contain any chlorofluorocarbon (CFC) propellants.
The contents of ATROVENT HFA are under pressure. Do not puncture the canister. Do not use 
or store near heat or open flame. Exposure to temperatures above 120°F may cause bursting. 
Never throw the container into a fire or incinerator.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 159 of 194
Keep ATROVENT HFA and all medicines out of the reach of children.
Address medical inquiries to: http://us.boehringer-ingelheim.com, (800) 542-6257 or (800) 
459-9906 TTY.
Store ATROVENT HFA at Room Temperature [77°F (25°C)]. Short-term exposure to 
higher or lower temperatures [from 59°F (15°C) to 86°F (30°C)] is acceptable. 
Distributed by:
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT 06877 USA
Licensed from:
Boehringer Ingelheim International GmbH
Copyright 2012 Boehringer Ingelheim International GmbH
ALL RIGHTS RESERVED
IT1902II122012
10003001/09
Revised: August 2012
Atrovent HFA (ipratropium bromide HFA)
NDC 0597-0087-17
200 metered actuations

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 160 of 194
Appendix 6
Instructions for Use of Ventolin HFA Inhaler
Instructions for Use
For Oral Inhalation Only
Your VENTOLIN HFA inhaler
•
The metal canister holds the medicine. See Figure A.
Figure A
Figure A
The canister has a counter to show how many sprays of medicine you have left. The 
number shows through a window in the back of the actuator. See Figure B.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 161 of 194
Figure B
Figure B
•
The counter starts at either 204 or 064, depending on which size inhaler you have. The 
number will count down by 1 each time you spray the inhaler. The counter will stop 
counting at 000.
•
Do not try to change the numbers or take the counter off the metal canister. The counter 
cannot be reset, and it is permanently attached to the canister.
•
The blue plastic actuator sprays the medicine from the canister. The actuator has a 
protective cap that covers the mouthpiece. See Figure A. Keep the protective cap on the 
mouthpiece when the canister is not in use. The strap keeps the cap attached to the 
actuator.
•
Do not use the actuator with a canister of medicine from any other inhaler.
•
Do not use a VENTOLIN HFA canister with an actuator from any other inhaler.
Before using your VENTOLIN HFA inhaler
Before you use VENTOLIN HFA for the first time, you must prime the inhaler so 
that you will get the right amount of medicine when you use it.
To prime the inhaler, take the cap off the mouthpiece and shake the inhaler well. Then 
spray the inhaler 1 time into the air away from your face. See Figure C. Avoid spraying 
in eyes.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 162 of 194
Figure C
Figure C
•
Shake and spray the inhaler like this 3 more times to finish priming it. The counter should 
now read 200 or 060, depending on which size inhaler you have. See Figure D.
Figure D
Figure D
You must prime your inhaler again if you have not used it in more than 14 days or if you 
drop it. Take the cap off the mouthpiece and shake and spray the inhaler 4 times into the 
air away from your face.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 163 of 194
How to use your VENTOLIN HFA inhaler
Follow these steps every time you use VENTOLIN HFA.
Step 1. Make sure the canister fits firmly in the actuator. The counter should show through 
the window in the actuator.
Shake the inhaler well before each spray.
Take the cap off the mouthpiece of the actuator. Look inside the mouthpiece for foreign 
objects and take out any you see.
Step 2. Hold the inhaler with the mouthpiece down. See Figure E.
Figure E
Figure E
Step 3. Breathe out through your mouth and push as much air from your lungs as you can. 
Put the mouthpiece in your mouth and close your lips around it. See Figure F.
Figure F
Figure F

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 164 of 194
Step 4. Push the top of the canister all the way down while you breathe in deeply and slowly 
through your mouth. See Figure F.
Step 5. After the spray comes out, take your finger off the canister. After you have breathed 
in all the way, take the inhaler out of your mouth and close your mouth.
Step 6. Hold your breath for about 10 seconds, or for as long as is comfortable. Breathe 
out slowly as long as you can.
If your healthcare provider has told you to use more sprays, wait 1 minute and shake the 
inhaler again. Repeat Steps 2 through Step 6.
Step 7. Put the cap back on the mouthpiece after every time you use the inhaler. Make sure it 
snaps firmly into place.
Cleaning your VENTOLIN HFA inhaler
Clean your inhaler at least 1 time each week. You may not see any medicine build-up on the 
inhaler, but it is important to keep it clean so medicine build-up will not block the spray. See 
Figure G.
Figure G
Figure G
Step 8. Take the canister out of the actuator and take the cap off the mouthpiece. The strap 
on the cap will stay attached to the actuator.
Step 9. Hold the actuator under the faucet and run warm water through it for about 30 
seconds. See Figure H.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 165 of 194
Figure H
Figure H
Step 10. Turn the actuator upside down and run warm water through the mouthpiece for 
about 30 seconds. See Figure I.
Figure I
Figure I
Step 11. Shake off as much water from the actuator as you can. Look into the mouthpiece to 
make sure any medicine build-up has been completely washed away. If there is any build-up,
repeat Steps 9 and 10.
Step 12. Let the actuator air-dry overnight. See Figure J.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 166 of 194
Figure J
Figure J
Step 13. When the actuator is dry, put the protective cap on the mouthpiece and then put the 
canister in the actuator and make sure it fits firmly. Shake the inhaler well, remove the cap, 
and spray the inhaler once into the air away from your face. (The counter will count down by 
1 number.) Put the cap back on
the mouthpiece.
If you need to use your inhaler before the actuator is completely dry:
•
Shake as much water off the actuator as you can.
•
Put the cap on the mouthpiece and then put the canister in the actuator and make sure 
it fits firmly.
•
Shake the inhaler well and spray it 1 time into the air away from your face.
•
Take your VENTOLIN HFA dose as prescribed.
•
Follow cleaning Steps 8 through 13 above.
Replacing your VENTOLIN HFA inhaler:
•
When the counter reads 020, you should refill your prescription or ask your 
healthcare provider if you need another prescription for VENTOLIN HFA.
•
Throw the inhaler away when the counter reads 000 or 12 months after you opened 
the foil pouch, whichever comes first. You should not keep using the inhaler when the 
counter reads 000 because you will not receive the right amount of medicine.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 167 of 194
•
Do not use the inhaler after the expiration date, which is on the packaging it comes 
in.
For correct use of your VENTOLIN HFA inhaler, remember:
•
The canister should always fit firmly in the actuator.
•
Breathe in deeply and slowly to make sure you get all the medicine.
•
Hold your breath for about 10 seconds after breathing in the medicine. Then breathe 
out fully.
•
Always keep the protective cap on the mouthpiece when your inhaler is not in use.
•
Always store your inhaler with the mouthpiece pointing down.
•
Clean your inhaler at least 1 time each week.
If you have questions about VENTOLIN HFA or how to use your inhaler, call 
GlaxoSmithKline (GSK) at 1-888-825-5249 or visit www.ventolin.com.
This Patient Information and Instructions for Use have been approved by the U.S. Food and 
Drug Administration.
VENTOLIN is a registered trademark of the GSK group of companies.
GlaxoSmithKline
Research Triangle Park, NC 27709
©2014, the GSK group of companies. All rights reserved.
December 2014
VNT:9PIL

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 168 of 194
Appendix 7
COPD Assessment Test
(The CAT in English is found online at: www.catestonline.org/english/indexEN.htm);
the CAT in other languages is found online at: http://www.catestonline.org/)

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 169 of 194
Appendix 8
St. George’s Respiratory Questionnaire
(The sample provided here is for illustrative purposes only)

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 170 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 171 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 172 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 173 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 174 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 175 of 194
Appendix 9
BDI/TDI Questionnaire
(The sample provided here is for illustrative purposes only)

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 176 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 177 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 178 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 179 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 180 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 181 of 194
Appendix 10
EuroQol 5 Dimensions Questionnaire

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 182 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 183 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 184 of 194
Appendix 11
Exacerbations of Chronic Obstructive Pulmonary Disease (EXACT)

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 185 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
 
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 187 of 194

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
 
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 189 of 194
Appendix 12
Dose Indicator Display Reading Instructions
For the purposes of this study, when recording the dose indicator display value, review the 
indicator display at the top of the MDI and record the number of inhalations remaining that 
matches the chart below: 
130 Count (Actuation) Version Shown 
 
If your dose 
indicator 
display looks 
like this record 
120+  
 
If your dose 
indicator 
display looks 
like this record 
120 
 
If your dose 
indicator 
display looks 
like this record 
110 
 
If your dose 
indicator 
display looks 
like this record 
100 
 
If your dose 
indicator display 
looks like this 
record 90 
 
If your dose 
indicator 
display looks 
like this record 
80 
 
If your dose 
indicator 
display looks 
like this record 
70 
 
If your dose 
indicator 
display looks 
like this record 
60 
 
If your dose 
indicator 
display looks 
like this record 
50 
 
If your dose 
indicator display 
looks like this 
record 40 
 
If your dose 
indicator 
display looks 
like this record 
30 
 
If your dose 
indicator 
display looks 
like this record 
20 
 
If your dose 
indicator 
display looks 
like this record 
10 
 
If your dose 
indicator 
display looks 
like this record 
0  
 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 190 of 194
Appendix 13
Rules for Evaluation of Abnormal Liver Laboratory 
Values
INTRODUCTION
During the course of the study the Investigator will remain vigilant for increases in liver 
biochemistry.  The Investigator is responsible for determining whether a subject meets 
potential Hy’s Law (PHL) criteria at any point during the study.
The Investigator participates, together with Pearl clinical representatives, in review and 
assessment of cases meeting PHL criteria to agree whether Hy’s Law (HL) criteria are met.  
Hy’s Law criteria are met if there is no alternative explanation for the elevations in liver 
biochemistry other than Drug-Induced Liver Injury (DILI) caused by study drug. 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting AEs and SAEs according to the outcome of the review and assessment in line with 
standard safety reporting processes.
DEFINITIONS
•
Potential Hy’s Law
The levels of AST or ALT 3x ULN with TBL 2x ULN at any point during the study 
irrespective of an increase in ALP.  The elevations do not have to occur at the same time or 
within a specified time frame.
•
Hy’s Law
The levels of AST or ALT 3x ULN  with TBL 2x ULN, where no other reason, other than 
the study drug, can be found to explain the combination of increases, e.g., elevated ALP 
indicating cholestasis, viral hepatitis, or another drug.  The elevations do not have to occur at 
the same time or within a specified time frame.
IDENTIFICATION OF POTENTIAL HY’S LAW CASES
In order to identify cases of PHL it is important to perform a comprehensive review of 
laboratory data for any subject who meets any of the following identification criteria in 
isolation or in combination:
•
ALT 3x ULN
•
AST 3x ULN
•
TBL 2x ULN
When a subject meets any of the identification criteria in combination, the central laboratory 
will immediately send an alert to the Investigator and Pearl representative. 

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 191 of 194
The Investigator will also remain vigilant for any laboratory reports where the identification 
criteria are met, the Investigator will:
•
Request a repeat of the test (new blood draw) by the central laboratory.
When the identification criteria are met from central laboratory results the Investigator will 
without delay:
•
Determine whether the subject meets PHL criteria by reviewing all laboratory reports 
including previous visits.
•
Notify the Pearl representative.
FOLLOW-UP
Potential Hy’s Law Criteria not met
If the subject does not meet PHL criteria the Investigator will:
•
Inform the Pearl representative that the subject has not met PHL criteria.
•
Perform follow up on subsequent laboratory results according to the guidance provided in 
the Clinical Study Protocol.
Potential Hy’s Law Criteria met
If the subject does meet PHL criteria the Investigator will:
•
Notify the Pearl representative who will then inform the central Study Team.
The Medical Monitor contacts the Investigator, to provide guidance, discuss, and agree on 
method of follow up and the continuous review of data.  Subsequent to this contact, the 
Investigator will:
•
Monitor the subject until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically indicated.
•
Investigate the etiology of the event and perform diagnostic investigations as discussed 
with the Pearl Medical Monitor.
•
If at any time (in consultation with the Pearl Medical Monitor) the PHL case meets 
serious criteria, report the event as an SAE using standard reporting procedures.
REVIEW AND ASSESSMENT OF POTENTIAL HY’S LAW CASES
The instructions in this section should be followed for all cases where PHL criteria are met.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 192 of 194
No later than 2 weeks after the biochemistry abnormality was initially detected, the Pearl 
Medical Monitor contacts the Investigator in order to review available data and agree on 
whether there is an alternative explanation for meeting PHL criteria other than DILI caused 
by the study drug.  The Pearl Medical Monitor and other subject matter experts (as 
appropriate) will collaborate in the review and assessment of these cases.
According to the outcome of the review and assessment, the Investigator will follow the 
instructions below.
If there is an agreed alternative explanation for the ALT or AST with TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequently 
whether the AE meets the criteria for an SAE:
•
If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate CRF.
•
If the alternative explanation is an AE/SAE, record the AE /SAE in the CRF accordingly 
and follow the standard reporting procedures.
If it is agreed that there is no explanation that would explain the ALT or AST with  TBL 
elevations other than the study drug:
•
Report as an SAE (report term “Hy’s Law case”) according to Pearl standard processes. 
•
The “Medically Important” serious criterion should be used if no other serious 
criteria apply.
•
As there is no alternative explanation for the HL case, a causality assessment of 
“related” should be assigned.
If, there is an unavoidable delay of over 2 weeks in obtaining the information necessary to 
assess whether or not the case meets the criteria for HL, then it is assumed that there is no 
alternative explanation. Until an informed decision can be made, the following procedure 
should be followed:
•
Report as an SAE (report term “Potential Hy’s Law”) applying serious criteria and 
causality assessment as per above.
Continue follow up and review according to the agreed plan.  Once the necessary 
supplementary information is obtained, repeat the review and assessment to determine 
whether HL criteria are met.  Update the SAE Report Form according to the outcome of the 
review.

Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol 
Pearl Therapeutics, Inc.
Clinical Study Protocol: PT010005-05
Version 6.1, 21 June 2019
Confidential and Proprietary
Page 194 of 194
Appendix 15
Investigator’s Agreement and Signature Page
Study Title:
A Randomized, Double Blind, Multi Center, Parallel Group Study to Assess the 
Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD 
Exacerbations over a 52 Week Treatment Period in Subjects With Moderate to 
Very Severe COPD
Study Number:
PT010005-05
Final Date: Version 6.1, 21 June 2019
I agree:
•
To assume responsibility for the proper conduct of the study at this site. 
•
To conduct the study in compliance with the protocol and with any other study conduct procedures 
provided by Pearl Therapeutics, Inc. (hereafter referred to as Pearl) 
•
Not to implement any changes to the protocol without agreement from Pearl and prior review and written 
approval from the IRB/IEC, except where necessary to eliminate an immediate hazard to the subjects, or 
for administrative aspects of the study (where permitted by all applicable regulatory requirements). 
•
That I am aware of and will comply with GCP and all applicable regulatory requirements. 
•
That I am thoroughly familiar with the appropriate use of the investigational product(s), and other 
information provided by Pearl including, but not limited to, the following:  the protocol and the current IB. 
•
To ensure that all persons assisting me with the study are qualified, adequately informed about the 
investigational product(s) and of their study-related duties and functions. 
•
To supply Pearl with any necessary information regarding ownership interest and financial ties; to promptly 
update this information if any relevant changes occur during the course of the study and for 1 year 
following completion of the study; and agree that Pearl may disclose any information it has about such 
ownership interests and financial ties to regulatory authorities. 
•
I agree to report all information or data in accordance with the protocol and any other study conduct 
procedures provided by Pearl. 
•
That since the information in this protocol and IB is confidential, I understand that its disclosure to any 
third parties, other than those involved in approval, supervision, or conduct of the study is prohibited. 
•
To accurately transfer all required data from each subject’s source document to the eCRFs.
•
To allow authorized representatives of Pearl or regulatory authority representatives to conduct on-site visits 
to review, audit and copy study documents.  I will personally meet with these representatives to answer any 
study-related questions.
Signature:
Date:
Name:
Site Name: